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Résumé
Le syndrome de Rett est une maladie neurodéveloppementale progressive conduisant
à un polyhandicap lourd associé à des retards mentaux sévères. Cette pathologie a pour
principale origine des mutations du gène codant pour la protéine Methyl-CpG Binding Pro-
tein 2 (MeCP2), localisé sur le chromosome X. Elle touche essentiellement les filles avec une
fréquence d’environ 1/10 000 naissances. Différentes fonctions ont été attribuées à MeCP2 :
modulateur transcriptionnel (active ou réprime la transcription), épissage alternatif de cer-
tains ARN, maintien de l’état de méthylation des gènes au cours de la réplication de l’ADN
et modification de la structure tridimensionnelle et/ou du niveau de compaction de la chro-
matine.
Initialement, mes travaux de thèse ont consisté à explorer l’hypothèse que MeCP2 aurait
la capacité de passer d’une cellule à l’autre. Les résultats obtenus suggèrent fortement que
le transfert intercellulaire de MeCP2 ne se produit pas in vivo mais serait dû à une diffusion
inter-cellulaire de la protéine suite à l’étape de fixation cellulaire à l’acétone nécessaire à la
suite de l’expérimentation. Cependant, ces travaux nous ont permis de mettre au point une
nouvelle méthode pour la détection des protéines dans les cellules de mammifères basée sur
le système de split GFP.
Dans le cadre de mon projet de thèse, j’ai également produit et caractérisé des anticorps
dirigés spécifiquement contre chacune des 2 isoformes de MeCP2. Ces anticorps origin-
aux vont permettre d’étudier les niveaux d’expression et le rôle de chaque isoforme dans
divers types cellulaires de l’organisme. Cela va pouvoir améliorer notre compréhension de
la pathologie du syndrome de Rett.
Plus récemment, mes travaux se sont focalisés sur la relation entre MeCP2 et les mé-
canismes de réparation de l’ADN, et nous ont permis de mettre en évidence la capacité de
MeCP2 de s’accumuler sur l’ADN endommagé. Cette accumulation est indépendante de la
transcription et des voies GG-NER et TC-NER. Mais, elle dépend de la région C-terminal
de la protéine MeCP2. Les futurs projets de l’équipe viseront à élucider les mécanismes
impliqués dans cette nouvelle fonction de MeCP2.
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Abstract
Rett syndrome is a severe and progressive X-linked neurodevelopmental disorder that
affects 1/10000 female birth. RTT is caused by mutations in the mecp2 gene, encoding the
Methyl CpG binding Protein 2. MeCP2 binds to methylated DNA and has several roles in:
transcription activation or repression, chromatin remodeling, alternative splicing of mRNA,
etc.
Initially, my thesis project was to explore the hypothesis that MeCP2 may be able to
transfer between cells. My results suggest that this phenomenon appears after cell fixation
with acetone and doesn’t occur in vivo. This work, however, allowed us to develop a new
staining method to detect and localize proteins in mammalian cells using the split GFP sys-
tem.
Within the frame of this project, I have also produced antibodies specific for each of
the two MeCP2 isoforms. These novel antibodies should prove to be interesting tools to
understand the role of each isoform in the pathology of Rett syndrome.
More recently, my work was focalized on the relationship between MeCP2 and DNA
damage. I was able to show that MeCP2 accumulates on DNA damage. This accumulation
is independent from transcription, GG-NER and TC-NER pathways but depend on the C-
terminal region of MeCP2. Future work will be aimed at understanding the mechanisms
involved in this newly uncovered function of MeCP2, and will hopefully improve our un-
derstanding of Rett syndrome pathogenesis.
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Résumé général des travaux de
thèse et perspectives
LE syndrome de Rett est une maladie neuro-développementale progressive conduisantà un polyhandicap lourd associé à des retards mentaux sévères. Cette maladie touche
principalement les filles avec une fréquence d’environ 1/10 000 naissances et représente la
première cause de polyhandicap dans les sociétés occidentales. Après une première année
asymptomatique, ce syndrome est caractérisé, entre autres, par l’apparition progressive de
troubles moteurs, de mouvements stéréotypés, de dysfonctionnements massifs du système
nerveux autonome, avec épilepsie, autisme et retard mental.
En 1999, l’équipe du Dr Huda Y. Zoghbi a découvert que le syndrome de Rett (RTT)
est dû à des mutations dominantes du gène mecp2, localisé sur le chromosome X. La pro-
téine MeCP2 appartient à la famille des MBP (Methyl-CpG-Binding Protein), qui sont des
répresseurs de transcription se liant à l’ADN au niveau des dinucléotides CpG méthylés. Il
existe 2 isoformes de MeCP2 (e1 et e2) issues de l’épissage alternatif d’un même ARNm ; la
forme MeCP2e1 (ou MeCP2B) est majoritaire dans le cerveau. Différentes fonctions ont été
attribuées à MeCP2 : modulateur transcriptionnel (active/réprime la transcription), épis-
sage alternatif de certains ARN messagers, maintien de l’état de méthylation des gènes au
cours de la réplication de l’ADN et modification de la structure tridimensionnelle et/ou du
niveau de compaction de la chromatine. Ces différentes fonctions peuvent expliquer les
larges variétés de symptômes observés chez les patientes atteintes du syndrome de Rett.
Au cours d’une étude, menée dans l’équipe de Dr Joly, visant à étudier la régulation,
par MeCP2, de l’expression des gènes codant pour le complexe majeur d’histocompatibilité
CMH I (cf. Appendix), l’équipe a observé que, dans des co-cultures de cellules neuronales
transfectées par une forme étiquetée de MeCP2 et des cellules non transfectées, MeCP2 fai-
sait l’objet d’un transfert intercellulaire.
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Des données préliminaires indiquent que le passage de MeCP2 est rapide: un marquage
du noyau des cellules receveuses adjacentes aux cellules donneuses est détectable après
quelques dizaines de minutes. Ce passage est également spécifique car le transfert inter-
cellulaire de MeCP2 s’opère vers d’autres cellules neuronales murines, mais pas vers des
fibroblastes murins ou humains, ni vers des cellules neuronales humaines. De plus, dans les
mêmes conditions, le répresseur transcriptionnel MBD2, qui appartient à la même famille,
n’est pas transféré.
La première partie de ma thèse (cf. Appendix et Chapitre 5) a consisté à caractériser les
mécanismes moléculaires impliqués dans ce phénomène et de caractériser la région de la
protéine qui est nécessaire à ce transfert intercellulaire.
Les résultats préliminaires de ce projet ont été obtenus en réalisant des expériences
d’immunofluorescences sur des cellules fixées. La première étape a donc été de confirmer
ces résultats sur des cellules vivantes. Pour cela, MeCP2 a été fusionnée à la protéine fluores-
cente GFP. Après des expériences de co-cultures entre des cellules exprimant MeCP2-GFP
et des cellules ne l’exprimant pas, nous n’avons pas pu observé le passage intercellulaire
de MeCP2. Ces résultats peuvent être dus à la grande taille de la GFP qui peut gêner le
transfert. Nous avons donc décidé d’utiliser le système de la split-GFP.
Le système « split-GFP » est basé sur l’auto-complémentation de deux fragments de la
GFP : un fragment de 15 acides aminés appelé GFP 11, correspondant au dernier brin β de
la GFP et le fragment complémentaire GFP 1-10 correspondant au reste de la molécule GFP.
Ces deux fragments exprimés séparément ne sont pas fluorescents ; ce n’est que lorsqu’ils
sont mis en commun qu’ils s’associent spontanément, permettant la reconstitution de la
molécule GFP et la formation du chromophore.
Il a été montré que lorsque le fragment GFP 11 est fusionné avec une autre protéine, il
est toujours capable de s’associer à GFP 1-10, et de restaurer la fluorescence GFP de façon
quantitative au nombre de molécules étiquetées avec la GFP 11.
Pour notre projet, nous avons fusionné MeCP2 au petit fragment GFP 11. Cette con-
struction a été exprimée d’une façon stable dans des cellules neuronales donneuses. Le
fragment complémentaire de la GFP (GFP 1-10) a été exprimé dans d’autres cellules neu-
ronales receveuses. Après co-culture, nous n’avons pas pu détecter l’apparition d’un signal
fluorescent dans les cellules donneuses.
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Malgré l’absence de contrôle positif lors des expériences de co-cultures cellulaires (par
exemple les protéines Engrailed -1 ou 2, fusionnées à la GFP 11, connues pour trans-
férer du noyau d’une cellule à l’autre), nous suspectons que le transfert inter-cellulaire de
MeCP2 soit dû aux étapes de fixation et de perméabilisation instantanées avec l’acétone
lors des expériences d’immunofluorescence. En effet, quand les cellules sont fixées avec le
paraformaldéhyde et perméabilisées avec le Triton X100, nous n’observons plus le transfert
de MeCP2.
Ce travail avec la split-GFP nous a permis de développer une nouvelle application à
ce système. Nous avons montré que la protéine GFP1-10 recombinante peut être utilisée
comme réactif en microscopie ou en cytométrie de flux pour détecter la présence de pro-
téines fusionnées à la GFP 11 quelque soit leur localisation dans les cellules de mammifères.
En comparaison avec les marquages avec des anticorps, cette technique s’avère être plus
rapide et plus spécifique avec un ratio signal/bruit très élevé.
La deuxième partie de ma thèse (cf. Chapitre 6) a permis de produire et de caractériser,
pour la première fois, de nouveaux anticorps capables de détecter séparément et spécifique-
ment chacune des deux isoformes de MeCP2.
Au laboratoire, nous avons montré que ces anticorps peuvent être utilisés pour
des expériences de Western blot, d’immunofluorescence, d’immunohistochime et
d’immunoprécipitation de la chromatine (ChIP).
Des expériences de western blot sur des extraits nucléaires issus de différents tissus
(cerveau, poumon, coeur, foie, thymus, rate et rein) d’une souris âgée de 3 mois ont
montré que l’isoforme MeCP2e1 est fortement exprimée dans le système nerveux central
et moyennement exprimée dans les poumons et le rein. D’autre part, des expériences
d’immunohistochimie sur des coupes de cerveau issues de cerveaux de souris âgées de 24
et de 55 jours, sauvages ou KO pour le gène mecp2, ont montré que l’isoforme MeCP2e1
est exprimée dans différentes structures du cerveau comme par exemple l’hippocampe, le
noyau paraventriculaire et le noyau arque. Dans ces deux types d’experiences, nous n’avons
pas pu détecter la présence de l’isoforme MeCP2e2 suggérant que cette isoforme n’est pas
exprimée dans l’organisme ou bien elle est exprimée à un très faible niveau non détectable
dans nos conditions expérimentales.
La troisième partie de ma thèse (cf. Chapitre 7) a consisté à étudier le rôle de MeCP2 dans
la réponse aux dommages à l’ADN. En effet, quand nous avons induit des lésions à l’ADN
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avec une micro-irradiation laser à 800 nm, nous avons observé une accumulation de MeCP2
dans la région du dommage. Nous avons aussi démontré que le recrutement de MeCP2 sur
les lésions est indépendant de la transcription, et il est indépendant des 2 voies de réparation
de l’ADN par excision des nucléotides : GG-NER et TC-NER. En revanche, nous avons
observé que la partie C-terminale de MeCP2 (après l’acide aminé 308) est nécessaire pour
ce recrutement. Cette partie de la protéine, qui est absente dans le modèle de souris de Dr.
Zoghbi présentant des symptômes du syndrome de Rett, est importante pour la liaison de
MeCP2 à l’ADN non méthylé et aux interactions protéines/ protéines.
En parallèle à ce travail nous avons pu montrer qu’en absence de la protéine CSB,
l’interaction de MeCP2 avec la chromatine est diminuée.
La protéine CSB est une protéine de 168 kDa membre de la famille des hélicases
SWI/SNF. Elle joue un rôle dans la réparation de l’ADN couplée à la transcription (TC-
NER) en interagissant avec l’ARN polymérase II bloquée sur les lésions d’ADN. De plus, il
a été montré que CSB joue un rôle dans le remodelage de la chromatine. Des mutations dans
cette protéine ont été retrouvées chez des patients atteints du syndrome de Cockayne. Ces
patients présentent un tableau de symptômes neurologiques très similaire à celui observé
pour les patientes atteintes du syndrome de Rett. Ces symptômes neurologiques pour-
raient être causés par l’impossibilité pour MeCP2 de se lier correctement à la chromatine
et d’effectuer sa fonction correctement dans le cerveau.
Il est maintenant important de comprendre le rôle de MeCP2 dans la réponse aux dom-
mages à l’ADN. Est ce que MeCP2 agit directement au niveau d’une voie de réparation ?
Est-elle capable de détecter une lésion et de recruter les protéines nécessaires pour la répa-
ration du dommage ? Peut-elle jouer un rôle dans l’architecture de la chromatine autour de
l’ADN endommagé ?
Ensuite, il est important de comprendre la relation entre MeCP2 et CSB. MeCP2 intéragit-
elle directement avec CSB ? Sinon, se trouvent-elles dans le même complexe protéique ?
La découverte de ce nouveau rôle potentiel de MeCP2 dans la réponse aux dommages à
l’ADN augmente la complexité des études réalisées sur cette protéine. Le fait que la partie
C-terminal de la protéine soit impliquée dans le recrutement de MeCP2 sur les lésions de
l’ADN et que des mutations dans cette région soient identifiées chez des patientes atteintes
du syndrome de Rett implique que ce nouveau rôle pour la protéine doit être pris en compte
dans la pathologie de Rett.
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Les résultats de notre étude sont donc importants pour le syndrome de Rett mais aussi
pour la maladie de Cockayne. À la fois ils pourraient permettre d’avancer dans la com-
préhension de ces deux maladies mais aussi de pouvoir envisager des thérapies communes,
comme la supplémentation en anti-oxidants pour les patientes Rett.
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1 Rett Syndrome
1.1 Definition
Rett syndrome (RTT, MIM 312750) is a severe postnatal progressive neurodevelopmen-
tal disorder that manifests mainly in girls during early childhood. Rett syndrome is one of
the most common causes of mental retardation in females with an incidence of 1 birth in
10000 to 20000.
This syndrome was described for the first time in 1966 by Andreas Rett, an Austrian
neurologist in Vienna. But the syndrome became internationally recognised 17 years later
when Dr. B. Hagberg, a Swedish neurologist, reported 35 cases of RTT [1, 2].
1.2 Clinical features
There is a large variability in the progression and the severity of Rett syndrome. We can
distinguish between the classical and the atypical forms of RTT.
1.2.1 The classical form
At birth, girls with the classic form of the disease have a normal head circumference, ap-
pear to develop normally until 6-18 months and achieve the expected motor skills, language
and social milestones. Nevertheless, some studies revealed subtle behavioural abnormal-
ities soon after birth. After this period, the neurological development is arrested and the
regression phase begins. This regression is commonly divided into four stages [2, 3, 4] and
(Figure 1.1):
⪧ Stage I: The stagnation period (6-18 months): In this stage, developmental progress
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is stopped and the head growth undergoes deceleration that usually leads to micro-
cephaly. Babies may show less eye contact and start to lose interest in toys. They may
also show signs of hypotonia and have delays in the acquisition of sitting, crawling or
walking.
⪧ Stage II: The regressive stage (1-4 years): Children with Rett syndrome gradually lose
the ability to speak and to use their hands purposefully. They show the classic "hand-
washing" stereotypic activity. Some children with Rett syndrome hold their breath or
hyperventilate and may scream or cry for no apparent reason. It’s often difficult for
them to move on their own. Girls show autistic features and half of them develop
seizures.
⪧ Stage III: The relative stabilization period (2-10 years): Although problems with move-
ment continue, behavior may improve. Children in this stage often cry less and become
less irritable. During this stage, the use of eye contact and hands for communication
generally improve. Many people affected by Rett syndrome remain in stage III for the
rest of their lives.
⪧ Stage IV: The late motor impairment period (10-15 years): The last stage is marked by
reduced mobility, muscle weakness and scoliosis. Understanding, communication and
hand skills generally don’t decline during this stage but repetitive hand movements
may decrease.
1.2.2 The atypical form
Five distinct categories of atypical RTT have been described on the basis of clinical crite-
ria. These variants can be either milder or more severe than the classic RTT phenotype. We
can distinguish 3 types of milder variants [2, 3, 4] and (Figure 1.1):
⪧ the ”forme fruste” where regression begins later than classic RTT (between 1 and 3
years old). In this form the hand use is sometimes preserved with minimal stereotypic
movement.
⪧ the preserved speech variant where girls can speak a few words. Patients with this
variant have a normal head size.
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Figure 1.1 — Revised diagnostic criteria for classical and variant RTT. (Figure adapted
from [2]).
⪧ the late regression variant is characterized by normal head circumference and gradual
loss of acquired speech and fine motor skills in late childhood.
And 2 types of more severe forms:
⪧ the congenital form where patients show RTT features straight from birth. In addition
to lacking the typical early normal period, they are floppy and very retarded.
⪧ the early seizure-onset variant: In this variant, the normal perinatal period is soon
followed by the appearance of seizures preceding the regression period.
1.3 Genetic origin of Rett Syndrome
Early reports suggested that RTT is an X-linked dominant disorder because of the almost
exclusive occurrence in females, the high concordance rate among monozygotic twins and
the rare familial cases with maternal inheritance.
The causes of RTT were difficult to determine because only 1 % of the RTT cases are fa-
milial (99% of RTT cases are sporadic). Genetic mapping studies on the X chromosome in
familial cases identified the Xq28 locus as the origin of RTT [5, 6]. In 1999, Huda Zoghbi’s
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group carried out systematic mutational analysis of genes located in Xq28 in patients af-
fected by the sporadic or the familial forms of RTT. They identified mutations in the MeCP2
gene encoding for the X-linked methyl CpG binding protein 2 as the causes of some cases
of RTT [7]. As many other genes located on the X chromosome, this gene undergoes X
inactivation.
1.4 RTT causing mutations
1.4.1 Mutations in MeCP2 gene
MeCP2 mutations account for up to 95% of classic RTT cases [7, 8]. Almost all muta-
tions occur de novo and they include missense, frameshift, nonsense and intragenic deletions
([9, 10] and Figure 1.2). About 70% of MeCP2 mutations are caused by a C to T transition
at 8 CpG nucleotides located in the third and the fourth exons, whereas carboxy-terminal
deletions occur in 10 to 15% of RTT patients [11].
Figure 1.2 — Summary of mutations found in coding region from exon 2 to exon 4
of MeCP2 gene: Missense mutations are shown above the genomic structure of MeCP2
whereas nonsense or frameshift mutations are shown below. Asterisks represent muta-
tions causing non-syndromic mental retardation. (Figure adapted from [10]).
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1.4.2 Mutations in other genes
Some RTT patients don’t show mutations in MeCP2 gene. It was proposed that there is at
least one other gene responsible for RTT syndrome. Two groups showed that some cases of
RTT-like phenotypes (with severe mental retardation and early seizure onset) are caused by
truncating frameshift and missense mutations in the gene coding for the cyclin-dependant
kinase-like 5 (CDKL5/ STK9) [12].
Another group reported that some mutations in the FOXG1 gene are responsible for the
congenital form of Rett syndrome, a severe variant where girls are retarded from the first
months of life. The first studies revealed deletions and nonsense mutations in this gene as
the origin of variant Rett syndrome [13, 14]. Recently a study revealed a frameshift point
mutation in a boy with the congenital variant form of Rett syndrome [15].
1.5 Genotype/Phenotype correlations
RTT patients present a large phenotypic variability associated with different MeCP2 mu-
tations. Recent genotype-phenotype studies showed that severity of RTT phenotype de-
pends on the type of the mutation, the genetic background and the X-chromosome inactiva-
tion balance.
1.5.1 Type of mutations
Patients carrying mutations that truncate the protein in the C-terminal domain (late trun-
cating mutations) present milder phenotype and are less typical of classical Rett Syndrome
than those carrying missense or early truncating mutations. Jian et al. reported in 2005 that
R270X mutation (X representing here a stop codon) is associated with elevated mortality.
Wan et al. showed that girls carrying the same mutations could sometimes present different
phenotypes. This observation is consistent with an important role for the X-chromosome
inactivation (XCI) balance [16, 11].
1.5.2 Effect of XCI
The purpose of the inactivation of one of the X chromosome is to equalize X-linked gene
products between XX females and XY males. This process occurs randomly in differenti-
MECP2 11
1Rett Syndrome
ating embryonic cells in females, resulting in cells that are mosaic with respect to which
chromosome is active.
MeCP2 gene is located on the X-chromosome and is subjected to XCI. Girls with Rett
syndrome are thus mosaic for MeCP2 mutations, meaning that, on average, half of their
cells express the wild-type MeCP2 allele and the other half express the mutated one. Some
studies reported that healthy-carrier mothers or females with less severe RTT phenotype
have a skewed XCI with inactivation of the mutated allele. This was illustrated, for ex-
ample, with a study showing monozygotic twins with R294X mutation with very different
phenotypes. While one of the twins with a severe phenotype presented a balanced XCI, the
other one showed a less severe phenotype caused by a skewed XCI towards the maternal
wild-type allele [17]. These results are, however, controversial because, in these studies, the
XCI profile was determined on peripheral lymphocytes. In fact, it was demonstrated that
the lymphocyte clone carrying the wild-type allele developed and proliferated faster than
the clones carrying the mutated allele, thus biasing the XCI skewing [18]. Studies performed
on RTT brain tissues suggest that balanced XCI patterns are prevalent [4].
1.5.3 MeCP2 Mutations in boys
At the beginning, RTT was considered to be an X-linked dominant disorder with male
lethality. In 1999, Jan et al. identified males with Rett syndrome [19]. Screening of MeCP2
mutations in males with neurological pathologies revealed that these mutations can cause
variable phenotypes such as:
⪧ Classical RTT phenotype due to somatic mosaicism for mutations in MeCP2 or in cases
of Klinefelter syndrome (XXY).
⪧ Mild to severe mental retardation: These patients carry mutations different from the
ones found in girls.
⪧ Severe neonatal encephalopathy: These patients carry the same mutations identified in
girls but the phenotype is more severe due to the presence of just one X chromosome in
males. Male patients usually die in the first two years of life [20].
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1.6 Mouse Models of Rett syndrome
To understand the molecular mechanisms implicated in RTT, different mouse models
have been generated. These mouse models mimic the clinical features observed in RTT
patients.
1.6.1 MeCP2-null mouse model
The first attempts to create MeCP2-null mice using male mouse embryonic stem (ES)
cells lacking MeCP2 were unsuccessful. Chimeric embryos exhibited high lethality. In 2001,
two groups directed by Dr Adrian Bird and Dr. Rudolph Jaenisch decided to use condi-
tional knock-out approaches based on Cre-Lox technologies. Dr. Jaenisch generated the
MeCP21lox mouse model with MeCP2 with conditionally deleted exon 3 [21] and Dr. Bird
the MeCP2tl1−1Bird with MeCP2 with conditionally deleted exons 3 and 4 [22].
MeCP2-null male mice are apparently healthy at birth until 3 to 8 weeks of age. After
this period, mice begin to show neurological symptoms like those observed in RTT patients:
stiff and uncoordinated gait, hindlimb clasping, and irregular breathing. Uneven wearing
of the teeth and misalignment of the jaws are also observed. Testes of MeCP2-null males
were always internal. Symptoms progression leads to weight loss and early death around
54 days. Brain architecture in null mice is grossly normal, although a slight decrease in the
size and weight can be noticed in comparison with wild-type littermates. This is due to
neurons compaction in hippocampus, cerebral cortex and cerebellum.
MeCP2+/− females mice are viable, fertile and grow normally until adulthood. At 3
months, they start showing hind limb clasping and by 9 months they show RTT phenotypes
such as breathing irregularity and inertia.
These results show that MeCP2-null mice can be a good model to study RTT because of
delayed onset of neurological symptoms affecting posture, gait, breathing and spontaneous
movements.
In 2006, Dr Patrick Tam generated mice with a targeted deletion of the methyl binding
domain (MBD) resulting in complete loss of MeCP2 protein. MeCP2tm1Tam phenotype is
comparable with that of the Jaenisch and Bird’s mice phenotype. In addition, at 8 to 10
weeks after birth, they display reduced level of anxiety, locomotors activity and cerebellar
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learning. In this study, authors wanted to verify if the Y chromosome has an effect on the
mouse phenotype. For this heterozygous female, called MeCP2tm1neoTam , were mated with
Paf males on a C3H/HeSNJ background. Paf (or Patchy fur) is a mutation that provokes
default in X and Y chromosome segregation during meiosis leading to a frequent loss of
the Y chromosome. Comparison between MeCP2tm1Tam 39XO females and MeCP2tm1Tam
40XY males carrying mutated X alleles and differing only by expression of Y chromosome
show similar profiles of postnatal viability and growth suggesting that Y chromosome has
no impact on MeCP2-null phenotype [23].
1.6.2 MeCP2 conditional mutants
The group of Dr Jaenisch wanted to study the effect of specific deletion of MeCP2 in the
central nervous system. MeCP2-null mice were hence crossed with transgenic mice carrying
Nestin-Cre transgene. This crossing gave birth to mice in which MeCP2 was deleted specif-
ically in neurons and glial cells. These mice displayed a phenotype similar to that observed
in MeCP2-null mice suggesting that the primary site where the lack of MeCP2 is causing the
Rett pathology is indeed in the brain. Chen et al also investigated the role of MeCP2 in post-
mitotic neurons. In order to do this, they introduced the Cam kinase Cre transgene which is
active in the excitatory neurons in the postnatal forebrain, hippocampus and brainstem. For
these conditional mutants the phenotype seemed to be less severe than null mice or Nestin-
Cre conditional mutants. CamK-Cre conditional mutants were healthy until 3 months. After
this period, they began to show symptoms including gain of body wait, ataxic gait and re-
duced nocturnal activity. The brain weight of these mice was reduced with smaller neuronal
cell bodies in cortex and hippocampus [21].
1.6.3 MeCP2 truncation
In 2002, Dr Huda Zoghbi’s group generated a mouse carrying a truncation at amino acid
308. This truncation eliminates the C-terminal region of MeCP2.
In these mice the phenotype is milder than those seen previously. MeCP2308/y are nor-
mal until 6 weeks and then they develop symptoms like tremors, kyphosis, learning and
memory deficits, social behaviour abnormalities, etc. Heterozygote females MeCP2308/+
have impaired motor features starting at 35-39 weeks after birth. As in the case of human
female patients, these mice show phenotypic variability due to the XCI. In this study, au-
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thors show that the truncated protein has a normal nuclear localization on heterochromatic
regions but histone H3 is hyperacetylated in the brain. In contrast, the acetylation level of
histone H4 was the same as the one observed in their wild-type animals [24].
1.6.4 MeCP2 transgenic mice
In 2004, Luikenhuis et al. overexpressed a MeCP2 transgene, coding for MeCP2e2, in
postmitotic neurons under the control of the Tau promoter [25]. Expression of tau-MeCP2
transgene in neurons is sufficient to rescue RTT phenotype as shown by the fact that when
this transgene is expressed in MeCP2 deficient mice, the latter show a phenotype similar
to wild-type animals. In 2007, Dr. Bird’s group created a mouse model in which MeCP2
is silenced by the insertion of a lox-stop cassette [26]. The expression of MeCP2 can be
re-activated by the addition of a transgene expressing a fusion between the Cre recombi-
nase and a modified estrogen receptor (Cre-ER). The Cre-ER fusion protein remains in the
cytoplasm until treatement with the estrogen analog tamoxifen. After treatement with ta-
moxifen, authors were able to rescue symptomatic animals suggesting that in the absence
of MeCP2, neurons do not die and the phenotype can be reversible by delayed restoration
of MeCP2 gene [26]. However, transgenic mice overexpressing MeCP2 show severe motor
dysfunction: Collins et al. generated transgenic mice overexpressing the wild-type human
MeCP2e2 protein at 2 fold the wild-type level. Early in the development, these mice show
increased learning ability and synaptic plasticity. However, after the age of 10 weeks they
developed seizures, hypoactivity and spasticity, dying by one year of age [27]
It was demonstrated that overexpression of MeCP2 in human males can cause autis-
tic features and profound mental retardation [28, 29]. All these observations indicate that
deficiency or elevated expression of MeCP2 cause neurodevelopmental disorders with a
variability of phenotypes. These observations should be considered when attempting to
develop therapies against Rett syndrome.
1.6.5 MeCP2-eGFP knock-in mice
This mouse was generated by Schmid et al. in 2007 [30]. In these mice, MeCP2 was
tagged by eGFP in frame into exon 4 just before the stop-codon. These mice are viable, fertile
and without any detectable abnormalities suggesting that MeCP2-GFP fusion is functional.
Immunofluorescence colocalisation and confocal microscopy analysis revealed that MeCP2-
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eGFP expression is restricted to the nucleus and targeted to heterochromatic regions. Results
revealed that the fusion protein is expressed in all neurons, interneuron and astrocytes at dif-
ferent levels as described in other earlier studies. Authors didn’t detect any MeCP2 expres-
sion in proliferative cells. In conclusion, this study revealed that MeCP2-eGFP expression
matches endogenous MeCP2 expression suggesting that these mice can be an important tool
to study MeCP2 expression or MeCP2 dynamics in vivo.
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2 Methyl CpG Binding Protein 2(MeCP2)
2.1 MeCP2 gene and protein
The mecp2 protein was identified and purified for the first time in 1992 in Dr Adrian Bird’s
group based on its capacity to bind methylated DNA [1].
The MeCP2 gene consists of four exons encoding for different variants of transcripts due
to differential splicing or alternative usage of the polyadenylation sites in the highly con-
served 3’-untranslated region (3’-UTR) [2, 3]. Northern blot analysis revealed the presence
of 3 transcripts of 1.8, 7.5 and 10 kb. 1.8 and 10kb are the major transcripts. They have simi-
lar half-lives but differ by their translation efficiency [2, 4, 5]. The functional significance of
these different transcripts is unknown (Figure 2.1).
In 2004, two studies revealed the presence of two isoforms of MeCP2 that differ in their
N-terminal region [6, 7]. This is due to an alternative splicing of exon 2. The first transcript
(MeCP2e1 or MeCP2α in mice or MeCP2B in human) lacks exon 2 and the initiation site is
in exon 1. The second transcript (MeCP2e2 or MeCP2β in mouse or MeCP2A in human)
contains the 4 exons and the initiation site is in exon 2 (Figure 2.1). The two splice variants
differ in translation efficiency and are expressed at different relative amounts in different
tissues. MeCP2e1 is more abundant in the brain, thymus and lung and during neuronal
differentiation.
MeCP2e1 protein (498 aa) is 12 amino acids longer than MeCP2e2 (486 aa). It contains 21
amino acids encoded by exon 1 and lacks the 9 amino acids encoded by exon 2. The major
difference between the two isoforms is the presence of a poly-alanine and a poly-glycine
repeats in the N-terminal region of the longer isoform, MeCP2e1. Both MeCP2 isoforms are
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nuclear and colocalize with methylated heterochromatic foci in mouse cells [6, 7].
Figure 2.1 — The MeCP2 gene and its splicing isoforms: Structure of the MeCP2 gene
with its four exons and the different polyadenylation sites generating transcripts of 1.8,
5, 7.2 and 10.2 Kb. The presence of the 5Kb transcript remains controversial (8). The two
main protein isoforms, MeCP2e2 (486 amino acids) and MeCP2e1 (498 amino acids) are
produced by alternative splicing of the MeCP2 transcript and differ in their N-terminal
regions which are encoded by exon 1 in the case of MeCP2e1 and exon 2 for MeP2e2.
(Figure adapted from [8]).
2.2 MeCP2 function domain
MeCP2 belongs to a family of proteins that contain a MBD domain which binds to methy-
lated DNA (Figure 2.2).
Three domains compose MeCP2: the methyl binding domain (MBD), the transcription
repression domain (TRD) and the C-terminal domain (Figure 2.1).
The MBD, an 85 amino acids domain (from amino acid 78 to 162 in MeCP2) [10], specif-
ically binds to symmetrically methylated CpG dinucleotides, with a preference for CpG
sequences with adjacent A/T-rich motifs [11]. The MBD can also bind to four-way DNA
junctions (also called Holliday junctions formed during homologous recombination) on un-
methylated DNA with the same affinity as on methylated CpG [12].
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Figure 2.2 — Characteristic domains of the methyl CpG binding (MBD) protein fam-
ily: MBD proteins display homology within their MBD domain. The family contains five
members: MBD1 and MBD2 are transcriptional repressors, MeCP2, the founding mem-
ber, plays different roles as transcription modulator or mRNA splicing factor. MBD3 is a
member of the Mi2/NuRD co-repressor complex and MBD4 is a G-T mismatch glycosy-
lase playing a role in DNA repair. (Figure adapted from [9])
The TRD, a 104 amino acids domain (from amino acid 207 to 310), is very basic containing
26% lysine and arginine. It also contains non-polar amino acids (12.5% alanine, 10.5% valine
and 8% proline) [13]. TRD is required to repress transcription by recruiting transcriptional
co-repressors such as Sin3a, c-ski, N-COR and histone deactylase complex HDAC 1 and 2
[14, 15, 16]. The TRD can repress transcription at long-range distance ranging from 500 to
1500 bp away from the promoter [13]. The TRD contains also the MeCP2 nuclear localisation
signal between amino acids 255 and 271 [17].
Although the C-terminal region is not well characterized, this region is very important
for MeCP2 function. In fact, the mouse model carrying the R308X mutation (X is a stop
codon) reproduces many features of RTT phenotype [18]. MeCP2 C-terminus presents a
WDR domain (amino acids 325 to 486) containing a poly-proline rich sequence (amino acids
376 to 405). This region can bind to splicing factors containing a group II WW domain like
the FBP11 (Formin binding protein 11) and HYPC proteins [19]. Furthermore, the C-terminal
region allows MeCP2 fixation on naked DNA and on nucleosomal cores [20, 21].
Amino acids 188-194, between the MBD and the TRD, are identical to those found within
the AT hook DNA binding domains of HMGA1 [22]. This region can bind to the xenopus
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protein p20, this interaction reduces the turnover and stabilize MeCP2 [23].
2.3 MeCP2 expression profile
Several studies, carried out in rodents [24, 25, 5], monkeys [26] and human [5], aimed to
analyse the expression profile of MeCP2. From these studies, it appears that MeCP2 is ex-
pressed in many tissues. Western blot analysis on mice tissue samples revealed that the
MeCP2 protein is not abundant in liver, stomach and small intestine, moderately expressed
in kidney and heart and highly abundant in brain, lung and spleen [5]. Within the cerebral
tissue, MeCP2 is not abundant in astrocytes [27] and immature neurons. However its ex-
pression increases to be highest in mature neurons and it is maintained high in these cells
throughout life. LaSalle et al. showed that MeCP2 expression varies between neuronal pop-
ulations from different regions and different structures within the central nervous system
(CNS) [28]. In this study, they characterised two populations of cells: The MeCP2lo cells,
expressing low levels of MeCP2, were found in the brain (glial and neuronal cells) and in
the periphery whereas the MeCP2hi cells, expressing high levels of MeCP2, were found in
a higher proportion in the layer IV of the cerebral cortex and in the molecular layer of the
cerebellum.
MeCP2 expression is regulated in a developmental stage and cell type specific manner.
Few things are known about molecular mechanisms implicated in this regulation. It was
shown that the mecp2 gene contains multiple transcription starting sites embedded in a re-
gion that is GC rich and contains CpG islands. In this study, they showed that the mouse
mecp2 promoter does not contain any canonical boxes like TATA or CAAT. They also iden-
tified a promoter region (-677/+56) that is responsible for the expression of MeCP2 in neu-
ronal cells. In this region, there is a positive regulatory element of 19 bp (-64 to +46) that
controls the major activity of the promoter region [29].
In 2006, a study focused on mapping the regulatory regions of the locus of human
MeCP2 showed that the locus is characterized by a very large intron 2 (60 Kb), a 3’- UTR
of 8,5 kb with highly conserved domains and different polyadenylation sites and a 40 kb
intergenic region separating MeCP2 from the nearest upstream gene [30]. It also identi-
fied a region supposed to be the core promoter (-179 to -309 bp upstream the initiation site)
supporting basal gene expression. Two positive regulatory elements were characterized
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(-681/-847) and (-847/-1071) as well as two negative regulatory elements (-309/-370) and
(-553/-681). In order to identify potential Cis-regulatory elements able to control spatio-
temporal expression of MeCP2, authors performed an interspecies sequence comparison
and identified four enhancers and two silencer elements in the 210 kb surrounding MeCP2
locus [30].
2.4 MeCP2 biological function
2.4.1 Transcription repression
As previously mentioned, MeCP2 contains two domains: The MBD domain that binds to
methylated DNA and a TRD domain that represses transcription by interacting with differ-
ent partners. It was shown that MeCP2 could repress transcription by different mechanisms:
2.4.1.1 Histone deactylation
Transcription can be regulated by histone modifications: histone acetylation contributes to
gene activation whereas histone deacetylation is accompanied by transcription repression.
It was shown that MeCP2 can repress transcription by deacetylating histones. In fact, the
transcription repression domain of MeCP2 interacts with the co-repressor Sin3a complex.
This complex contains the histone deacetylase complex (HDAC 1 and HDAC 2). This inter-
action leads to the chromatin remodelling and compaction causing transcription repression
[14, 16]. MeCP2 interacts also with c-ski and NCOR that are components of the HDAC
complex [15].
Uta Francke’s group analysed the histone acetylation profile in clonal lymphoblastoid
cell culture from RTT female carrying the R168X and in cells from hemizygous male carrying
the V288X mutation. Western blot analysis showed that histone H4 was hyperacetylated on
residue 16, whilst histone H3 acetylation profile was not modified [31]. In contrast, another
study done in the MeCP2308/y mice showed an elevated level of histone H3 acetylation [18].
Finally, Thatcher and Lasalle demonstrated that H3K9 acetylation (H3K9ac) shows a
dynamic developmental localization pattern coincident with MeCP2 increase. Nuclei with
mature neuronal phenotype characterized by a large euchromatic nucleus and a single large
nucleolus presented concomitantly a high level of MeCP2 and a reduced level of H3K9ac
MECP2 25
2Methyl CpG Binding Protein 2 (MeCP2)
[32].
However some studies revealed that transcription repression by MeCP2 is partially alle-
viated by treatment with Trichostatin A (TSA), an inhibitor of the histone deacetylase activ-
ity. This partial inhibition suggests that an alternative mechanism probably exists, indepen-
dent from the histone deacetylase complex, and able to repress transcription [33].
2.4.1.2 Histone methylation
MeCP2 can inhibit transcription by histone methylation. In fact, it was suggested that
methylation at lysine 9 of histone H3 (H3K9me) is associated with gene silencing. In 2003,
Fuks et al, showed that MeCP2 associates with histone H3 methyltransferase activity to in-
duce H3K9 methylation on gene H19 [34].
2.4.1.3 Chromatin Compaction and architecture
Additionally it has been found that MeCP2 binds in vitro to 12-mer nucleosomal array (12
octamers/DNA) and can induce its compaction. MeCP2 carrying the R133C mutation (af-
fecting the binding to methylated DNA) or R168X mutation lacking the C-terminal region
of the protein are unable to compact the chromatin showing that the chromatin-condensing
domain resides in the TRD and/or C-terminal regions of MeCP2 [21].
Another study showed that the C-terminal region of MeCP2 (amino acids 294 to 370 and
371 to 453) is important for chromatin compaction in a methylation-independent manner.
This compaction is due to a nucleosome-MeCP2-nucleosome interaction [21].
It was also shown that MeCP2, like H1, binds to the linker DNA very close to the DNA
entry and exit sites of the nucleosome forming a "stem"motif [35, 36, 21].
In 2005, Horike et al. showed also that MeCP2 can repress transcription of the Dlx5-Dlx6
locus by forming a silent chromatin loop [37].
2.4.1.4 Direct interaction with the transcriptional machinery
An in vitro study revealed that the TRD can interact with TFIIB and prevent the formation
of the pre-initiation complex [38].
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2.4.2 Transcription activator
In contrast to the data showing that MeCP2 is a transcription inhibitor, in 2008, Chahrour et
al. carried out a study to examine gene expression patterns in the hypothalamus of MeCP2-
null and transgenic mice. Surprisingly, in this study, authors showed that MeCP2 binds to
promoters of activated genes and associates with the transcription activator CREB1. More-
over, they showed that MeCP2 can activate the expression of the Creb1 gene. An increased
level of CREB1 induces miR132 microRNA and represses MeCP2 translation suggesting a
negative regulatory loop between MeCP2 and CREB1 [39]. These results confirm another
study, in which, by using Chip-chip analysis in SH-SY5Y cells, MeCP2 has been found as-
sociated more frequently with promoters that are also associated with RNA polymerase II
[40].
All these data suggest that MeCP2 would be a "transcriptional modulator" rather than a
repressor.
2.4.3 Alternative splicing of mRNA
By co-immunoprecipitation and mass spectrometry analysis, Young et al. characterized an
RNA dependant interaction between MeCP2 and the Y box binding protein1 (YB-1) [41]. YB-
1 is implicated in transcription and translation regulation, in DNA repair and in response to
stress. The region of MeCP2 required for this interaction is between amino acid 195 and 329.
C-terminal truncation of MeCP2 after amino acid 308 (the same as MeCP2308 mice generated
by Zoghbi’s group (cf. chapter 1 section 1.6.3)) decreases this interaction from 50 to 70% in-
dicating that sequence beyond the TRD is important for this interaction. Analysis of mRNA
splicing profile in cerebral cortex of wild-type and MeCP2308/y mice showed aberration in
alternative splicing of different genes like Dlx5 and NR1 (an NMDA receptor subunit). In-
teraction of MeCP2 with YB-1 and with FBP11 and HYPC (two others splicing factors) [19]
suggests an important role of MeCP2 in splicing regulation.
2.4.4 Maintaining of DNA methylation
In vertebrates, DNA methylation is very important to maintain the chromatin structure and
gene silencing [42]. DNA methylation occurs at position 5 of cytosine. During DNA replica-
tion, eukaryotic cells should maintain the methylation pattern along the newly synthesized
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DNA strand. This epigenetic "mark" is preserved by DNA methyltransferase 1 (DNMT1).
This protein lacks a DNA binding domain.
To understand how this enzyme is recruited to hemi-methylated DNA, Kimura and Sh-
iota carried out a study in 2003 and they revealed that MeCP2 interacts with DNMT1 via
its TRD. However, MBD deletion decreases the interaction between MeCP2 and DNMT1
suggesting that the MBD also contributes to this interaction [43].
2.5 MeCP2 mutations and other diseases
MeCP2 mutations were also found in pathologies other than Rett syndrome like:
2.5.1 The Angelman syndrome (AS)
The AS is a neuro-developmental disorder with some phenotypic similarities to RTT. It
occurs in 1:12,000 to 1:20,000 in the general population (affecting girls and boys equally). Un-
like RTT, AS is characterized by an earlier onset (like hypotonicity at birth). However, there
is no developmental regression, and purposeful hand movements are retained. Angelman
Syndrome is primarily caused by deletions, mutations or imprinting errors in UBE3A gene
on chromosome 15 coding for the ubiquitin protein ligase E3A. MeCP2 mutations causing
RTT have been diagnosed in girls and boys presenting AS features [44].
2.5.2 The severe neonatal encephalopathy (SNE)
The SNE is characterized by a static encephalopathy, seizures and respiratory abnormal-
ities. It affects boys that inherit MeCP2 mutation from their mother who present a favorable
XCI skewing towards the non-mutated allele. Frequently, these boys die at an early age.
2.5.3 The X-linked Mental retardation (XLMR)
It’s an inherited condition that causes failure to develop cognitive abilities because of
mutations or duplications of genes across the X chromosome. Couvert et al. identified
MeCP2 point mutations in up to 2% of individuals with XLMR. These mutations were not
observed in RTT patients [45]. Lugtenberg et al. also showed that duplication of the region
Xq28, including MeCP2, is identified in 1% of patients with XLMR and in 2% of patients
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with severe progressive neurological symptoms [46].
2.5.4 Autism
Autism is relatively rare in girls. Autism is characterized by severe impairments in social
interaction and communication. The onset of symptoms generally occurs around 1 to 3 years
of age and phenotypic features overlap with those of Rett syndrome.
A study identified two females with autistic disorder carrying mutations in MeCP2 gene.
The first one is a 1157del41 mutation resulting in a MeCP2 protein truncated to 389 amino
acids from the normal 486. This mutation has previously been reported in two females
with classic RTT. The second one is a nonsense mutation (R294X) which is one of the most
frequent mutations found in RTT [47, 48].
2.6 Conclusions
MeCP2 is highly abundant in mature neurons, with a number of molecules approaching
the number of histone octamers [49]. Its expression level is tightly regulated and the slightest
perturbation results in deleterious neurological consequences. This chromatin-associated
protein is widely distributed in the genome. It interacts with a high number of different
partners: proteins, chromatin, DNA and RNA, suggesting that it is a multifunctional pro-
tein, with roles in chromatin remodeling and RNA splicing. Significant progress has been
made over the last 10 years but the complex situation still remains to be clarified. Diverse
questions remained unanswered, such as: Do the two isoforms of MeCP2 exist in signifi-
cant amounts, and what are their respective roles? What is the function of MeCP2 outside
the nervous system? What are the fundamental molecular interactions between MeCP2 and
chromatin? Are there cellular functions of MeCP2 that have yet to be discovered?
To understand precisely the molecular mechanisms behind the Rett syndrome and to
consider potential treatment for the affected girls, it is important to understand the exact
function of MeCP2 in the cell.
MECP2 29
2Methyl CpG Binding Protein 2 (MeCP2)
Bibliography
[1] J. D. Lewis, R. R. Meehan, W. J. Henzel, I. Maurer-Fogy, P. Jeppesen, F. Klein, and
A. Bird. Purification, sequence, and cellular localization of a novel chromosomal pro-
tein that binds to methylated DNA. Cell, 69(6):905–14, 1992.
[2] J. F. Coy, Z. Sedlacek, D. Bachner, H. Delius, and A. Poustka. A complex pattern of evo-
lutionary conservation and alternative polyadenylation within the long 3"-untranslated
region of the methyl-CpG-binding protein 2 gene (mecp2) suggests a regulatory role in
gene expression. Hum Mol Genet, 8(7):1253–62, 1999.
[3] K. Reichwald, J. Thiesen, T. Wiehe, J. Weitzel, W. A. Poustka, A. Rosenthal, M. Platzer,
W. H. Stratling, and P. Kioschis. Comparative sequence analysis of the MeCP2-locus in
human and mouse reveals new transcribed regions. Mamm Genome, 11(3):182–90, 2000.
[4] G. J. Pelka, C. M. Watson, J. Christodoulou, and P. P. Tam. Distinct expression profiles
of MeCP2 transcripts with different lengths of 3’UTR in the brain and visceral organs
during mouse development. Genomics, 85(4):441–52, 2005.
[5] M. D. Shahbazian, B. Antalffy, D. L. Armstrong, and H. Y. Zoghbi. Insight into Rett
Syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with
neuronal maturation. Hum Mol Genet, 11(2):115–24, 2002.
[6] S. Kriaucionis and A. Bird. The major form of MeCP2 has a novel N-terminus generated
by alternative splicing. Nucleic Acids Res, 32(5):1818–23, 2004.
[7] G. N. Mnatzakanian, H. Lohi, I. Munteanu, S. E. Alfred, T. Yamada, P. J. MacLeod,
J. R. Jones, S. W. Scherer, N. C. Schanen, M. J. Friez, J. B. Vincent, and B. A. Minassian.
A previously unidentified MeCP2 open reading frame defines a new protein isoform
relevant to Rett Syndrome. Nat Genet, 36(4):339–41, 2004.
[8] T. Bienvenu and J. Chelly. Molecular genetics of Rett Syndrome: when DNA methyla-
tion goes unrecognized. Nat Rev Genet, 7(6):415–26, 2006.
[9] M. Fatemi and P. A. Wade. MBD family proteins: reading the epigenetic code. J Cell
Sci, 119(Pt 15):3033–7, 2006.
[10] X. Nan, R. R. Meehan, and A. Bird. Dissection of the methyl-CpG binding domain from
the chromosomal protein MeCP2. Nucleic Acids Res, 21(21):4886–92, 1993.
[11] R. J. Klose, S. A. Sarraf, L. Schmiedeberg, S. M. McDermott, I. Stancheva, and A. P. Bird.
DNA binding selectivity of MeCP2 due to a requirement for A/T sequences adjacent
to methyl-CpG. Mol Cell, 19(5):667–78, 2005.
[12] T. C. Galvao and J. O. Thomas. Structure-specific binding of MeCP2 to four-way junc-
tion DNA through its methyl CpG-binding domain. Nucleic Acids Res, 33(20):6603–9,
2005.
[13] X. Nan, F. J. Campoy, and A. Bird. MeCP2 is a transcriptional repressor with abundant
binding sites in genomic chromatin. Cell, 88(4):471–81, 1997.
[14] P. L. Jones, G. J. Veenstra, P. A. Wade, D. Vermaak, S. U. Kass, N. Landsberger,
J. Strouboulis, and A. P. Wolffe. Methylated DNA and MeCP2 recruit histone deacety-
lase to repress transcription. Nat Genet, 19(2):187–91, 1998.
[15] K. Kokura, S. C. Kaul, R. Wadhwa, T. Nomura, M. M. Khan, T. Shinagawa, T. Yasukawa,
C. Colmenares, and S. Ishii. The Ski protein family is required for MeCP2-mediated
transcriptional repression. J Biol Chem, 276(36):34115–21, 2001.
30 MECP2
Bibliography
2
[16] X. Nan, H. H. Ng, C. A. Johnson, C. D. Laherty, B. M. Turner, R. N. Eisenman, and
A. Bird. Transcriptional repression by the methyl-CpG-binding protein MeCP2 in-
volves a histone deacetylase complex. Nature, 393(6683):386–9, 1998.
[17] X. Nan, P. Tate, E. Li, and A. Bird. DNA methylation specifies chromosomal localization
of MeCP2. Mol Cell Biol, 16(1):414–21, 1996.
[18] M. Shahbazian, J. Young, L. Yuva-Paylor, C. Spencer, B. Antalffy, J. Noebels, D. Arm-
strong, R. Paylor, and H. Zoghbi. Mice with truncated MeCP2 recapitulate many Rett
Syndrome features and display hyperacetylation of histone H3. Neuron, 35(2):243–54,
2002.
[19] J. P. Buschdorf and W. H. Stratling. A WW domain binding region in methyl-CpG-
binding protein MeCP2: impact on Rett Syndrome. J Mol Med, 82(2):135–43, 2004.
[20] T. Nikitina, R. P. Ghosh, R. A. Horowitz-Scherer, J. C. Hansen, S. A. Grigoryev, and C. L.
Woodcock. MeCP2-chromatin interactions include the formation of chromatosome-
like structures and are altered in mutations causing Rett Syndrome. J Biol Chem,
282(38):28237–45, 2007.
[21] T. Nikitina, X. Shi, R. P. Ghosh, R. A. Horowitz-Scherer, J. C. Hansen, and C. L. Wood-
cock. Multiple modes of interaction between the methylated DNA binding protein
MeCP2 and chromatin. Mol Cell Biol, 27(3):864–77, 2007.
[22] V. H. Adams, S. J. McBryant, P. A. Wade, C. L. Woodcock, and J. C. Hansen. Intrin-
sic disorder and autonomous domain function in the multifunctional nuclear protein,
MeCP2. J Biol Chem, 282(20):15057–64, 2007.
[23] S. Carro, A. Bergo, M. Mengoni, A. Bachi, G. Badaracco, C. Kilstrup-Nielsen, and
N. Landsberger. A novel protein, Xenopus p20, influences the stability of MeCP2
through direct interaction. J Biol Chem, 279(24):25623–31, 2004.
[24] S. Cassel, M. O. Revel, C. Kelche, and J. Zwiller. Expression of the methyl-CpG-binding
protein MeCP2 in rat brain. An ontogenetic study. Neurobiol Dis, 15(2):206–11, 2004.
[25] B. C. Mullaney, M. V. Johnston, and M. E. Blue. Developmental expression of methyl-
CpG binding protein 2 is dynamically regulated in the rodent brain. Neuroscience,
123(4):939–49, 2004.
[26] S. Akbarian, R. Z. Chen, J. Gribnau, T. P. Rasmussen, H. Fong, R. Jaenisch, and E. G.
Jones. Expression pattern of the Rett Syndrome gene mecp2 in primate prefrontal cortex.
Neurobiol Dis, 8(5):784–91, 2001.
[27] I. Maezawa, S. Swanberg, D. Harvey, J. M. LaSalle, and L. W. Jin. Rett Syndrome as-
trocytes are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci,
29(16):5051–61, 2009.
[28] J. M. LaSalle, J. Goldstine, D. Balmer, and C. M. Greco. Quantitative localization of het-
erogeneous methyl-CpG-binding protein 2 (MeCP2) expression phenotypes in normal
and Rett Syndrome brain by laser scanning cytometry. HumMol Genet, 10(17):1729–40,
2001.
[29] M. Adachi, E. W. Keefer, and F. S. Jones. A segment of the Mecp2 promoter is sufficient
to drive expression in neurons. Hum Mol Genet, 14(23):3709–22, 2005.
[30] J. Liu and U. Francke. Identification of cis-regulatory elements for MeCP2 expression.
Hum Mol Genet, 15(11):1769–82, 2006.
[31] M. Wan, K. Zhao, S. S. Lee, and U. Francke. MeCP2 truncating mutations cause histone
H4 hyperacetylation in Rett Syndrome. Hum Mol Genet, 10(10):1085–92, 2001.
MECP2 31
2Methyl CpG Binding Protein 2 (MeCP2)
[32] K. N. Thatcher and J. M. LaSalle. Dynamic changes in Histone H3 lysine 9 acetylation
localization patterns during neuronal maturation require MeCP2. Epigenetics, 1(1):24–
31, 2006.
[33] F. Yu, J. Thiesen, and W. H. Stratling. Histone deacetylase-independent transcriptional
repression by methyl-CpG-binding protein 2. Nucleic Acids Res, 28(10):2201–6, 2000.
[34] F. Fuks, P. J. Hurd, D. Wolf, X. Nan, A. P. Bird, and T. Kouzarides. The methyl-CpG-
binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem,
278(6):4035–40, 2003.
[35] P. T. Georgel, R. A. Horowitz-Scherer, N. Adkins, C. L. Woodcock, P. A. Wade, and
J. C. Hansen. Chromatin compaction by human MeCP2. Assembly of novel secondary
chromatin structures in the absence of DNA methylation. J Biol Chem, 278(34):32181–8,
2003.
[36] T. Ishibashi, A. A. Thambirajah, and J. Ausio. MeCP2 preferentially binds to methylated
linker DNA in the absence of the terminal tail of histone H3 and independently of
histone acetylation. FEBS Lett, 582(7):1157–62, 2008.
[37] S. Horike, S. Cai, M. Miyano, J. F. Cheng, and T. Kohwi-Shigematsu. Loss of silent-
chromatin looping and impaired imprinting of DLX5 in Rett Syndrome. Nat Genet,
37(1):31–40, 2005.
[38] N. K. Kaludov and A. P. Wolffe. MeCP2 driven transcriptional repression in vitro:
selectivity for methylated DNA, action at a distance and contacts with the basal tran-
scription machinery. Nucleic Acids Res, 28(9):1921–8, 2000.
[39] M. Chahrour, S. Y. Jung, C. Shaw, X. Zhou, S. T. Wong, J. Qin, and H. Y. Zoghbi. MeCP2,
a key contributor to neurological disease, activates and represses transcription. Science,
320(5880):1224–9, 2008.
[40] D. H. Yasui, S. Peddada, M. C. Bieda, R. O. Vallero, A. Hogart, R. P. Nagarajan, K. N.
Thatcher, P. J. Farnham, and J. M. Lasalle. Integrated epigenomic analyses of neuronal
MeCP2 reveal a role for long-range interaction with active genes. Proc Natl Acad Sci U
S A, 104(49):19416–21, 2007.
[41] J. I. Young, E. P. Hong, J. C. Castle, J. Crespo-Barreto, A. B. Bowman, M. F. Rose,
D. Kang, R. Richman, J. M. Johnson, S. Berget, and H. Y. Zoghbi. Regulation of RNA
splicing by the methylation-dependent transcriptional repressor methyl-CpG binding
protein 2. Proc Natl Acad Sci U S A, 102(49):17551–8, 2005.
[42] T. Kouzarides. Histone methylation in transcriptional control. Curr Opin Genet Dev,
12(2):198–209, 2002.
[43] H. Kimura and K. Shiota. Methyl-CpG-binding protein, MeCP2, is a target molecule
for maintenance DNA methyltransferase, Dnmt1. J Biol Chem, 278(7):4806–12, 2003.
[44] P. Watson, G. Black, S. Ramsden, M. Barrow, M. Super, B. Kerr, and J. Clayton-Smith.
Angelman Syndrome phenotype associated with mutations in MeCP2, a gene encoding
a methyl CpG binding protein. J Med Genet, 38(4):224–8, 2001.
[45] P. Couvert, T. Bienvenu, C. Aquaviva, K. Poirier, C. Moraine, C. Gendrot, A. Verloes,
C. Andres, A. C. Le Fevre, I. Souville, J. Steffann, V. des Portes, H. H. Ropers, H. G.
Yntema, J. P. Fryns, S. Briault, J. Chelly, and B. Cherif. MeCP2 is highly mutated in
X-linked mental retardation. Hum Mol Genet, 10(9):941–6, 2001.
[46] D. Lugtenberg, T. Kleefstra, A. R. Oudakker, W. M. Nillesen, H. G. Yntema,
A. Tzschach, M. Raynaud, D. Rating, H. Journel, J. Chelly, C. Goizet, D. Lacombe, J. M.
32 MECP2
Bibliography
2
Pedespan, B. Echenne, G. Tariverdian, D. O’Rourke, M. D. King, A. Green, M. van Ko-
gelenberg, H. Van Esch, J. Gecz, B. C. Hamel, H. van Bokhoven, and A. P. de Brouwer.
Structural variation in Xq28: MeCP2 duplications in 1% of patients with unexplained
XLMR and in 2% of male patients with severe encephalopathy. Eur J Hum Genet,
17(4):444–53, 2009.
[47] R. M. Carney, C. M. Wolpert, S. A. Ravan, M. Shahbazian, A. Ashley-Koch, M. L. Cuc-
caro, J. M. Vance, and M. A. Pericak-Vance. Identification of MeCP2 mutations in a
series of females with autistic disorder. Pediatr Neurol, 28(3):205–11, 2003.
[48] J. M. Lasalle and D. H. Yasui. Evolving role of MeCP2 in Rett Syndrome and autism.
Epigenomics, 1(1):119–130, 2009.
[49] P. J. Skene, R. S. Illingworth, S. Webb, A. R. Kerr, K. D. James, D. J. Turner, R. Andrews,
and A. P. Bird. Neuronal MeCP2 is expressed at near histone-octamer levels and glob-
ally alters the chromatin state. Mol Cell, 37(4):457–68, 2010.
MECP2 33

3 Green Fluorescent protein andMicroscopy
3.1 Introduction
Visualization of proteins in cells was performed using techniques like histochemistry
and immunohistochemistry. To detect native intra-cellular proteins, monoclonal antibodies
are sometimes available. Otherwise, a large choice of epitope tags (myc, His, HA, Flag) is
nowadays available to specifically detect or isolate proteins in cells. Detection of such tags
either involves specific monoclonal antibodies directly linked to a fluorochrome, or succes-
sive steps of unlabelled antibody and fluorochrome-conjugated secondary reagents. The
major drawback of these techniques is that they need cells fixation and permeabilization,
that they can affect the behaviour of some proteins. Understanding protein dynamics and
measuring spatio-temporal modifications of protein expression and/or localization require
sensitive and quantitative tools adapted to studies in living cells. One of the most important
recent technological development in cell biology has been the use of the Green Fluorescent
Protein (GFP) isolated from the jellyfish Aequorea victoria [1]. Fusion to GFP enables direct
visualization of intracellular proteins in their biological environment without the need for
secondary reagents, cofactors or treatments of the cells.
3.2 Green Fluorescent Protein (GFP)
GFP is a 27 kDa protein (238 amino acids) [2]. It absorbs blue light with an excitation
maximum of 395 nm, with a smaller peak at 475 nm, and fluoresces with an emission max-
imum at 510 nm [3]. GFP owes its visible absorbance and fluorescence to a chromophore
formed by the cyclization and subsequent oxidation of three amino acids: Ser65, Tyr66 and
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Gly67. These posttranslational modifications are established in an autocatalytic way and
allow formation of fluorescent molecule when the protein is expressed in other species from
prokaryotes to eukaryotes [4].
The crystal structure of GFP was solved in 1996. Analysis of this structure revealed the
presence of eleven β-sheets that form a barrel with a diagonal α-helix in the inside of the
barrel. The chromophore is located in the middle of the α-helix chain [5, 6] (Figure 3.1).
Figure 3.1 — Two representations of the Green Fluorescent Protein: A) Schematic repre-
sentation and amino acid residue number, at the beginning and the end, of each of the
11 β-sheets and the α-helix constituting the GFP. B) β-barrel representation of the GFP.
The chromophore is embedded inside the barrel. Adapted from [5] and captured from
http://fr.academic.ru/pictures/frwiki/71/GFP.png
Wild-type GFP presents poor expression in certain mammalian species and low fluo-
rescence intensity when excited with the 488 nm line of an argon laser, the standard laser
used for live cell imaging studies by microscopy or by flow cytometry. Mutagenesis exper-
iments were performed on wild-type GFP and different mutants have been selected. For
example the mutant carrying a double mutation on Serine 65 (S65T) and Phenylalanine 64
(F64L) results in a 30-fold increase of fluorescence intensity over WT. The excitation max-
ima of this mutant was also red-shifted by about 100 nm, permitting efficient excitation at
488 nm (Figure 3.2) [7]. Finally the gene sequence of this mutant was re-engineered with
codons preferentially found in human proteins, providing an enhanced GFP (eGFP) that
combined increased fluorescence activity and high expression levels in mammalian cells [8].
The screen of different mutants has also lead to the identification of different colour variants
like the Blue, the Cyan and the Yellow Fluorescent Protein (BFP, CFP and YFP) [3, 5]. All
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these variants provide interesting tools to study the dynamic of particular protein in living
cells (Figure 3.2).
Figure 3.2 — Excitation and emission spectra of eGFP and its variants BFP, CFP and YFP.
Captured from http://fr.academic.ru/pictures/frwiki/71/GFP.png
3.3 Split GFP system
Sometimes, the large size of GFP may alter protein localization and behaviour, and in
some cases the permanent fluorescence of the reporter can be a hindrance to detect other
markers.
In 2005, Cabantous et al. engineered soluble, self-associating fragments of GFP that can
be used to tag and detect either soluble or insoluble proteins in living cells or cell lysates.
The split GFP system is simple and is based on the auto-assembly capacity of two non-
fluorescent portions of GFP, GFP 1-10 and GFP11, to restore a fully fluorescent GFP. The
GFP11 tag, which is only 15 amino-acids long (β-strand 11, residues 215-230), is fused to the
N or C-terminus of the coding sequence of the protein of interest, and can then be expressed
in eukaryotic cells. The GFP 1-10 detector fragment (β-strands 1-10, residues 1-214) is ex-
pressed separately. Neither fragment alone is fluorescent. When mixed, the small and the
large GFP fragments spontaneously associate, resulting in GFP folding and formation of the
fluorophore [9] (Figure 3.3).
During my thesis, I used the split GFP tagging system in which the GFP 1-10 was used
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Figure 3.3— Principle of the split GFP complementation system: the protein of interest (X)
is fused to the GFP11 fragment (β-strand 11) via a linker (L). The GFP 1-10 fragment (β-
strand 1-10) is expressed and purified separatly. When these two fragments are separated,
there is no fluorescence. On the other side, when mixed, these two fragments associate
spontaneously resulting in GFP folding and forming of the fluophore. When the GFP11 is
not accessible, due to aggregation or misfolding of protein X, the fluorescence is abolished.
Adapted from [9]
as a reagent for the detection of GFP11-tagged proteins in mammalian cells. The GFP1-10
fragment was produced separately in Escherichia coli and purified from inclusion bodies.
This new application allows fast and sensitive detection of proteins by both flow cytometry
and microscopy analysis.
3.4 Fluorescence Recovery After Photobleaching (FRAP)
Fluorescence is the process that occurs when fluorescent molecules absorb photons of
certain wavelength and, following this absorption, emit light at a higher wavelength. When
the GFP (or other fluorophores) is excited with a high intensity laser pulse, it becomes non-
fluorescent due to the limited number of excitation-emission cycles that it can undergo. This
process is called photobleaching [10]. This property allowed the development of an interest-
ing technique called Fluorescence Recovery After Photobleaching (FRAP). It is an important
technique to study the dynamic of proteins in living cells [11, 12].
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It consists on photobleaching molecules in a small area of the cell with a high intensity
laser pulse. Then the redistribution of fluorescence in the photobleached area is monitored
over time. Results will provide information on the mobility parameters of fluorescently
tagged proteins and allow the identification of possible bound or transient immobile frac-
tions.
Immediately after the bleach-pulse, the majority of the GFP will lose their fluorescence,
and we can then distinguish between three different situations (Figure 3.4):
⪧ When the GFP-tagged proteins are very mobile; the photobleached area becomes green
again rapidly after photobleaching.
⪧ In contrast, if the GFP-tagged proteins are immobile they will not diffuse back into the
bleached area and the bleached area will recover its intensity very slowly.
⪧ When a GFP-tagged protein is transiently immobile due to its interaction with other
molecules; it will result in a biphasic recovery plot. First, the plot will show a rela-
tively fast recovery of fluorescence caused by free diffusing proteins. Then the bleached
molecules that are released from their bound state will increase the fluorescence recov-
ery in the strip.
FRAP is an important tool and if combined with GFP or GFP-variants, as a fluorescent
tag, it allows the characterization and the determination of the localization, activity and the
dynamics of proteins in their biological environment: the living cell.
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Figure 3.4— Schematic representation of strip-FRAP experiments: A) The green ellipsoids
represent a cell nucleus expressing GFP. The experiment consists on defining a small strip
in the middle of the nucleus which is photobleached. Then the fluorescence recovery
is monitored along time. This results in different curves B) with multiple shapes that
characterize the mobility of each protein of interest.
40 MECP2
Bibliography
3
Bibliography
[1] O. Shimomura, F. H. Johnson, and Y. Saiga. Extraction, purification and properties of
aequorin, a bioluminescent protein from the luminous hydromedusan, Aequorea. J Cell
Comp Physiol, 59:223–39, 1962.
[2] D. C. Prasher, V. K. Eckenrode, W. W. Ward, F. G. Prendergast, and M. J. Cormier. Pri-
mary structure of the Aequorea victoria green-fluorescent protein. Gene, 111(2):229–33,
1992.
[3] R. Heim, D. C. Prasher, and R. Y. Tsien. Wavelength mutations and posttranslational
autoxidation of green fluorescent protein. Proc Natl Acad Sci U S A, 91(26):12501–4,
1994.
[4] A. B. Cubitt, R. Heim, S. R. Adams, A. E. Boyd, L. A. Gross, and R. Y. Tsien. Understand-
ing, improving and using green fluorescent proteins. Trends Biochem Sci, 20(11):448–55,
1995.
[5] M. Ormo, A. B. Cubitt, K. Kallio, L. A. Gross, R. Y. Tsien, and S. J. Remington. Crystal
structure of the Aequorea victoria green fluorescent protein. Science, 273(5280):1392–5,
1996.
[6] F. Yang, L. G. Moss, and Jr. Phillips, G. N. The molecular structure of green fluorescent
protein. Nat Biotechnol, 14(10):1246–51, 1996.
[7] B. P. Cormack, R. H. Valdivia, and S. Falkow. FACS-optimized mutants of the green
fluorescent protein (GFP). Gene, 173(1 Spec No):33–8, 1996.
[8] T. T. Yang, L. Cheng, and S. R. Kain. Optimized codon usage and chromophore mu-
tations provide enhanced sensitivity with the green fluorescent protein. Nucleic Acids
Res, 24(22):4592–3, 1996.
[9] S. Cabantous, T. C. Terwilliger, and G. S. Waldo. Protein tagging and detection with
engineered self-assembling fragments of green fluorescent protein. Nat Biotechnol,
23(1):102–7, 2005.
[10] U. Kubitscheck, O. Kuckmann, T. Kues, and R. Peters. Imaging and tracking of single
GFP molecules in solution. Biophys J, 78(4):2170–9, 2000.
[11] A. B. Houtsmuller and W. Vermeulen. Macromolecular dynamics in living cell nu-
clei revealed by fluorescence redistribution after photobleaching. Histochem Cell Biol,
115(1):13–21, 2001.
[12] E. A. Reits and J. J. Neefjes. From fixed to FRAP: measuring protein mobility and
activity in living cells. Nat Cell Biol, 3(6):E145–7, 2001.
MECP2 41

4 DNA Damage Repair
4.1 Introduction
DNA is located mostly in the nucleus of living cells. It contains all the genetic informa-
tion needed by the cell to develop and function properly. Therefore it is vital for the cell to
maintain and protect the integrity of genomic DNA. Nevertheless, cellular DNA is continu-
ously exposed to genotoxic stress producing a large variety of DNA lesions. This stress can
be caused by [1] (Figure 4.1):
⪧ Endogenous damaging sources produced by normal cellular metabolism (like reactive
oxygen species or lipid peroxidation), errors made during DNA replication or from
spontaneous hydrolysis of nucleotides resulting in the loss of bases (abasic sites) or
deamination of cytosine, 5-methylcytosine, adenine and guanine.
⪧ Environmental agents such as ionizing radiation, ultra-violet light or cigarette smoke
etc.
Many of these lesions block transcription or interfere with DNA replication. If these le-
sions remained unrepaired, they can cause mutations that enhance cancer risk or cell death.
In order to counteract the deleterious effects of DNA damage, cells developed five major re-
pair pathways that detect and repair different kinds of DNA damage. Double strand breaks
are repaired by Homologous Recombination (HR) or NonHomologous End Joining (NHEJ),
base-base mismatches and insertion/deletion mutations are repaired by Mismatch Repair
(MMR). Base Excision Repair (BER) repairs single strand breaks, oxidative or alkylating
damages. Nucleotide Excision Repair (NER), is responsible for eliminating helix distorting
lesions, bulky adducts and intra-strand crosslinks ([1, 2]).
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Figure 4.1 — DNA damage, repair mechanisms and consequences. a) DNA damages
are caused by a variety of damaging agents, that when left unrepaired, cause mutations
that can either induce cancer or accelerate ageing. To face this problem, cells developed
five major repair pathways to deal with these different lesions. b) Upon damage sensing,
cell cycle is arrested to allow the DNA repair. If the damage still remain unrepaired, cells
undergo apoptosis (Figure adapted from [1]).
4.2 DNA repair pathways
4.2.1 DNA Double Strand Breaks (DSB) repair
Around 10 DSBs are produced daily per cell. These breaks can result from either endoge-
nous sources:
1. When the replication fork encounters a damaged template.
2. When topoisomerases II accidently breaks DNA both strands.
3. During VDJ recombination.
Or exogenous sources when the cell is exposed to ionizing radiation (X-rays or gamma
rays), topoisomerase poisons and radiomimetic drugs. Cells developed two major pathways
to repair DSB: the Non Homologous End Joining (NHEJ) and the Homologous Recombina-
tion (HR) [3, 4].
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4.2.1.1 Non Homologous End Joining (NHEJ)
NHEJ is the dominant pathway to remove DSBs in higher eukaryotes. It allows the
ligation of the two ends of DSBs independently of the cell cycle because the presence of a
sister chromatid is not required [5]. NHEJ is initiated by the binding of the heterodimer
Ku70/Ku80 to the broken ends followed by the recruitment of DNA-PKcs (DNA dependant
protein kinase catalytic subunit) and Artemis [6, 7]. Artemis-DNA-PKcs complex is able to
cut DNA overhangs in the region of DSBs [8]. This allows the recruitment of XRCC4 and
the DNA ligase IV complex that carry out the ligation step to complete repair. This step
is stimulated by the XLF protein (also called Cernunnos) that stabilizes the XRCC4/DNA
ligase IV complex on the DSB site [9, 10, 4] and (Figure 4.2).
NHEJ is considered as an error-prone mechanism because the Artemis-DNA-PKcs com-
plex is required to process DNA ends before ligation causing loss of some genetic material.
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Figure 4.2 — Schematic representation of the Non Homologous End Joining pathway.
DNA double strand breaks are recognised by Ku proteins that recruit DNA-PKcs followed
by Artemis that allowed DNA overhangs resection. The ligation step is performed by the
DNA ligase IV associated to XRCC4 and XLF. (Figure adapted from ([11])).
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4.2.1.2 Homologous Recombination (HR)
Another mechanism involved in the repair of DSBs is the Homologous Recombination
(HR). HR is an error-free repair mechanisms that occurs dominantly in S and G2 phases
because it requires the presence of a homologous template such as the sister chromatid
([5, 12])). In HR (Figure 4.3), broken ends are recognized by the Mre11-Rad50-NBS1 (MRN)
complex which can activate and recruit ATM (via its direct interaction with Nbs1), a protein
kinase that phosphorylate numerous substrates in the DNA damage response, including hi-
stone H2AX (an early marker of DSB formation) ([13, 14]). MRN complex carries also a 5’-3’
exonuclease activity creating free 3’-ends on both sides of the break [15]. The newly synthe-
sized 3’ overhangs ends are stabilized by RPA and, in cooperation with RAD52, BRCA1 and
BRCA2, it allows the recruitment of RAD51 to form the nucleoprotein filament. The RAD51
filament (with RAD52 and RAD54) is required to find homologous sequences like the neigh-
bouring intact sister chromatid. Strand invasion into a homologous sequence forms a D-loop
intermediate and allow the 3’-end to be extended by polymerase. Intersection between DNA
strands, also called Holliday junction, are resolved by resolvases like BLM-topoisomerase III
complex, MUS81-EME1 complex or GEN1 ([1, 16]).
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Figure 4.3 — Schematic representation of the Homologous Recombination pathway. a)
DNA double strand breaks are recognized by the MRN complex (Mre11-Rad50-NBS11)
which generates single strand DNA by resection. Single strand ends are protected by RPA.
RAD52 and RAD51 are then required to find homologous sequences (Figure adapted from
[17]).
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4.2.2 Mismatch repair (MMR)
MMR corrects base-base mismatches and insertion/deletion (ID) mispairs generated
during DNA replication and/or recombination [1].
In higher eukaryotes, repair of base-base mismatches or IDs of 1 to 2 nucleotides are ini-
tiated by MutSα (composed by MSH2 and MSH6) whereas the repair of larger ID is prefer-
entially initiated by MutSβ (composed by MSH2 and MSH3) ([18, 19]). MutSα moves along
the DNA and after the detection of a mismatch, it recruits MutLα (composed by hMLH1
and hPMS2). MutSα- MutLα dissociates from the mismatch and translocate along the DNA
to encounter a DNA strand break bound by PCNA in 3’ and by RFC in 5’. If the complex
moves upstream (Figure 4.4a), it encounters RFC, displaces it and recruits EXO1 that de-
grades DNA from 5’ to 3’. Complex that migrates downstream (Figure 4.4b), encounters
PCNA. The RFC molecule at 5’ extremity would not be displaced preventing degradation
of the 5’ to 3’ strand. The degradation occurs from 3’ to 5’ towards the mismatch. In both
cases, single strand DNA is protected by RPA and the gap is filled by DNA pol δ. Finally,
the remaining nick is ligated by the DNA ligase I [16].
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Figure 4.4 — Schematic representation of the Mismatch Repair pathway. DNA dam-
age is recognized by MutSα. MutLα is then recruited followed by the exonuclease EXO1
which degrades DNA to eliminate the mismatch. Gap is filled by the DNA polymerase
δ bound to PCNA. The last step is the ligation by the DNA ligase I (Figure adapted from
[16]).
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4.2.3 Base Excision Repair (BER)
BER is required to correct lesions caused by oxidative, alkylation, deamination, depuri-
nation or depyrimidation damages. These lesions cause base modifications that can in-
duce the incorporation of an incorrect base by DNA polymerase during replication caus-
ing mutations. The first step in BER consists of lesion recognition by a DNA glycosylase,
which removes the damaged base by cleaving the N-glycosidic bond and generating an
apurinic/apyrimidic site (AP). This site is recognized and cut by the endonuclease APE1
which creates a single strand break (or a gap). After this step, two sub-pathways exist that
carry on the repair ([20, 21, 22], Figure 4.5):
1. The short-patch BER: in this pathway, the DNA polymerase β fills the single nucleotide
gap and removes the sugar moiety remaining after incision by APE1, the nick is sealed
by the DNA ligase III and XRCC1 complex.
2. The long-patch BER: in this pathway, the gap is recognized by PCNA and DNA poly-
merase δ/e which fill the gap by synthesizing multiple nucleotides (2-20 bases). The
DNA flap is removed by the endonuclease FEN1 and the nick is sealed by the DNA
ligase I. Additionally, when BER is initiated by a single strand breaks on DNA caused
by irradiation or incomplete topoisomerase action, the lesion is recognized by PARP1.
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Figure 4.5 — Schematic representation of the Base Excision Repair pathway. In BER;
damage is recognized by DNA glycosylase and APE1 in the case of base modifications
and by XRCC1, PARP and PNK when the damage is a single strand break. Thereafter,
there are two pathways: the Short-patch BER (at the left) that requires DNA pol β XRCC1
and DNA ligase 3 to perform a one-nucleotide gap-filling reaction. Or the Long-patch
BER (at the right) involving by PCNA, DNA pol δ/e FEN1 and the DNA ligase I to fill the
gap with multiple nucleotides (2-20 bases) (Figure adapted from [1]).
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4.2.4 Nucleotide Excision Repair (NER)
The NER pathway is specifically responsible for recognition and elimination of lesions
that cause distortion to the DNA structure such as pyrimidine (6-4) pyrimidone Photo-
Products (6-4PPs) and cyclobutane pyrimidine dimers (CPDs) [23]. NER is divided in two
sub-pathways depending on the localization of the damage and the damage detection step
([24, 25], Figure 4.6):
⪧ Global genome repair (GGR) pathway repairs damages located on untranscribed region
of active genes or unexpressed regions of the genome. In this pathway, the lesion is
detected by the binding of XPC-HRad23-centrin2 complex.
⪧ Transcription coupled repair (TCR) pathway repairs lesions located in an active tran-
scribed region. In this case, lesion detection is initiated by the stalling of the RNA
polymerase II elongation complex. Two TCR-specific factors: CSB and CSA participate
in coordinating the pre-incision and the post-incision reactions.
After the recognition step, TCR and GGR funnel into a common mechanismin which
TFIIH complex is recruited to the lesion site. TFIIH is a basal transcription factor that is able
to open up a region of approximately 20 nucleotides around the lesion thanks to the helicase
activities of its two subunits XPB and XPD. Subsequently, XPA and RPA are recruited to
the site of damage to stabilize the open intermediates and protect the single strand DNA.
Then, the two nucleases XPG and XPF (associated to ERCC1) excise the damaged strand
respectively in 3’ and 5’.
At the end, the gap is filled by DNA polymerase δ/e and the remaining nick is sealed
by the DNA ligase I or the DNA ligase III [26].
Defect in NER pathways is manifested by rare autosomal recessive human disorders
all charachterized by sun sensitivity such as Xeroderma pigmentosum (XP), trichothiodys-
trophy (TTD) and Cockayne syndrome (CS). While XP patients have more than 1000-fold
increase in susceptibility to skin cancer; TTD and CS patients have normal skin cancer risk
[27].
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Figure 4.6 — Schematic representation of the Nucleotide Excision Repair pathway. He-
lix distorting lesions are detected by XPC-HR23B complex in Global Genome Repair
(GGR) or by RNA pol II elongation complex blocked at the damage in Transcription Cou-
pled Repair (TCR). After DNA damage recognition, TFIIH complex is recruited to open
the helix of DNA. The endonucleases XPG and XPF/ERCC1 excise the damaged strand.
Finally, the replication machinery performs gap-filling DNA synthesis and the nick is
sealed (Figure adapted from [28])
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4.2.4.1 Xeroderma pigmentosum (XP)
Mutations in either one of the seven different genes encoding for XPA to XPG cause Xe-
roderma pigmentosum (XP). XP patients present burns or freckles-like pigmentation on skin
regions exposed to the sun. They develop skin cancer at a mean age of less than 10 years
old [29, 30] (29). In addition to skin abnormalities, about 30% of XP patients exhibit pro-
gressive neurological degeneration characterized by symptoms that include microcephaly,
ataxia, mental retardation, reduced tendon reflexes, hearing loss, deafness and swallowing
difficulties, etc. [31]
4.2.4.2 Trichothiodystrophy (TTD)
TTD patients are characterized by sulfur-deficient brittle hair and ichthyosis. Clinical
features of this syndrome vary between patients from mild cases, with only hair problems to
severe cases presenting growth retardation, microcephaly, intellectual impairement, skeletal
abnormalities and decreased fertility. Although some TTD patients show photosensitivity,
they do not have cutaneous lesions and skin cancer predisposition [27].
4.2.4.3 Cockayne Syndrome (CS)
Mutations in CSA or CSB genes, disrupting TCR pathway, give rise to the severe Cock-
ayne Syndrome. CS patients appear normal at birth and then suffer from severe neurological
problems like neurodemyelinnation, mental retardation, and hearing loss. In addition, they
present developmental pathologies like growth failure, microcephaly. Unlike XP and TTD
patients, they show immature sexual development. They are sun sensitive but do not have
the pigmentary changes or increased skin cancer frequencies seen in XP. The average life
span of CS patients is 12,5 years and the main causes of death are pneumonia and respi-
ratory infections which could well be due to the generally poor condition of the patients
[27, 32].
A mouse model for CS-B was generated by mimicking a mutation found in a CSB patient
(CS1AN mutation: Lys337 stop), resulting in a truncated form of the protein [33]. This
modification of the CSB gene is analogous to the mutation found in CS1AN CSB-deficient
human fibroblasts. CSB−/− mice show similar repair features as CS patients.
The Cockayne Syndrome B (CS-B) gene encodes for a 168 kDa protein and is a mem-
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ber of the SWI/SNF family of putative helicases [34]. This family of proteins is involved in
transcription, chromatin remodeling, DNA repair and translesion synthesis processes. CSB
protein contains an Snf2-like helicase domain, an acidic stretch (aa 356-394), a glycin-rich
region (aa442-446) and a nuclear localization signal (aa446-481). In addition, two putative
casein kinase II phosphorylation sites are found close to the NLS motif [34]. CSB displays
DNA-dependant ATPase and DNA binding activities, but not a helicase activity [35]. Be-
sides its role in TC-NER, CSB is implicated in RNA Polymerases I, II and III transcription.
It can act as a chromatin remodeling factor and can interact with core histones, inducing
negative supercoiling [35]. CSB cells have been shown to be sensitive to genotoxic agents
such as IR and Paraquat that give rise to oxidative damage suggesting a role for CSB in the
removal of this kind of lesions [36]. Taken together, CSB represents a versatile protein with
many different functions involved in a diversity of distinct and overlapping processes.
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In 1999 Huda Zoghbi’s group identified different mutations in the Mecp2 gene as the
origin of Rett syndrome. To understand this pathology, it was essential to identify and char-
acterize the function of the protein. Early studies revealed that MeCP2 is a transcriptional
repressor due to its capacity to bind to CpG methylated DNA and to compact the chro-
matin, thus preventing recruitment of the transcription machinery. These results suggest
that pathologies associated with mecp2 mutations are due to the misregulation of neuronal
genes. That’s why different groups tried to identify MeCP2 target genes.
In the laboratory, the group was interested to explore the hypothesis that genes encoding
for the Major Histocompatibilty Complex class I molecules (MHC I) are regulated by MeCP2
in the central nervous system (CNS). This hypothesis stemmed from the report by the group
of Carla Shatz that MHC I molecules are important for the activity-dependant synaptic re-
arrangements that occur during normal brain development [1]. Furthermore, these genes
have a particularly high GC content and they are expressed during the post-natal develop-
ment and are repressed in adult brain except in response to cytokines or injuries. For all
these reasons, it was tempting to think that mecp2 mutations could induce misregulations of
CMH I genes that would provoke abnormal neuronal connection in the brain giving rise to
neurodevelopmental disorders of RTT [2, 1, 3].
Although initial results showed that overexpression of either of the two isoforms of
MeCP2 by transient transfection of neuronal and fibroblastic cell lines resulted in reduced
levels of MHC class I and β2-microglobulin at the cell surface, the same results were ob-
tained after overexpression of mutated MeCP2 proteins, carrying mutations in the MBD do-
main (R133C and T158M) and in the TRD domain (R306C and the truncated form R308X).
These mutations, however, do not affect the capacity of MeCP2 to condense chromatin by
binding to linker DNA and bringing nucleosome together in a ”stem” conformation through
DNA-protein interactions. A possible interpretation of these results was thus that effects of
MeCP2 on MHC class I are independent from the methylation status of the genes’ promoters
but could involve conformational changes in chromatin preventing the access of transcrip-
tional machinery. These data suggest also that repression of MHC class I expression by the
over-expression of MeCP2 in cells cultured in vitro is not relevant for the pathogenesis of
RTT, at least for the mutations tested in this study (Cf Appendix).
During this work, Julie Miralvès used fluorescence microscopy to verify the localization
of MeCP2 in murine neuroblastoma (N2A) cells overexpressing the wild-type and the mu-
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tated forms of the protein. After immunofluorescence staining against MeCP2, she noticed
that very bright cells (expressing a high level of MeCP2) were surrounded by cells express-
ing a lower level of MeCP2, with this level decreasing progressively with the distance from
the brightest cell. This observation suggested that, either expression of MeCP2 in transfected
cell resulted in the activation of endogenous gene in neighbouring cells or MeCP2 protein
was able to transfer from the transfected cell to the adjacent ones, similarly to what has been
previously described for the homeoproteins [4].
To discriminate between these two mechanisms, she tagged the human MeCP2 protein
by a myc epitope recognized by the 9E10 monoclonal antibody. These constructs were trans-
fected in N2A cells. She then labelled transfected cells with CMTMR and co-cultivated them
with unlabelled and untransfected N2A cells. After immunostaining experiments against
myc epitope, she noticed that nuclei of untransfected cells inherited myc-tagged MeCP2
from neighbouring cells expressing a high level of MeCP2 and this could be detected as
early as 1h after co-culture. These results suggested that MeCP2 could have the capacity to
transfer from cell to cell. She noticed also that mouse fibroblastic cell lines (such as MC57
and L cells) failed to transmit MeCP2 to adjacent neighbouring cells.
Preliminary experiments allowed the goup to suggest that MeCP2 can have the capacity
to transfer between the nucleus of adjacent cells and this phenomenon is specific to neuronal
cells.
Initially, the main direction of my PhD project was to identify the mechanism responsible
for this inter-neuronal transfer and to characterize the portion of the MeCP2 protein required
for this function.
Before my arrival, all experiments were performed by immunostaining on fixed cell.
To verify if this mechanism occurred in living cells, we tagged MeCP2 with GFP but we
were unable to detect the intercellular transfer. The problem can arise from the size of the
GFP which can block the mechanism of transfer. To overcome this problem, we decided
to use the split GFP complementation system: when separated these two parts of the GFP
are not fluorescent but when together, they can assemble spontaneously to regenerate a
fluorescent protein. We thus tagged MeCP2 with GFP11, the small peptide of 15 amino
acids corresponding to the β-strand 11 of the GFP. This construct was stably expressed in
"donor" cells, and the other part of the GFP (GFP1-10) was stably expressed in "receiver"
cells, co-culture experiments did not reveal any increase in fluorescence, which led us to
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suspect that there may not be a transfer of MeCP2 between living cells.
Although we did not have a positive control in our experiments, such as a GFP11-tagged
homeoprotein (like Engrailed-1 or 2) which is a nuclear protein like MeCP2 that has been
characterised as having the capacity to pass from cell to cell, we have come to suspect that
the inter-cellular transfer of MeCP2 we were seeing may be related to the protocol of acetone
fixation which was being used. Indeed, when the cells were treated with formaldehyde
before the acetone treatment, there was no longer any detectable transfer. We thus envisage
that in cells expressing high levels of MeCP2, some molecules are not irreversibly fixed by
the acetone treatment and can thus go back into in solution. Since these molecules have
a strong affinity for chromatin, they would be recruited to the chromatin of neighbouring
nuclei, but their transfer would have taken place after fixation, and not between living cells.
Working with split GFP, we also developed a new application for this system, whereby
recombinant GFP1-10 is used as a staining reagent. This enables us to detect GFP11-tagged
proteins by microscopy and flow cytometry in the mammalian cells via a one-step assay
which allows detection of protein with high specificity and with very low background of
fluorescence in comparison with antibodies.
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5.1 Abstract
Although epitope tags are useful to detect intracellular proteins and follow their localiza-
tion with antibodies, background and nonspecific staining often remain problematic. We de-
scribe a simple assay based on the split GFP complementation system. Proteins tagged with
the 15-amino acid GFP 11 fragment are detected with a solution of the recombinant nonflu-
orescent complementary GFP 1-10 fragment to reconstitute a fluorescent GFP. In contrast to
antibody-based staining methods, this one-step assay presents high specificity and very low
background of fluorescence, thus conferring higher signal-to-noise ratios. We demonstrate
that this new application of the split GFP tagging system facilitates detection of proteins
displaying various subcellular localizations using flow cytometry and microscopy analysis.
5.2 Introduction
Understanding protein dynamics in living cells requires sensitive and quantitative tools
for measuring spatiotemporal modifications of protein expression and/or localization. Fu-
sion to green fluorescent protein (GFP) or its derivatives enables direct visualization of intra-
cellular proteins without the need for secondary reagents or treatment of the cell [1]. How-
ever, the large size of GFP may alter protein localization and behavior [2], and the permanent
fluorescence of the reporter can be a hindrance to detect other markers. To detect native in-
tracellular proteins, monoclonal or polyclonal antibodies are sometimes available, but they
need to recognize an epitope conserved after fixation. Alternatively, various epitope tags
(myc, His, HA, Flag) have been developed to specifically detect or isolate proteins in cells
[3]. Detection of such tags either involves specific monoclonal antibodies directly linked
to a fluorochrome or successive steps of unlabeled antibody and fluorochrome-conjugated
secondary reagents [4]. Such protocols are often time-consuming, as they require several
washing steps to remove all unbound reagents between binding reactions. Moreover, low
signal-to-noise ratios are often observed, due to the presence of nonspecifically bound anti-
bodies, especially for polyclonal antibodies, or due to endogenous expression of the epitope
in the parent cell [5].
As a possible alternative, we have investigated whether we could use the split GFP
tagging system for the intracellular detection of proteins [6], which is based on the auto-
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assembly capacity of two nonfluorescent portions of GFP-GFP 1-10 and GFP 11-to restore a
fully fluorescent GFP. The GFP 11 tag, which is only 15 amino acids long, is fused to the N
or C terminus of the coding sequence of the protein of interest and can then be expressed
in eukaryotic cells. The GFP 1-10 detector fragment is produced separately in Escherichia
coli and purified from inclusion bodies as previously described [7]. After fixation and per-
meabilization of cells expressing the GFP 11-tagged protein, the refolded GFP 1-10 protein
is added in trans, allowing the two split GFP fragments to associate spontaneously and re-
store the GFP fluorescence (Figure 5.1A). Here, we describe the application of the split GFP
protein complementation assay for detecting GFP 11-tagged proteins in mammalian cells
relative to antibody staining using FACS and microscopy analysis.
5.3 Materials and methods
5.3.1 Plasmids
pcDNA 3.1 vector expressing human MeCP2e1-Myc-His was provided by Dr. Berge A.
Minassian of the Hospital for Sick Children, Toronto, Ontario, Canada [8]. For FK506 bind-
ing protein 12 and MeCP2e1, the respective coding sequences were inserted at the N termi-
nus of GFP 11, in a vector derived from pEGFP_N3 (Clontech Laboratories, Saint-Germain-
en-Laye, France) (see sequence of the mammalian GFP 11 cassette below). To generate GFP
11-H-Ras, full-length GFP was replaced by the 15-amino acid mammalian GFP 11 peptide
(GFP11m) in the pEGFP-H-Ras plasmid kindly provided by J. Lippincot-Schwartz [9].
5.3.2 DNA sequence of the GFP11m vector cassette
5.3.2.1 GFP11m N-terminal fusion
5’ATGGGCCGGGACCACATGGTGCTGCACGAGTACGTGAACGCCGCCGGCAT
CACAGACGGCGGCAGCGGCGGCGGCAGC-3’.
5.3.2.2 GFP11m C-terminal fusion
5’GGCGACGGCGGCAGCGGCGGCGGCAGCCGGGACCACATGGTGCTGCACGA
GTACGTGAACGCCGCCGGCATCACATAA-3’.
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5.3.2.3 Recombinant GFP 1-10
Expression of GFP 1-10 detection reagent was performed in E. coli BL21 (DE3). Recom-
binant protein was purified from inclusion bodies as described previously [7]. For each set
of assays, 37.5 mg purified inclusion bodies were used to prepare 15 mL GFP 1-10 solution
(2.5 mg/mL) in 50 mM Tris, pH 7.4, 0.1 M NaCl, 10% glycerol (TNG).
5.3.3 Cell culture
Neuro2A (N2A) cells were maintained in DMEM supplemented with 10% FCS, 100
U/mL penicillin, 100 µg/mL streptomycin, 10 mM HEPES, 0.1 mM nonessential amino
acids, and 1 mM sodium pyruvate. Human embryonic kidney (HEK) 293 cells were grown
in RPMI-1640 medium supplemented with 10% FCS, 100 U/mL penicillin, 100 µg/mL strep-
tomycin, and 2 mM L-glutamine.
5.3.4 Transfection
Transfections were carried out using JetPEI (Polyplus Transfection, Illkirch, France) fol-
lowing the manufacturer’s instructions. Depending on the resistance gene carried by the
plasmid vector, stable clones were selected with either 500 µg /mL G418 (Invitrogen, Cergy
Pontoise, France) or 125 µg/mL Zeocin (InvivoGen, Toulouse, France) and thereafter main-
tained at these concentrations. Monoclonal cell lines were obtained by single cell dilution
in 96-well plates. Cells used as negative control were untransfected, and were thereby not
cultured in the presence of selecting drugs.
5.3.5 Antibodies
5.3.5.1 Primary antibodies
Rabbit polyclonal anti-MeCP2 antibody (crude serum) was generated after immuniza-
tion of a rabbit with a synthetic peptide corresponding to amino acids 465-478 of mouse
MeCP2 (C-PRPNREEPVDSRTP; performed by Millegen, Labège, France). Mouse anti-Myc
IgG1 antibody was purified with protein A beads (Pierce, Thermo Scientific, Brebières,
France) from clone 9E10 hybridoma supernatants (purchased from ATCC, Manassas, VA,
USA). Rat monoclonal anti-H-Ras antibody was purchased from Santa Cruz Biotechnology
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(Cat. no. sc-35; Santa Cruz, CA, USA).
5.3.5.2 Secondary antibodies
Alexa Fluor 488-conjugated goat anti-rabbit, Alexa Fluor 647-conjugated goat anti-rabbit,
rhodamine-conjugated goat anti-rabbit, Alexa Fluor 488-conjugated goat anti-mouse, Alexa
Fluor 647-conjugated goat anti-rat, and rhodamine-conjugated goat anti-rat were obtained
from Molecular Probes, Invitrogen.
5.3.6 Flow cytometry analysis
For each condition, 2×105 cells were trypsinized, washed three times with PBS, then
fixed with 4% paraformaldehyde for 10 min at 4°C. After two washes with PBS, cells were
permeabilized in 0.1% Triton-X 100 in PBS for 10 min at 4°C. Cells were then washed twice
with 2% FCS PBS before incubation with the primary antibody (rabbit anti-MeCP2 serum,
dilution 1/300, or mouse anti-Myc, dilution 1/300, home-purified solution at 4 mg/mL,
or rat anti-H-Ras, dilution 1/200) for 45 min at 4°C (dilution in 2% FCS PBS). After three
washes with 2% FCS PBS, cells were incubated with secondary antibody (dilution 1/200)
for 30 min at 4°C. Cells were washed again three times with 2% FCS PBS buffer and then
analyzed using a FACS Calibur cytometer and CellQuest software (BD Biosciences, Le Pont
de Claix, France).
For GFP 1-10 detection, the recombinant protein solution was diluted to 0.15 mg/mL in
2% FCS PBS and directly added to the fixed/permeabilized cells. After incubation at room
temperature (RT) for 3 h, fluorescence was analyzed using a FACScalibur flow cytometer.
For double staining, cells were labeled with GFP 1-10 for 3 h at RT, washed twice with 2%
FCS PBS buffer, and then incubated with the appropriate antibodies.
5.3.7 Immunofluorescence staining and microscopy
N2A cells (1 × 105 cells per well) or HEK 293 cells (1 × 105 cells per well) stably express-
ing MeCP2, FKBP, or H-Ras tagged with either GFP 11 or GFP were plated overnight on
glass coverslips in 24-well plates. Cells were washed twice with PBS and fixed with 3.7%
paraformaldehyde (PFA) in PBS for 30 min at RT. After two washes with PBS, cells were
permeabilized in 0.3% Triton-X 100 for 10 min at RT. For GFP fusions, cells were washed
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twice with 2% FCS PBS, and after a final wash with PBS, coverslips were mounted in 4’,6’-
diamidino-2-phenylindole (DAPI)-containing ProLong Gold antifading reagent (Molecular
Probes, Invitrogen). For GFP 1-10 detection, GFP 11-expressing cells were incubated for 3
h at RT with GFP 1-10 protein solution diluted to 0.15 mg/mL in 2% FCS PBS. Cells were
washed with PBS and mounted in DAPI-containing ProLong Gold antifading reagent. For
double staining, cells were labeled with GFP 1-10, washed twice with 2% FCS PBS and then
incubated with primary antibody (rabbit anti-MeCP2 diluted to 1/300 and rat anti-H-R as
diluted to 1/200) for 1h at RT. After three washes with 2% FCS PBS, cells were incubated
with secondary antibodies (anti-rabbit IgG, rhodamine, and anti-rat IgG, rhodamine, di-
luted to 1/400) for 1 h at RT. Cells were washed with PBS and mounted in DAPI-containing
ProLong Gold antifading reagent. We used a DM-RB fluorescence microscope (Leica, Nan-
terre, France) with a 40× and 100× oil immersion objective to visualize the stained cells.
Images were acquired with a CoolSNAP HQ camera (Photometrics, Roper Scientific, Evry,
France) and analyzed with MetaMorph (Molecular Devices, Sunnyvale, CA, USA) or ImageJ
(http://rsbweb.nih.gov/ij).
5.3.8 Microplate assay
Cells (5× 106) were trypsinized and washed three times with PBS. The cell pellet was
flash-frozen in liquid nitrogen. The frozen pellet was resuspended in 40 µL extraction buffer
(25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 20 mM HEPES, pH 7.9, 0.5 mM
DTT).In a 96-well fluorescence plate, 50 µL total cell extracts were serial diluted in 100 µL
final volume of TNG buffer. These dilutions (50 µL) were mixed with 100 µL 0.3 mg/mL
GFP 1-10 protein solution. The plate was incubated overnight at 4°C. Fluorescence was
measured using a FLx800 Fluorescence Microplate Reader (BioTek, Colmar, France). For
titration curves, starting concentrations of GFP 11 peptide (0.03 mg/mL) were used and
diluted serially in 50 µL TNG buffer.
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5.4 Results and discussion
5.4.1 Characterization of the GFP 1-10 staining assay for FACS
We initially developed this method for the detection of the nuclear methyl-CpG binding
protein 2 (hMeCP2e1) in mammalian cells [8]. The results shown in Figures 5.1 and 5.2 were
obtained with a monoclonal cell line that expresses homogenous levels of MeCP2-GFP 11,
as detected with an anti-MeCP2 polyclonal antibody. Cells in suspension were fixed in 4%
PFA, permeabilized with 0.1% Triton, and then incubated in a solution of 0.3 mg/mL GFP
1-10 protein at 4°, 20°, and 37°C. Fluorescence increase was followed by flow cytometry
(FACS) at different time intervals for 24h. Kinetic plots demonstrated a first order reaction
with temperature-dependent rates (Figure 5.1B). A slower kinetic of complementation was
observed at 4°C, reaching a plateau after overnight incubation (Figure 5.1B and Figure 5.5).
At 37°C, a faster reaction rate was observed, but final fluorescence value was considerably
reduced, probably because of unfolding of the renatured GFP 1-10 protein. Our optimal con-
dition was obtained at RT, in which maximum fluorescence was reached after 12h, similarly
to what had been observed previously in E. coli [6]. Background fluorescence, determined
by incubating nontransfected N2A cells with GFP 1-10 was very low, but increased slightly
over time, and the best signal-to-noise ratios, in excess of 130, were thus attained after 3-4h
of staining (Figure 5.5).
5.4.2 Sensitivity of the GFP 1-10 staining in microplate assay
To evaluate the sensitivity of the split GFP assay with eukaryotic cell extracts, we per-
formed the complementation in 96-well plates. N2A cells (6× 106) expressing MeCP2-GFP
11 were used to obtain a final volume of 100 µL total cell extract. Serial 2-fold dilutions
of the sample were performed in 50 µL TNG buffer and then incubated with GFP 1-10 at
4°C. Fluorescence was measured on a microplate reader after overnight incubation. As a
control, cell extract from N2A cells was also measured in the same dilution range and was
substracted from the signal. As observed previously with bacterially produced proteins [7],
sensitivity plots showed an excellent linear relationship between fluorescence and protein
quantity (Figure 5.1C, left). To evaluate protein concentration of MeCP2-GFP 11, a standard
titration curve was performed using GFP 11 peptide (Figure 5.1C, right). From this, we eval-
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Figure 5.1 — Characterization of the GFP 1-10 in vitro assay in mammalian cells. (A)
Cells expressing GFP 11-tagged protein are fixed and permeabilized. Reconstituted GFP
1-10 protein solution is added and incubated at RT for 3 h. Fluorescence is measured and
compared with control cells. (B) Kinetic profiles of complementation reaction of N2A-
MeCP2-GFP 11 cells incubated with GFP 1-10 at three temperatures: 4°C (●), 20°C (∎),
and 37°C (▲). FACS measurements of fluorescence intensity were performed at various
time intervals. (C) Using the GFP 1-10 complementation assay to evaluate the amounts of
protein in cell extracts. Cell extracts (left graph) and peptide dilutions (right graph) were
complemented with recombinant GFP 1-10 in solution in a 96-well plate, and fluorescence
was measured after an overnight incubation at 4°C. The quantity of GFP 11-tagged pro-
tein in cell extract dilutions was then deduced from a standard calibration curve with GFP
11 peptide solution (right graph). a.u., arbitrary units.
uated that this particular clone of N2A transfectants contained, on average, 1.5× 106 copies
of GFP 11-tagged MeCP2 protein of the same order of magnitude as levels reported in phys-
iological conditions [10]. The limit of sensitivity of the plate-based assay was 0.5 pmol GFP
11 peptide, as previously observed with bacterially produced proteins [6], and this corre-
sponded to a 1/100 dilution of the starting cellular extract (8 µg total protein) (Figure 5.1C).
These results demonstrate that the linearity and the sensitivity of the assay are suited for
monitoring protein expression in mammalian cells.
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5.4.3 Comparison with MAb staining
Using FACS, we then compared the sensitivity of the split GFP detection system with
antibody staining [5] (Figure 5.2A). We used another clone of N2A cells transfected with a
vector coding for MeCP2 tagged with the myc-His double epitope, which expresses protein
levels similarly to the MeCP2-GFP 11 clone, as detected by anti-MeCP2 antibody (Figure
5.2A, bottom row, middle panel). As expected with polyclonal antibodies, staining with the
rabbit pre-immune serum gave some background compared with cells reacted solely with
the secondary anti-rabbit antibody. Staining with immune anti-MeCP2 serum resulted in a
higher signal than the pre-immune serum from the same rabbit, although undifferentiated
N2A cells do not express detectable levels of endogenous MeCP2 protein ([11], and our own
observations). Detection of the myc epitope using the 9E10 MAb (mouse anti-myc; ATCC)
gave higher levels of staining than its isotype control on N2A control cells, presumably be-
cause of the binding of the antibody to the endogenous myc protein (Figure 5.2A, top left
panel). Nevertheless, specific staining with anti-myc or anti-MeCP2 on N2A cells trans-
fected with the MeCP2-myc-His vector resulted in 3- to 5-fold higher signal values relative
to nontransfected N2A cells (Figure 5.2A). With the GFP 1-10 assay, no detectable difference
was observed in fluorescence intensities between unstained and stained N2A control cells
(Figure 5.2A, top right panel). In cells expressing MeCP2-GFP 11, fluorescence signal was
clearly separated from the negative control, resulting in signal-to-noise ratios ≻60 (Figure
5.2B). Similar results were obtained after stable expression of the same constructs in HEK
293 cells (Figures 5.4 and 5.2B).
5.4.4 Validation of the GFP 1-10 staining assay for FACS measurements
To further document the versatility of this system, we fused the GFP 11 tag to the N ter-
minus of the H-Ras oncogene protein [localized mostly at the plasma membrane [12]] and to
the C terminus of the nucleocytosolic immunophilin FK506 binding protein 12 (FKBP) [13].
We established stable populations for these constructs in N2A and HEK cells and stained
them using GFP 1-10 protein for FACS analysis. For both proteins tagged with GFP 11, al-
though the levels of expression were considerably lower than for MeCP2, the very low levels
of background fluorescence of GFP 1-10 on nontransfected cells resulted in well-separated
peaks (Figure 5.2C). To verify that the split GFP method can be combined with antibody
staining, we then performed double staining on N2A-MeCP2-GFP 11 and HEK 293-GFP
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Figure 5.2 — GFP 1-10 staining assay for FACS analysis. (A) Comparison with MAb
staining. FACS detection of MeCP2-myc-His and MeCP2-GFP 11 in N2A cells using anti-
myc MAb (left), anti-MeCP2 polyclonal (middle), or recombinant GFP 1-10 (right). Neg-
ative controls are shown on the top row. Positive signals obtained from transfected N2A
cells expressing MeCP2 are shown in the bottom row: MeCP2-myc-His (gray) or MeCP2-
GFP 11 (black). (B) Signal-to-noise ratio for FACS detection of MeCP2 using staining with
either anti-myc, anti-MeCP2 antibody, or recombinant GFP 1-10, in N2A and HEK cells.
(C) FACS detection of FKBP-GFP 11 and GFP 11-H-Ras in N2A and HEK cells. Non-
transfected N2A or HEK cells, dashed line; N2A or HEK cells expressing GFP 11-tagged
proteins, black. (D) Double staining with antibodies (far red, FL4, x axis) and GFP1-10
(green, FL1, y axis). (Top row) N2A stably expressing MeCP2-GFP 11 or not. (Bottom
row) HEK cells transiently transfected with GFP 11-H-Ras or not. Left panel, fluorescence
of secondary antibodies on control cells; middle panel, anti-MeCP2 or anti-H-Ras signals
on nontransfected control cells; right panel, double staining of transfectants.
11-H-Ras cells. The procedure involved a first step using the GFP 1-10 assay, followed by
immunostaining using rhodamine-conjugated antibodies (see section 5.3). FACS analysis al-
lowed the detection of both epitopes in the green (GFP) and red (anti-MeCP2 or anti-H-Ras)
fluorescence (Figure 5.2D). Similar levels of detection were obtained for GFP 11 and MeCP2
(Figure 5.2D, top right graph), suggesting a good sensitivity of the split GFP method. More-
over, a clear correlation was observed between monoclonal anti-H-Ras Ab detection and
GFP 1-10 staining for HEK cells transiently transfected with GFP 11-H-Ras, in which only
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25% of the cell population expressed significant levels of the GFP 11-H-Ras protein (Figure
5.2D). We noticed that background on control cells with monoclonal anti-H-Ras antibody
was very low (Figure 5.2D, middle panel). Even in these conditions, although the differ-
ence was less striking than for the anti-myc and anti-MeCP2 antibodies presented above,
we found that GFP 1-10 staining of transiently transfected HEK cells still yielded better
signal-to-noise ratios than antibody staining (50 versus 13) (Figure 5.6).
5.4.5 GFP 1-10 staining for microscopy
We next compared cellular localization of the three proteins tagged either with full-
length GFP or with GFP 11 (Figure 5.3). In N2A cells stably expressing either MeCP2-GFP or
MeCP2-GFP 11, fluorescence revealed a typical punctuated nuclear pattern seen in murine
cells, due to the binding of MeCP2 to heterochromatin foci [14] (Figure 5.3A, top row). In
HEK cells, heterochromatin is less condensed, and fluorescence was thus diffused through-
out the nuclei [15] (Figure 5.3B, top row). The FKBP protein is generally distributed through
the nucleus and the cytosol, but may be predominantly nuclear when it dimerizes [16]. In
N2A and HEK cells, both FKBP-GFP and FKBP-GFP 11 fusions were found mostly localized
in the perinuclear region (Figure 5.3, A and B, middle rows). Finally, both GFP-H-Ras and
GFP 11-H-Ras fusions were found mostly associated with the plasma membrane. For GFP-
H-Ras however, we noticed the presence of additional intracellular vesicular structures in
both cell types [Figure 5.3, A and B (lower rows) and D]. This observation is reminiscent
of previous reports showing that fusion of H-Ras to the whole GFP molecule resulted in its
redistribution toward the ER and Golgi membrane, whereas unmodified H-Ras was found
mostly at the plasma membrane [17]. Our results thereby suggest that the smaller size of the
GFP 11 tag may alter the natural distribution of the tagged protein less than full-length GFP.
To confirm that staining with split GFP is nonperturbing and correlates accurately with true
protein localization, we performed double staining experiments, using specific antibodies
against MeCP2 and H-Ras followed by rhodamine-coupled secondary antibody, for both
GFP 11-tagged and GFP-tagged fusions of MeCP2 and H-Ras; this resulted in perfect co-
localization of the red and green signals (Figure 5.3, C and D). Importantly, for both MeCP2
and H-Ras fusions, no background fluorescence was observed in the other channel when
only one of the stainings was performed (Figures 5.7 and 5.8).
The split GFP detection system is particularly well-suited for protein tagging and detec-
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Figure 5.3 — GFP 1-10 staining for studying protein localization by fluorescence mi-
croscopy. Three proteins -MeCP2, FKBP, and H-Ras- were expressed in (A) N2A cells or
(B) HEK 293 cells, as GFP fusions (left panels) or GFP 11 fusions (right panels). MeCP2-
GFP 11, FKBP-GFP 11, and GFP 11-H-Ras were stained with recombinant GFP 1-10
reagent before mounting on microscope slides. Left image, green fluorescence at 488-
nm excitation. Right image, overlay of green fluorescence and DAPI nuclear staining
(blue). Scale bars, 10 µm. Double staining experiments are shown in panels C and D.
Fluorescein isothiocyanate (FITC) emission channel at 530 nm with excitation at 488 nm
(left), rhodamine emission channel detected at 590 nm with excitation at 545 nm (mid-
dle), superimposition of both images (right). (C) Anti-MeCP2 sera and GFP 1-10 staining
were performed on N2A-MeCP2-GFP 11 cells and compared with N2A cells expressing
MeCP2-GFP fusions. (D) Anti-H-Ras MAb and GFP 1-10 staining on HEK-GFP 11-H-Ras
and GFP-H-Ras HEK cells.
tion in eukaryotic cells using multiple formats. Expression and localization can be simulta-
neously performed either in fixed models or in living cells with transient or stable expression
of GFP 1-10 [18]. The main advantages over existing epitope tags [19, 20] are the high speci-
ficity and quantitative recognition between GFP 11 and GFP 1-10 fragments and the absence
of fluorescence of the GFP 1-10 protein. This confers very low background signals and fa-
cilitates staining procedures, as it does not require extensive washing steps compared with
classical immunostaining methods. The small size of the GFP 11 fragment (15 amino acids)
should be less perturbing than the bulky GFP, and GFP 1-10 staining can be performed in
combination with other immunostaining procedures as for GFP. The versatility of the sys-
tem will be further enhanced by the possibilities of combining the split GFP method with
chromatic variants of GFP, such as cyan and yellow 1-10. Engineering red autofluorescent
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split proteins would expand the color repertoire of the split GFP system to perform simul-
taneous detections in vitro and ultimately in vivo, for example, in mice expressing the 1-10
fragment ubiquitously. Both possibilities are currently being pursued in our laboratories.
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Supplementary Materials For:
One-step split GFP staining for sensitive pro-
tein detection and localization in mammalian
cells
Preparation of GFP 1-10 for in vitro assays
Bacterial cell culture
A solution of purified GFP 1-10 needs to be prepared to perform in vitro detection of GFP
11 fusion proteins. The engineered GFP 1-10 is 50% soluble, and the inclusion body fraction
is processed to take advantage of the enrichment and partial purification afforded by using
inclusion bodies. A 3-mL overnight culture is used to inoculate 500mL Luria-Bertani broth
containing 35µg/mL kanamycin. GFP 1-10 expression is induced in the exponential phase
(2h after inoculation) with 1 mM IPTG for 5h at 37°C (this forces the GFP 1-10 to aggre-
gate into inclusion bodies). After centrifugation, cell culture pellets are resuspended in 15
mL 100 mM Tris-HCl, pH 7.4, 0.1 M NaCl, 10% glycerol (v/v, TNG buffer), sonicated, and
centrifuged again to recover pellet cell debris containing crude inclusion bodies (discard
supernatant).
Inclusion bodies purification
Ten milliliters protein extraction reagent (e.g., Bugbuster, Novagen, EMD Chemicals,
Gibbstown, NJ, USA) are added to the pellet and sonicated to resuspend the crude inclusion
bodies. After centrifugation at 8,000×g for 20 min, the supernatant is removed. Three of
these Bugbuster washes are performed, followed by two washes with 10 mL TNG buffer
(this step enables residual detergent from the pellet mass). The pellet is weighed and re-
suspended in appropriate TNG volume to obtain a concentration of 37.5 mg/mL washed
pellet. Inclusion bodies are resuspended by sonication and dispensed into 1-mL aliquots in
1.7-mL microcentrifuge tubes. After centrifugation, the supernatant is removed. The pellet
can be stored at -80°C for several months.
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Preparation of GFP 1-10 reagent for assay
GFP 1-10 inclusion body pellet is dissolved by adding 1mL 9 M urea containing 5mM
DTT and by incubating the tube in a 37°C water bath to help dissolution of the inclusion bod-
ies. After complete dissolution, the microcentrifuge tube is centrifuged for 1min at 16,000×g
to remove any aggregated material, and the supernatant is transferred into a 50-mL Falcon
tube containing 25 mL TNG buffer. The solution is mixed gently by inversion and filtered
through a 0.2-µm syringe filter. This solution is ready to use for in vitro protein quantifica-
tion assays. The remaining solution may be stored up to 2 weeks at −20°C.
Figure 5.4 — FACS detecting of MeCP2-GFP 11 in HEK cells. Top panels represent
staining of nontransfected HEK cells (U), and bottom panels represent staining of G418-
resistant HEK cells after transfection with MeCP2-GFP 11(T), of which only around 15%
are expressing detectable levels of the protein. (Left panels) Anti-MeCP2 immunostain-
ing. Gray line in the upper left panel represents staining with secondary antibody only.
(Right panels) Staining with GFP 1-10. The number adjacent to each peak corresponds to
the mean fluorescence intensity of these peaks.
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Figure 5.5 — FACS fluorescence values of N2A cells after GFP 1-10 staining.
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Figure 5.6 — FACS detection of GFP 11-H-Ras in HEK cells. Top panels represent stain-
ing of nontransfected HEK cells (U), and bottom panels represent staining of HEK cells
after transient transfection with GFP 11-H-Ras (T). (Left panels) Anti-H-Ras immunos-
taining with anti-H-Ras MAb (Pierce, Thermo Scientific). Gray line in the upper left panel
represents staining with secondary antibody only. (Right panels) Staining with GFP 1-
10. The number adjacent to each peak corresponds to the mean fluorescence intensity
of these peaks. In transfected cells, these fluorescence intensities are indicated above for
each cell population, for those expressing basal levels of H-Ras and transfected cells. The
table summarizes these values. GFP 1-10 staining of transiently transfected HEK cells still
yielded better signal-to-noise ratios than antibody staining (50 versus 13).
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Figure 5.7 — Absence of green and red channel interference for single staining of N2A
MeCP2-GFP 11 cells with anti-MeCP2polyclonal antibody of GFP 1-10 reagent. No
green residual fluorescence is observed in the FITC channel when anti-MeCP2 rhodamine
immunostaining is performed (A). Inversely, GFP 1-10 staining reveals only fluorescence
in the FITC channel with no overlap in the red channel (B). Unstained N2A-MeCP2-GFP
fusions display very slight red fluorescence, which is not correlated with MeCP2 localiza-
tion but rather to background cell fluorescence (C).
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Figure 5.8 — Absence of green and red channel interference for single staining of HEK
cells expressing H-Ras using anti-H-Ras MAb of GFP 1-10 reagent. Anti-H-Ras rho-
damine immunostaining reveals membrane localization in the red channel for H-Ras-GFP
11 in HEK cells, while no green residual fluorescence is observed (A). With GFP 1-10 stain-
ing, clear membrane localization is revealed in the FITC channel with some background
cell fluorescence in the red channel, which is not related to H-Ras localization (B). Simi-
lar effect is observed in HEK cells as in N2A cells for the GFP-H-Ras fusion protein, with
some staining of interacellular membrane compartments not seen with the GFP 11-tagged
form (C).
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6 Generation and characterizationof isoform-specific anti-MeCP2
antibodies
6.1 Abstract
Rett syndrome is a neurodevelopmental disorder caused by mutations in the MeCP2
gene. mRNA for MECP2 is alternatively spliced to generate two protein isoforms (MeCP2e1
and MeCP2e2) that differ at their N-termini. Whilst mRNAs for both forms are expressed
ubiquitously, MeCP2e1 is more abundant than MeCP2e2 in the CNS. In transfected mouse
cells both protein isoforms are nuclear and colocalize with densely methylated heterochro-
matic foci. To understand the contribution of each isoform in the pathogenesis of Rett syn-
drome, it would be very useful to have access to reagents that can distinguish between
them, but until now, all antibodies directed against MeCP2 have been directed against re-
gions of the protein present in the two isoforms. We have therefore attempted to generate
isoform-specific anti-MeCP2 antibodies. To this end, we used peptides corresponding to
the short amino-terminal portions that are different between the two isoforms to immunise
rabbits. The polyclonal antibodies obtained detected their respective isoforms of MeCP2
specifically, both by Western Blot and immunofluorescence techniques. With those antibod-
ies, we could easily detect specific signals for MeCP2e1 in mouse brain tissues, whilst, in
our hands, MeCP2e2 remained below the level of detection.
6.2 Introduction
Rett syndrome is a dominant X-linked neurological disorder that affects girls during
early childhood. It is a progressive disease with symptoms appearing around 6 to 18 months
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after birth. After a normal developmental period, girls show growth retardation, micro-
cephaly, stereotypic hand movement, motor abnormalities, mental retardation and commu-
nication dysfunction [1]. Most RTT cases are sporadic. However, using information from the
rare familial cases, Amir et al. identified mutations in MeCP2 gene as the origin of 95% of
classic RTT cases [2]. MeCP2, methyl CpG binding protein 2, is an abundant nuclear protein
identified in 1992 for its capacity to bind methylated DNA [3].
The MeCP2 gene consists of four exons giving rise to two different isoforms of the pro-
tein due to alternative splicing of the mRNA. In addition, the MeCP2 mRNA has a long
highly conserved 3’-UTR with three sites of polyadenylation generating three different tran-
scripts for each isoform. The first isoform to be described, in 1992, was MeCP2e2 (also called
MeCP2A or MeCP2β) which contains all four exons with the initiation site in exon 1 giving
rise to a protein of 486 amino acids 5 [4]. The MeCP2e1 isoform (also called MeCP2B or
MeCP2α) was identified eleven years later, in 2004, both in human [5] and mouse [6]. It
lacks exon 2, and thus consists of exons 1, 3 and 4, and starting from the initiation site in
exon 1, gives rise to a protein of 498 amino acids [4] and Figure 6.1A).
RT-PCR analyses have revealed the presence of two transcripts in all tissues in human
and mouse, and also demonstrated that MeCP2e1 isoform is more abundant than MeCP2e2
in the brain, thymus and lung ([6, 5]). Many arguments suggest that the MeCP2e1 protein
may be more physiologically relevant than MeCP2e2.
Firstly, in the MeCP2e2 mRNA, the ATG start codon present in exon 1 is followed by a
very short open reading frame that terminates at the start of exon 2, and the initiation site
for the translation of the whole length MeCP2e2 protein is then found further down in exon
2 (Figure 6.1A.). Kriaucionis and Bird actually demonstrated that the presence of this first
ATG results in very inefficient translation of the MeCP2e2 protein.
Second, the ancestral form of MeCP2 inferred from sequence comparisons with non-
mammalian vertebrates corresponds to MeCP2e1.
Third, until now, in the hundreds of sequences for MeCP2 genes obtained from patients
affected by Rett syndrome, no mutation has yet been found in exon 2. On the other hand,
work carried out between 2005 and 2009 has revealed the presence of 10 different mutations
(deletions and missense) in exon 1 in patients with classical or atypical (mild and severe
form) Rett syndrome [7].
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Lastly, in 2 patients showing classical phenotype of Rett syndrome, but without seizures
or microcephaly, Saunders et al. identified mutations affecting the initiation codon of
MeCP2e1 [7], which would result in the lack of translation of the MeCP2e1 protein, but
would be expected to somewhat ’restore’ higher expression of MeCP2e2, similarly to what
has been reported for the mouse cDNA [6].
On the other hand, the MeCP2e2 protein must be able to fulfill most functions of
MecP2e1 since, in MeCP2 KO mice, the pathologic phenotype could be rescued by a tau-
MeCP2e2 transgene [8]. It is also worthy of note that for historical reasons, many of the
studies using on the expression of recombinant MeCP2 were based on cDNA constructs
coding for the MeCP2e2 isoform.
To explore the expression of each isoform in vivo, and understand their respective contri-
butions to Rett syndrome, it would be very valuable to have access antibodies to detect them
separately. In this regard, however, all the described antibodies directed against MeCP2
were raised against portions common to the two isoforms, and thus recognize them both.
With a view to obtain isoform-sepecific antibodies, we thus decided to immunize rabbits
with peptides found only in one or the other of the isoforms, and to characterize those by
western blot and immunofluorescence on both tissue culture cells and brain slices.
6.3 Material and methods
6.3.1 Rabbit immunization
For each antibody, two New Zealand white rabbits were immunized with a synthetic
peptide corresponding to amino acids 1-12 of mouse MeCP2e2 (MVAGMLGLREEK-C),
amino acids 19-29 of mouse MeCP2e1 (C-GGGEEERLEEK). The cysteine residues were
added for conjugation with carrier proteins. Rabbit immunizations were carried out by
Eurogentec France SASU, Angers, France. Four injections were performed on day 0, 21, 49,
and 77 with thyroglobuline-conjugated peptides. Serums were harvested and then affinity
purified on resins coupled to the respective peptides by Millegen (Labège, France). With the
e2 peptide, the sera obtained from both rabbits gave comparable results. For the e1 peptide,
however, only one rabbit responded satisfactorily.
The third antibody was raised against (C-PRPNREEPVDSRTP) corresponding to amino
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acids 465-478 of both isoforms of mouse MeCP2 as described previously by others [9] and
ourselves [10]. This polyclonal antibody was produced by Millegen (Labège, France). Rab-
bits received five injections on day 0, 12, 23, 44 and 57 with KLH-conjugated peptide. One of
the two rabbits responded satisfactorily, and that serum was used directly without further
affinity purification.
6.3.2 Cell culture and transfections
pcDNA3.1(A) vectors expressing Myc-tagged human MeCP2e1 and MeCP2e2 were pro-
vided by Dr. Berge A. Minassian of the Hospital for Sick Children, Toronto, Ontario, Canada
[5].
N2A cells and G418-resistant stably transfected N2A cells expressing Myc-His-tagged
human MeCP2e1 and MeCP2e2 were maintained in DMEM 10% FCS supplemented with
100 U/ml penicillin, 100 g/ml streptomycine, 0.1 mM Non-essential amino acids, 1 mM
sodium pyruvate (+ 0,5 mg/ml G418 for the transfectants).
6.3.3 Immunofluorescence staining of tissue culture cells and microscopy
2.5×105 N2A cells were plated overnight on glass coverslips in 24-well plates. Cells were
washed twice with PBS and fixed with PFA 3.7% in PBS for 30 min at room temperature.
Cells were washed twice with PBS followed by microwave antigen retrieval step. For this
cells were incubated in citrate buffer 0.1M (pH 6) and heated 4 × 30 seconds in microwave
(750 watts). After two washes with PBS, cells were permeabilized in 0.3% Triton-X100 for 10
min at room temperature (RT). After 3 washes with PBS/FCS 2%, cells were incubated with
Rabbit anti-MeCP2 serum (1:200 dilution in PBS/FCS 10%) for 45 min at RT. Cells were again
washed 3 times before incubation with Alexa Fluor 488-labelled Goat anti-Rabbit, molecular
probes Invitrogen (1:200 dilution in PBS/FCS 10%) for 30 min at RT. Cells were washed
3 times with PBS/FCS 2% and after a final wash with PBS, coverslips were mounted in
DAPI-containing ProLong Gold antifading reagent (Molecular Probes). We used a LEICA
DM-RB fluorescence microscope, with a 40X oil immersion objective to visualize the stained
cells. Images were acquired with a Photometric CoolSNAP HQ camera and analyzed with
Metamorph and/or ImageJ softwares.
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6.3.4 Western Blot
Nuclear extract preparation of N2A cells or mouse tissues was carried out as described
previously [11]. Various amounts of proteins from these nuclear extracts were loaded onto
acrylamide gels. After separation, proteins were transferred to nitrocellulose membrane
(0,45 µm BioRad). Membranes were blocked with TBS (Tris 10 mM, NaCL 0.15 M, pH
7.4) containing 3% skimmed powder milk (non-fat Régilait, France) and 0.1% Tween-20
overnight at 4°C. Before incubation, the TBS blocking buffer was always centrifuged (100000
g for 45 min) and filtered with 0,2 µm filters. Membranes were then incubated with rabbit
anti-MeCP2 antibodies diluted in blocking buffer for 1h at RT. Anti-MCP2e1 was diluted
to 1/2000, anti-MeCP2e2 to 1/5000 and anti-MeCP2 to 1/3000. After 4 × 10 min washes
in PBS/ 0.1% Tween buffer, membrane were incubated with goat anti-rabbit HRP (BioRad,
1:10000 dilution in blocking buffer) for 1h at RT. Finally, the blots were washed 4 × 10 min
in PBS/ 0.1% Tween buffer and revealed with an ECL kit (Pierce).
6.3.5 Brain tissue immunostaining
Mice were sacrificed with a lethal pentobarbitone injection (100 mg kg−1 i.p.) and tran-
scardially perfused by PBS 0.1M containing 4% paraformaldehyde (10 min). Brainstem were
postfixed 5 h in the same solution, placed in PBS 0.1 M containing 20% sucrose and frozen
at -80 °C.
Brain sections (20 µm) were cut using a cryostat (Microm, France), permeabilized 15 min
in PBS Triton 0.1%, blocked 45 min with 7% normal goat serum (NGS, Jackson Immuno)),
and incubated overnight at RT with primary antibodies diluted 1/300 in PBS containing 3%
NGS serum. The following day, sections were washed, incubated 2 h at RT with a secondary
antibody (goat anti-rabbit alexa 546 (Invitrogen) diluted 1:400 in PBS containing 3% serum
and re-washed. After 5 min incubation with DAPI (4’,6-diamidino-2-phenylindole, dihy-
drochloride), slides were mounted in Shandon Immu-Mount (ThermoFisher). Immunos-
tained slices were analyzed using a Leica DMR microscope (Leica Microsystems, Wetzlar,
Germany) equipped with a CoolSNAP camera (PrincetonTrenton, NJ, USA). Pictures were
then analyzed with ImageJ software.
MECP2 95
6Generation and characterization of isoform-specific anti-MeCP2 antibodies
6.4 Results and discussion
6.4.1 Peptide design and Rabbit immunization
Figure 6.1 — A.)Representation of the MECP2 gene and mRNA (adapted from [6] and
[5]). Alternative splicing for the e1 (or B) isoform is shown above the gene and for the
e2 (or A) isoform below the gene. B.) Alignment of mouse (m) and human (h) MeCP2e1
and MeCP2e2 N-termini show sequence similarities between the two species. Peptides
sequences correspond to the region that differs between the two isoforms. Synthetic pep-
tides was generated and conjugated to thyroglobulin before rabbit immunization.
MeCP2e1 and MeCP2e2 differ only by their N-terminal region. We designed and
synthesized two peptides that would be isoform specific, but matched both the human
and mouse sequences: the first corresponding to amino acids 19-29 of human MeCP2e1
(C-GGGEEERLEEK) and to amino acids 1-12 of human MeCP2e2 (MVAGMLGLREEK-C).
Cysteine residues were added to the N terminus of the e1 and the C terminus of the e2 pep-
tides for coupling with carrier proteins, for which we chosen thyroglobulin. Rabbits were
immunized as described in materials and methods and serum was harvested 9 days after
the final injection. Antibodies were affinity purified on columns coupled to peptide, and
yielded a solution of 0,6 mg/ml for the MeCP2e1 antibody and 1 mg/ml for the MeCP2e2
antibody. Crude serum was used for the third antibody directed against both isoforms of
MeCP2.
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6.4.2 Antibodies characterization
6.4.2.1 Immunofluorescence and western blot
Figure 6.2 — Antibodies characterization by immunofluorescence and western
blot: N2A cells stably expressing hMeCP2e1-myc-his and hMeCP2e2-myc-his were
plated on coverslips and labeled with antibodies directed against MeCP2e1 (A.)
or MeCP2e2 (B.) isoforms or with anti-MeCP2 (C.) directed against both isoforms.
Nuclei were stained with DAPI. D.) Nuclear extracts of N2A cells expressing MeCP2 were
separated by polyacrylamide gel electrophoresis, transferred to nitrocellulose and labeled
with the different antibodies. Results show specific staining for each isoform.
To test the specificity of the antibodies, we used clones of the mouse neuroblastoma
cell line Neuro2a (N2A) which stably express either MeCP2e1 or MeCP2e2. Despite the
neuronal lineage of the N2A cells, it is worth underlining that undifferentiated N2A cells
do not express any detectable level of MeCP2 [12]. As can be seen on figure 6.2(A-C) im-
munofluorescence staining with either of the isoform-specific antibodies led to nuclear la-
beling that co-localized with heterochromatin, as revealed by DAPI staining. For each of the
two isoforms-specific antibodies generated, this staining was found to be specific since no
cross-reaction was observed on the transfectants expressing the other isoform (Figure 6.2A.
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and B.). Of note, for the MeCP2e1 antibody, microwave treatment of the samples before
staining, which is commonly used for antigen retrieval, resulted in a noticeable improve-
ment of the staining. This suggests that the N-terminal portion of the MeCP2e1 protein may
not always be accessible, possibly because of interaction with other cellular components.
This hypothesis is also supported by the observation that, even after antigen retrieval, the
intensities attained were less intense than with the serum recognizing both forms of MeCP2
(Figure 6.2C). With the anti-MeCP2e2 antibody, no improvement of staining was obtained by
microwaving. On the other hand, some noticeable staining was obtained in the cytoplasm,
but this was clearly not specific for MeCP2 since similar levels of staining were also found in
untransfected N2A cells (Figure 6.2A.). Quite remarkably, those levels of cytoplasmic stain-
ing appeared much more intense in cells that did not express MeCP2e2, which suggests that
some antibodies that bind with high affinity to the N terminal portion of MeCP2 may ac-
tually cross react with some other cytoplasmic component(s), but with lower affinity. Blast
searches of mammalian protein sequences with the sequence of the peptide used for im-
munizing the rabbits identified proteins of the plectin family as prime suspects since those
have cytoplasmic distributions, and many start with MVAGML, the same six amino acids as
found in MeCP2e2.
Western blot analysis of nuclear extracts prepared from the same cells confirmed the
specific reactivity of both antibodies, with each revealing only the band corresponding to
the MeCP2 isoform it was raised against, whilst the antibody raised against the 465-478
peptide recognised both isoforms, yielding band of similar intensities.
6.4.2.2 Immunostaining on brain sections of wildtype and MeCP2 KO mice
To verify if these antibodies are suitable to be used for histological staining, we prepared
tissue sections from different regions of the brains of normal C57BL/6 and MeCP2 KO mice.
Figure 6.3 shows the results obtained on cortex region. Using the MeCP2e1 antibody, stain-
ing of WT tissues revealed a specific nuclear punctuated labeling that colocalised perfectly
with DAPI, whilst we did not detect any labeling on KO tissues. With the MeCP2e2 anti-
body, we did not detect any punctate nuclear signal which is so typical of MeCP2. Rather,
we observed similar cytoplasmic labeling of cells in tissues obtained from both the WT and
KO mice. This staining was thus non specific, and very similar to what we had observed on
N2A cells.
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Those two antibodies were then used to explore the expression of each isoform in dif-
ferent organs by western blot (Figure 6.5). For this we prepared nuclear extracts from brain
(cortex and cerebellum), lung, heart, liver, thymus, spleen and kidney. As a positive control
we used nuclear extracts from N2A cells transfected with either form of MeCP2, as described
above (Figure 6.2D). Western blot analyses revealed the presence of MeCP2e1 protein at high
levels in the CNS, and at lower levels in the lung and kidney. On the other hand, whilst the
MeCP2e2 protein was readily and specifically detected in the transfectants, no band of the
right size was obtained in any of the tissues. Several other bands of smaller sizes were, how-
ever, detected in all tissues, but those were clearly not due to MeCP2 since they were also
seen in CNS extracts from an MeCP2 KO mouse.
Figure 6.5 — MeCP2e1 and MeCP2e2 expression in different organs of the mouse: A.):
Western blot analysis revealed that MeCP2e1 isoform is expressed in the CNS, the lung
and the kidney. No MeCP2e2 expression was detected in any tissue. B.) Western blot on
KO brain revealed that the other bands on the gels correspond to non-specific proteins.
6.5 Conclusion
We have generated isoform-specific antibodies directed against each of the two MeCP2
isoforms: MeCP2e1 and MeCP2e2. Although the antibody directed against MeCP2e2 gives
much higher background than that against MeCP2e1, both these antibodies are clearly spe-
cific of their respective isoform, and shown to be suitable for using by western blot and
immunofluorescence.
100 MECP2
6.5. Conclusion
6
We showed also that the MeCP2e1 isoform is expressed at high level in the brain and
at low level in the lung and the kidney. On the other hand, we were unable to detect any
expression of the MeCP2e2 protein in all the tissues analyzed, suggesting that, if the MeCP2
protein is expressed in the organism, it is at levels which are below the level of detection
with our reagent.
Our data strongly support the already established view that the MeCP2e1 isoform is not
only the most abundant isform in the organism, but also probably the only one with an
important physiological role.
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7.1 Introduction
The methyl CpG binding protein (MeCP2) is a transcription factor that binds to methy-
lated DNA. When mutated, this protein is responsible for Rett syndrome, a neurodevelop-
mental X-linked disorder occurring in 1:10000 to 1:20000 female births [1, 2, 3].
The MeCP2 protein is encoded by a four-exon gene, giving rise to two different isoforms
due to alternative splicing of the exon 2. The MeCP2 protein is highly expressed in mature
neurons in the brain. It contains four functional domains: a methyl-CpG-binding domain
(MBD), a transcriptional repression domain (TRD), a nuclear localization signal and a C-
terminal region which facilitate its binding to the nucleosomes and is important for protein-
protein interactions [4, 5].
Different functions have been described for MeCP2. It was initially thought that MeCP2
was a transcription repressor that binds to CpG methylated promoters and recruits histone
deacetylase complex [6]. However, recently, 2 studies revealed that MeCP2 could act as a
transcription activator suggesting that MeCP2 should be considered as a transcription mod-
ulator [7, 8]. Other studies revealed that MeCP2 has a role in maintaining the methylation
profile of DNA by interacting with DNMT1 [9] and in modulating mRNA splicing by in-
teracting with the Y box-binding protein 1 [10]. It was also shown that MeCP2 can have a
role in regulating global chromatin architecture, suggesting that MeCP2 is a multifunctional
nuclear protein [11, 12].
In vitro studies revealed that the binding of MeCP2 to chromatin is affected when the
CpG sequence is altered. For example oxidative damage inhibits the binding of MeCP2 [13]
whereas halogenated pyrimidine lesions enhance its binding capacity [14]. Recently, other
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studies revealed that a decrease in MeCP2 expression is accompanied by an increase in dam-
aged DNA [15]. Importantly, MeCP2 could enhance the number of UV lesions by enhancing
photodimer formation but on the other side, it inhibits the deamination step required for the
photoproduct to become mutagenic [16, 17].
All these studies suggest a potential role of MeCP2 in the DNA damage response. In
this study we introduced different DNA lesions using multiphoton laser micro-irradiation
and DNA intercalators with laser photo-activation and we showed that MeCP2 is recruited
rapidly to the site of damage and that this recruitment depends on the C-terminal region
of MeCP2. We showed also that MeCP2 accumulation is independent from GG-NER and
TC-NER pathways and is independent from transcription.
7.2 Results
7.2.1 Expression and detection of MeCP2-GFP and mutants derivatives
In order to investigate the implication of MeCP2 in DNA damage response and to un-
derstand its role in this pathway, we stably expressed the human MeCP2 protein in fusion
with the GFP protein (Figure 7.1A) in different cell lines. For this, we chose to study the
e1 isoform since it is the major form expressed in the brain. We also elected to fuse the
GFP fluorescent marker at the C-terminal region of MeCP2 in agreement with a previous
study showing that a knock in mouse model expressing MeCP2-GFP protein are viable and
behaves like a normal wild-type mouse, suggesting that this fusion construct does not sig-
nificantly alter the most vital function(s) of MeCP2 [18]. To study the implication of each re-
gion of MeCP2 in the DNA damage response, we introduced different missense mutations:
in the MBD (R133C) and the TRD (R306C) domains of MeCP2 and one nonsense mutation
(∆308) lacking the C-terminal region of MeCP2 [19]. These mutants were all fused to the
GFP protein (Figure 7.1A). To verify the localization and the expression of the wild-type
hMeCP2-GFP fusion protein, we performed immunofluorescence staining with anti-MeCP2
antibody on Human Embryonic Kidney (HEK) cells stably expressing the MeCP2-GFP pro-
tein (Figure 7.1B). Results showed a nuclear labeling with a perfect co-localization between
the anti-MeCP2 and the GFP signals.
In order to exclude any degradation profile for MeCP2, we performed western blot anal-
ysis on nuclear extract from the HEK cells expressing or not the MeCP2-GFP protein (Figure
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(Figure 7.1E) and laser micro-irradiation techniques.
7.2.2 MeCP2 localization on locally damaged DNA.
To verify whether MeCP2 is localized at DNA damage sites, we generated lesions in
HEK cells expressing MeCP2-GFP, using microirradiation with a multiphoton laser, which
induces different types of DNA damages (DSB, SSB, oxidative damage, etc.) [20]. After irra-
diation, we observed an accumulation of MeCP2 in the region of damage (Figure 7.2A). The
accumulation of MeCP2 begins 30 seconds after irradiation, reaches its maximum 5 min af-
ter DNA damage and then gradually declines, to become barely detectable after 30 min. To
characterize the type of lesions needed for the recruitment of MeCP2, we induced different
types of DNA lesions separately and we detected in which conditions MeCP2 accumulates.
After induction of cyclobutane pyrimidine dimer (CPD) or pyrimidine pyrimidone (6-4PP)
photoproducts lesions by local UV irradiation through 5 µm filters using 60 J/m2 UV light
[21], no MeCP2 accumulation could be observed, either at 10 min or 30 min after UV dam-
age (Figure 7.2B left panel). As a positive control, we used cells expressing the XPC-GFP
protein, an essential protein whose role is to initiate GG-NER [22], and to recognize and re-
pair UV lesions. Unlike MeCP2, the XPC-GFP protein shows an accumulation 10 min after
irradiation (Figure 7.2B right panel).
Another way to induce DNA lesion is to use DNA intercalators with laser photo-
activation. In this study we used the Actinomycin D, which is usually used as a transcription
inhibitor, but also known to produce DNA lesions like single strand breaks, oxidative dam-
age and bulky lesions when photo-activated with the 488 nm laser used in strip-FRAP tech-
niques [23]. HEK-MeCP2-GFP cells treated with Actinomycin D (2 µg/ml, for 1h) showed
an accumulation of MeCP2-GFP in the region of the 488 nm illumination (Figure 7.2C). This
accumulation was also observed for other proteins implicated in DNA repair like XPC and
XPB [24] or Ku80, CSB, Fen1 (Figure 7.3). Other proteins like XPA, TTDA [24] or CSA (Figure
7.3 do not accumulate on this DNA damage.
7.2.3 MeCP2 recruitment on local damage is transcription and CSB independent
In order to determine in which pathway MeCP2 is implicated, we expressed MeCP2-
GFP in 2 different cell lines deficient in DNA repair: the XPC-/- cells deficient in GG-NER
and the CSB-/- deficient in TC-NER. Initially, we studied the localization and the mobility of
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analysis (488 nm repeated illuminations). For the three cell lines, FRAP curves (Figure 7.4A
blue curves) show an increase signal after a certain number of 488 nm laser pulses illumina-
tion. This dynamic behavior is typically observed when proteins accumulate in the region
of the photobleaching. We could verify that MeCP2 had indeed accumulated in this area by
imaging the treated cells 5 min after the procedure, as shown in living images (Figure 7.4B)
of HEK, XPC-/- and CSB-/- cells expressing MeCP2-GFP fusion protein. As previously
shown, MeCP2 co-localizes with heterochromatin in HEK and XPC-/- cells. However, in
CSB-/- cells this typical heterochromatin co-localization was replaced by a more diffuse nu-
clear localization. In conclusion, we found that MeCP2 is recruited on DNA lesions induced
by Actinomycin D and 488nm photo-activation. This recruitment is independent of XPC
and CSB suggesting that MeCP2 recognizes the damage before these two proteins or is im-
plicated in other pathways. Finally, we showed that MeCP2 needs CSB to bind properly to
the chromatin.
MeCP2 is a transcription modulator factor that tracks methylation genome wide. Chip-
chip analysis in the brain showed that the binding profile of MeCP2 to the chromatin overlap
the binding profile of the RNA polymerase II protein [8]. We thus wanted to verify if the
recruitment of MeCP2 to the damage is transcription dependent.
For this we treated the HEK and the CSB-/- (deficient in TC-NER) cells with α-amanitin,
a specific transcription inhibitor that binds the catalytic domain of RNA polymerase II
(RNAP2) and impedes the binding of RNAP2 with the DNA. In HEK cells, treatment with
α-amanitin provokes an increase in the immobile fraction of MeCP2, suggesting that after
transcription inhibition, MeCP2 binds more to the chromatin either to induce its compaction
(Figure 7.5 left panel), or in consequence of an increased number of methylated CpGs. Sur-
prisingly, in CSB-/- cells no changes between treated and untreated cells could be observed,
suggesting that the absence of CSB can hinder MeCP2 functions (Figure 7.5 right panel).
However, after induction of damage in α-amanitin treated cells, we observed similar accu-
mulation curves as in untreated cells in both HEK and CSB-/- cells, suggesting that MeCP2
accumulation to damaged areas is independent of transcription and of CSB presence.
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Figure 7.5 — Recruitement of MeCP2 on the lesions is independant from transcription:
Representation of FRAP analysis of MeCP2-GFP protein in α-amanitin treated HEK and
CSB-/- cells with (Red curves) and without (green curves) DNA damages. Blue and violet
curves are the same as shown in Figure 3A. Transcription inhibition after treatment with
α-amanitin increase the immobile fraction of MeCP2 in HEK cells in comparision with
the untreated cells (violet curve). α-amnitin does not have any effect on the mobility of
MeCP2 in CSB-/- cells. When we looked at the recruitment of MeCP2 on DNA lesions
before (Blue curves) and after (green curves) treatment with α-amanitin, we did not notice
any effect of transcription inhibition on MeCP2 accumulation.
and mutant proteins using strip-FRAP techniques. Wild-type MeCP2-GFP protein (Figure
7.6, left panel violet), showed a retarded fluorescence recovery with a relatively high immo-
bile fraction, suggesting that MeCP2 binds strongly to the chromatin. Strip-FRAP curves
for R306C (red) and ∆308 (blue) mutants showed a slight decrease in the immobile fraction.
In contrast, the R133C mutant (green) showed a very fast recovery of fluorescence and an
unusual mobile fraction, suggesting that the arginine at position 133 is important for the
binding of MeCP2 on the chromatin. When we treated the cells with actinomycine D/488
nm (Figure 7.6, right panel violet), wild type MeCP2 and two mutants (R133C and R306C)
showed accumulation in the region of damage. In contrast, the ∆308 mutant did not show
any accumulation suggesting that the C-terminal region of the MeCP2 protein (responsible
for its protein-protein interaction) is important for its recruitment to the damage. These re-
sults suggest that the accumulation of MeCP2 on the damaged DNA is independent from
methylation but requires the interaction with other partners.
7.2.5 MeCP2 Binding to chromatin is altered in neuron from CSB-/- mice
The localization pattern and the FRAP curves of the MeCP2 protein in CSB-/- cells re-
vealed that MeCP2 binds very weakly to chromatin. To confirm these results in living tissue,
we decided to extract MeCP2 from the brain of WT and CSB-/- mouse models [26]. MeCP2
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Figure 7.6 — The C-terminal region of MeCP2 is important for its function in the DNA
damage response: A: FRAP kinetics of MeCP2 and its mutant forms showed slight de-
crease in the immobile fraction of the R306 and the ∆308 mutants in comparison with
the WT form. In contrast, the R133C construct lacking its ability to bind methylated DNA
showed a high increase in the mobility of the protein. B) After treatment with actinomycin
D, FRAP curves revealed an increase in fluorescence characteristic of the recruitment of
the GFP protein in the photo-bleached region as showed with microscope images (white
arrows). We noticed that the accumulation of the mutant form lacking the C-terminal
region of MeCP2 is delayed in comparison with other forms.
was eluted from the DNA and the different fractions were loaded on an acrylamide gel. Re-
sults of Western blot directed against MeCP2 (Figure 7.7) showed that when the brain was
homogenized and incubated in a 450 mM NaCL buffer and sonicated two times, significant
and equivalent quantities of MeCP2 were released from the chromatin from the two brains.
In the brain from the WT mouse, however, a residual quantity of MeCP2 remained in the
pellet (3 folds more than in the KO mouse) and needed 3 additional sonication cycles to be
removed. These results suggest that in the WT brain MeCP2 bound more strongly to the
chromatin in comparison with the CSB-/- brain.
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Figure 7.7 — MeCP2 binding to the chromatin is altered in CSB-/- brain tissue: Different
fractions corresponding to the elution of MeCP2 from the WT vs the CSB KO mice were
loaded on acrylamide gel. Western blot revealed the presence of MeCP2 in the first two
fractions in similar quantities between the two brains. In the SN4 fraction, we detected the
presence of MeCP2 protein in the WT brain 3 folds more than in CSB-/- cells suggesting
that MeCP2 binds strongly to the chromatin in WT tissue and requires more steps to be
eluted.
7.3 Discussion
MeCP2 is a highly abundant protein in mature neurons, with a number of molecules
approaching the number of histone octamers. It is a nuclear protein playing different roles
in transcription modulation, chromatin remodelling, mRNA splicing etc. In this study, we
disclose a potential novel role for MeCP2 in the DNA damage response. We showed for the
first time a recruitment of the MeCP2 protein on the DNA lesions induced by multiphoton
laser micro-irradiation and by 488nm-photo-activated actinomycin D.
Multiphoton laser microirradiation induces different types of DNA damages such as
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DSB, SSB, oxidative damage, etc. [20], whereas Actinomycin D, usually used as a transcrip-
tion inhibitor, is known to induce single strand breaks, oxidative damage and bulky lesions
when photo-activated with the 488 nm laser [23]. In order to determine in which DNA
repair pathway MeCP2 is implicated, we stably expressed the hMeCP2-GFP fusion pro-
tein in XPC-/- cells deficient in GG-NER and in CSB-/- cells deficient for TC-NER. In these
cells, we showed that MeCP2 is recruited to the DNA lesions independently from these two
pathways, and that this accumulation is also independent of the transcription state of the
cell, since α-amanitin (a specific RNAP2 inhibitor) did not have any detectable effect on the
recruitment of MeCP2 to the lesions. These results suggest that MeCP2 either senses the
damage before XPC and CSB or that MeCP2 is implicated in other pathways. Several other
proteins implicated in DNA repair have been described to bind actinomycin D lesions, in
earlier studies (XPB, XPC) or in this work (CSB, Ku80 and Fen1). Other experiments should
be performed to determine if MeCP2 is implicated in NHEJ or in BER pathways or if this
protein recognizes the damage before all other proteins and initiates a signaling cascade to
allow the recruitment of the other proteins implicated in DNA repair.
The fact that the C-terminal region of MeCP2 is important for its recruitment to the dam-
aged region suggests that other proteins can be needed for its accumulation on the lesion. It
was shown that MeCP2 interacts with the Y box protein (Yb-1) in an RNA-dependent man-
ner to regulate the mRNA splicing activity and that MeCP2 lacking the C-terminal region
is responsible for 50 to 70% of this binding activity [10]. It was also demonstrated that the
Yb-1 protein is implicated in the DNA damage response: it recognizes cisplatin modified
base pairs, mispaired bases [27] and single stranded nucleic acid [28], it possesses 3’ to 5’ ex-
onuclease activity [28] and interacts with different proteins implicated in DNA repair such
as PCNA, MSH2, DNA polymerase delta, Ku80 and WRN proteins [27]. Other studies re-
vealed that MeCP2 interacts with the YY1 protein via its TRD domain to repress the ANT1
gene encoding a mitochondrial adenine nucleotide translocase [29]. It was also shown that
YY1 protein is essential for homologous recombination-based DNA repair (HRR) [30]. This
lets us hypothesize that, in the context of DNA lesions, MeCP2 can be recruited by these
proteins to the site of damage.
What is the role of MeCP2 on the DNA lesions? Different studies have previously re-
vealed that in the region of a locally damaged DNA (UV lesions [22] or DSB lesions [31]),
transcription is inhibited. Recently, Jackson’s laboratory showed that the proteins of the his-
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tone deacetylase complex HDAC1 and HDAC2 are recruited to DSB to promote NHEJ [32].
The transcription in the region where HDAC were recruited was also inhibited. Knowing
that MeCP2 interacts with HDAC1 and 2. It is tempting to hypothesize that MeCP2 can re-
cruit HDAC on DSB. Another study revealed that when a DSB occurs in a promoter region,
SIRT1, EZH2, DNMTI, DNMT3B are recruited to the area around the break site. DNMT1
and DNMT3B can methylate the DNA [33]. It’s known that DNMT1 can recruit MeCP2 to
methylated DNA to repress transcription [9]. Further experiments should be performed to
elucidate this question. For example, local damage can be induced in cells deficient or not
for MeCP2. After BrU incorporation we can monitor transcription in the damaged region.
We can also use a siRNA directed against DNMT1 to abolish the recruitment of MeCP2 on
methylated DNA.
To verify if the damaged DNA is methylated, an immunofluorescence experiment using
anti-methylcytosine antibody can be used.
Finally another important point of this study is the relation between the absence of CSB
and MeCP2 mobility. CSB is a 168 kDa protein related to the family of the SWI/SNF family.
It has an ATP-dependant chromatin remodeling activity [34]. It recognizes stalled RNAP2
on lesions and initiate transcription-coupled repair. It is important to know why MeCP2
binding to the chromatin is reduced in the absence of CSB. Does MeCP2 interact directly
with CSB or it is in a complex containing the CSB protein. Previous studies have revealed
that the transcription machinery is less tightly associated with chromatin and that the tran-
scription is reduced in CSB-deficient cells compared to wild type [35, 36].
Mutations in the CSB gene cause Cockayne syndrome. Patients with Cockayne syn-
drome present a panel of neurological symptoms which are very similar to those found in
Rett syndrome patients such as mental retardation, microcephaly, seizures or coordination
problem [37]. The fact that the chromatin binding capacity of MeCP2 is altered in CSB de-
ficient cells/mouse brain suggests that in the brain of Cockayne syndrome patients MeCP2
binding would also be altered, thus possibly explaining some neurological defects of CS
patients.
C-terminal mutations in MeCP2 lack their capacity to accumulate on DNA lesions. These
mutations can be found in Rett syndrome patients. The characterization of the role of MeCP2
in the DNA damage response will thus also be relevant for the pathogenesis of Rett syn-
drome.
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7.4 Materials and Methods
7.4.1 Cell lines and cell culture
Human Embryonic Kidney (HEK) cells were maintained in DMEM supplemented with
10% FCS, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.1 mM nonessential amino acids,
and 1 mM sodium pyruvate.
XP4PASV (XPC-/-), CS1aSNV (CSB-/-), CS1aSNV+ GFP-CSB, XR-V15B eGFP-Ku-80,
Mouse dermal fibroblast Fen1-YFP, CS3BESV+ CSA-GFP were maintained in DMEM/Ham
F10 mixture (1:1) supplemented with 10% FCS, 100 U/mL penicillin and 100 µg/mL strep-
tomycin.
Cells were treated with ActinomycinD 2 µg/ml for 1h at 37°C (2 mg/ml stock solution
in Ethanol), α-amanitin 25 µg/ml for 10h at 37°C (1 mg/ml stock solution in Water).
7.4.2 DNA constructs and cell transfection
pcDNA3.1 vector expressing the Myc-His human MeCP2e1 were a gift from Dr. Berge
Minassian (Hospital for sick children, Canada). Myc-His mutants forms (R133C, T158M,
R306C and ∆308) were generated in the laboratory as described earlier [38]. To generate
MeCP2e1-GFP (WT and mutants) constructs, the coding region was amplified from the
pcDNA3.1 vector expressing MeCPe1 isoform and its mutants forms using the following
primers:
⪧ Forward: 5’-GATAAGATCTATGGCCGCCGCCGCCGCC-3’
⪧ Reverse: 5’-ATAAGGGCCCCTAGAGCTAACTCTCT-3’
⪧ Reverse for the ∆308: 5’-ATAAGGGCCCCTAGAGGTCTTGCGCT-3’
The amplified products were inserted in the eGFP-N3 plasmid using BglII and ApaI
cloning sites.
7.4.3 Transfection and Generation of stable cell lines
Transfections were carried out using JetPEI (Polyplus Transfection, Illkirch, France) fol-
lowing the manufacturer’s instructions (1 µg of DNA and 6 µl of JetPei). Stable clones were
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selected using G418 (Invitrogen, Cergy Pontoise, France). At 0.5 mg/ml for HEK cells and
0.2 mg/ml for CSB and XPC cells.
7.4.4 Immunofluorescence staining
Cells (0,5 × 106) were plated overnight on 24 mm coverslips in 6-wells plate. Cells were
washed twice with PBS and then fixed with paraformaldehyde (PFA) solution (2% in PBS)
for 15 min at room temperature. After 3 shorts washes with PBS-Triton X100 0,1% solution,
cells were permeabilized 2×10 min at RT in the same solution. After 2 washes with PBS+
solution (100 ml PBS, BSA, Glycine), cells were incubated 1h at RT or overnight at 4°C in
PBS+. Incubation with the primary antibody (Home made rabbit anti-MeCP2 diluted to
1/300 in PBS+) were performed for 1 h at RT. After 3 short and 2×10 min washes with
PBS-Triton X100, cells were incubated with secondary antibody (anti-rabbit IgG, Alexa633,
Invitrogen diluted to 1/400 in PBS+) for 1 h at RT. Cells were washed again in PBS-Triton
X100 and after a final wash with PBS, coveslips were mounted in Vectashield mounting
medium with DAPI (Vector).
Images were captured using LSM 710 inverted confocal microscope and analyzed using
Image J software.
7.4.5 Western blot analysis
Nuclear extract preparation of HEK cells was carried out as described previously [39].
Briefly cells were collected and washed with PBS. Cytoplasmic fraction was preparaed by
incubating the cells for 10 min on ice in cytoplasmic buffer (Hepes-KOH 10 mM pH 7.9, KCl
10 mM, MgCl2 1.5 mM, DTT 0.5 mM and PMSF 0.2 mM). After incubation cells were vor-
texed for 10 sec and centrifuged at 14000 rpm for 10 seconds. The supernatant corresponds
to the cytoplasmic extract. Pellets were washed twice with cytoplasmic buffer and then in-
cubated with the nuclear buffer (Hepes 20 mM pH 7.9, NaCl 420 mM, MgCl2 1.5 mM, EDTA
0,2 mM, glycérol 25% , DTT 0.5 mM and PMSF 0.2 mM) for 20 min on ice. Nuclear extract
were collected after centrifugation (14000 rpm for 2 min).
Around 25 µg of proteins from these nuclear extracts were loaded onto acrylamide gels.
After separation, proteins were transferred to nitrocellulose membrane (0,45 µm BioRad).
Membranes were blocked with TBS (Tris 10 mM, NaCL 0.15 M, pH 7.4) containing 3%
116 MECP2
7.4. Materials and Methods
7
skimmed powder milk (non-fat Regilait, France) and 0.1% Tween-20 overnight at 4°C. Be-
fore incubation, the TBS blocking buffer was centrifuged (100000 g for 45 min) and filtered
with 0,2 µm filters. Membranes were then incubated with rabbit anti-MeCP2 antibodies di-
luted in blocking buffer for 1h at RT. Anti-MCP2e1 was diluted to 1/2000, anti-MeCP2 to
1/3000 (home made antibody cf. chapter 6). After 4 × 10 min washes in PBS/ 0.1% Tween
buffer, membrane strips were incubated with goat anti-rabbit HRP (BioRad, 1:10000 dilu-
tion in blocking buffer) for 1h at RT. Finally, the blots were washed 4 × 10 min in PBS/ 0.1%
Tween buffer and revealed with an ECL kit (Pierce).
For anti-GFP staining, membranes were blocked in PBS with 5% skimmed powder milk
(non-fat Regilait, France) and 0.1% Tween-20 for 1h at RT, incubated with monoclonal mouse
anti-GFP antibody (Euromedex, diluted to 1/5000 in blocking buffer) for 2h at RT followed
by 1h at RT in anti-Mouse HRP (Biorad, diluted to 1/4000 in blocking buffer).
7.4.6 MeCP2 extraction from Brain
Brains from WT and CSB-/- 3 months mice were collected and submitted to 25 passages
through a Dounce homogenizer in 3 ml of Buffer A (Tris 50 mM pH=7.9, NaCL 150 mM,
Glycerol 20%, NP40 0,1% and B-mercaptoethanol 5mM complemented at the last minute
with protease inhibitor Complete C Roche and PMSF 1mM). After Dounce homogenization
with A and B Douncers, 1ml of this mixture was centrifuged at 13200 rpm for 15 min at
4°C and the pellet was resuspended in 1 ml of Buffer B (Buffer A with NaCl adjusted to 450
mM) and incubated for 20 min on ice. After centrifugation (13200 rpm for 15 min at 4°C),
the supernatant was removed (SN2) and the pellet was resuspended in 250 µl of Buffer B
and sonicated 2×15 min. After another centrifugation the supernatant (SN3 fraction) was
collected and the pellet resuspended in 100 µl of Buffer B. After 3 × 15 min sonication and a
final centrifugation the supernatant was collected as SN4 fraction and the residual pellet (P)
resuspended in laemmli buffer 6X. Quantification of MeCP2 in each fraction was normalized
using GAPDH signal.
For anti-GAPDH staining, membrane were stripped after anti-MeCP2 staining and
blocked in TBS with 3% BSA and 0.1% Tween-20 for 1h at RT. Membranes were incu-
bated with monoclonal mouse anti-GAPDH antibody (Abcam, diluted to 1/2000 in blocking
buffer) for 2h at RT followed by 1h at RT in anti-Mouse HRP (Biorad, diluted to 1/5000 in
blocking buffer).
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7.4.7 Strip-FRAP experiments
Cells were grown on coverslips. The FRAP experiments were performed on a Zeiss
LSM 710 inverted confocal microscope, using a 40x/1.3 objective and under a controlled
environment (37°C, 5% CO2). All recordings were made using the 488nm line of a 25 mW
argon laser.
Briefly, a strip region of interest (10 pixels high) was measured at 500 ms intervals for 5
seconds (at 1% output power, pixel dwell time 3.2 µs and Zoom 6), and then the region was
photobleached using 3 iterations at 100% output. Immediately after, fluorescence recovery
was monitored within the strip region for 60 seconds (500 ms intervals). Error bars represent
the standard error off the mean.
7.4.8 UV treatment
Cells were grown on 24 mm coverslips 2 days before experiments. The coverslips were
washed twice in PBS and irradiated with 60 J/m2 UVC (254 nm) through a 5 µm pore poly-
carbonate filter (Millipore). After irradiation, cells were incubated in their media for 10 and
30 min. Cells were then fixed and immunofluorescence was performed as described before.
7.4.9 Laser micro-irradiation
Laser-induced DNA damage was conducted as previously described [20]. Briefly, a Ti-
tanium TI: Sapphire laser system (Chameleon Ultra II coherent) was directly coupled to a
LSM 510NLO microscope (Zeiss) to obtain an 800 nm pulsed output (200 fs pulse width at
76 MHz, 10 mW output at the sample). Single nuclei targeted with the multiphoton laser
received an approximately 250 ms exposure restricted to a 1 µm wide strip.
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Conclusion
In 1999, Dr Zoghbi’s group revealed for the first time that mutations in the MeCP2 gene
are the cause of Rett syndrome. From 1999 until now, several milestone progresses have
been made to understand and identify the function of MeCP2 in the cell. It is quite clear
now that MeCP2 is a complex multifunctional protein controlling the genomic integrity at
different level. It has a role in chromatin remodeling, transcription, mRNA splicing and the
maintenance of the DNA methylation profile. This can explain the large variety of symp-
toms observed in Rett patients.
Our work allowed us to establish new tools to detect the protein and to suggest a poten-
tial new role of MeCP2 in the DNA damage response.
The first part of my thesis was dedicated to develop new antibodies specific to each
isoform of MeCP2 and to explore the expression of each isoform in vivo. It is hoped that
this will ultimately help to understand their respective contributions to Rett syndrome. We
showed that antibodies we generated can be used to perform Western blot, Immunofluores-
cence and Immunohistochemistry experiments. Recent results in our laboratory have shown
that these antibodies can be also used for immunoprecipitation of native chromatin (NChIP).
In order to study the expression of each isoform in vivo, we performed immunohistochem-
istry study on brain tissue of P24 and P55 Wt and MeCP2 KO mice. Results showed the
expression of the MeCP2e1 isoform in different structures of the brain such as the hippocam-
pus, the paraventricular nucleus and the arcuate nucleus. In this study we were unable to
detect any expression of MeCP2e2 isoform. These results were confirmed by western blot
techniques performed on brain tissue but also on other organs like lung, heart, liver, thy-
mus, spleen and kidney. Western blot analyses revealed the presence of MeCP2e1 protein at
high levels in the CNS, and a little in the lung and kidney.
Consequently we suggest that the MeCP2e1 isoform is the most abundant form in the or-
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ganism, whilst the MeCP2e2 isoform is expressed at such low levels that it was not detected
in our experiments.
The second part of my project was to understand the role of the MeCP2 protein in the
DNA damage response. Indeed we showed that MeCP2 accumulate on the damaged DNA.
We also demonstrated that the recruitment of MeCP2 to the lesions was independent from
transcription, GG-NER and TC-NER pathways but depends on the C-terminal region of
MeCP2. This region is important for the binding of MECP2 on the unmethylated DNA and
for its protein / protein interactions.
My results revealed also that in the absence of the Cockayne syndrome protein, CSB,
MeCP2 were unable to bind tightly to the chromatin.
It is important now to understand the function of MeCP2 in the DNA damage response:
Does the protein act directly in the repair pathway? Does it recognize the damage and
constitute a platform to recruit all other proteins implicated directly in the repair? Does
MeCP2, as a chromatin remodeler, modify the chromatin in the damaged region to allow the
recruitment of proteins implicated in DNA repair? Does MeCP2 have a role in reconstituting
chromatin after DNA damage?
To determine in which pathway MeCP2 could be involved, the MeCP2-GFP construct
can be expressed in other DNA repair deficient cell lines (Ku80-/-, BRCA1-/-, OGG1-/-
or PARP-1-/-, etc.). The recruitment will be monitored after damage induction with laser
micro-irradiation or photo-activated actinomycin D. We can also identify the type of le-
sions recognized by MeCP2 by using different damaging agents (UV, Ionizing Radiation,
Paraquat, Mitomycin-C, MMS, etc.).
It is known that transcription is inhibited at the site of damaged area. Does MeCP2 act as
a transcription repressor at the lesion sites? To answer this question, transcription activity
can be measured in locally damaged region after BrU incorporation in MeCP2-/- cells vs Wt.
It is interesting also to understand the relationship between MeCP2 and CSB. Does
MeCP2 interact directly with CSB? Can MeCP2 be found in the same complex with CSB?
Immunoprecipitation or ChiP experiments with or without DNA damage followed by Mass
Spectrometry analysis can be performed to answer this question.
All these results increase the complexity to understand the real function of MeCP2 in the
cell. The fact that the C-terminal region of MeCP2 is important for it’s binding to damaged
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DNA, and that this kind of mutations is found in Rett patients suggest that this novel role
for MeCP2 should be considered in the pathogenesis of Rett syndrome.
On the other hand we observed that Cockayne syndrome patients present clinical symp-
toms very similar to those observed in Rett patients. The fact that the binding of MeCP2
to the chromatin is altered in the absence of CSB can explain the neurological problems
observed in patients with Cockayne syndrome.
It is hoped that the results obtained in the course of this research project will pave the
way towards a better understanding of MeCP2’s many function, and ultimately helps to
designing therapies for Rett syndrome patients.
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Studying the MeCP2 protein:
Exploring its involvement in the DNA Damage
Response, and developing new tools for its detection.
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MECP2 127

A Appendix
High Levels of MeCP2 Depress MHC Class I
Expression in Neuronal Cells
Julie Miralvès1, Eddy Magdeleine1, Lara Kaddoum1, Hélène Brun2, Sophie Peries1, Etienne
Joly1
1Institut de Pharmacologie et Biologie Structurale, Centre National de la Recherche Scien-
tifique (CNRS), Toulouse, France
2 Centre de Physiopathologie Toulouse-Purpan, INSERM, Toulouse, France
Adapted from PLoS One. 2007 Dec 26;2(12):e1354
MECP2 129
AAppendix
A.1 Abstract
Background.The expression of MHC class I genes is repressed in mature neurons. The
molecular basis of this regulation is poorly understood, but the genes are particularly rich
in CpG islands. MeCP2 is a transcriptional repressor that binds to methylated CpG dinu-
cleotides; mutations in this protein also cause the neurodevelopmental disease called Rett
syndrome. Because MHC class I molecules play a role in neuronal connectivity, we hypoth-
esised that MeCP2 might repress MHC class I expression in the CNS and that this might
play a role in the pathology of Rett syndrome. Methodology.We show here that transiently
transfected cells expressing high levels of MeCP2 specifically downregulate cell-surface ex-
pression of MHC class I molecules in the neuronal cell line N2A and they prevent the in-
duction of MHC class I expression in response to interferon in these cells, supporting our
first hypothesis. Surprisingly, however, overexpression of the mutated forms of MeCP2 that
cause Rett syndrome had a similar effect on MHC class I expression as the wild-type protein.
Immunohistological analyses of brain slices from MECP2 knockout mice (the MeCP2tm1.1Bird
strain) demonstrated a small but reproducible increase in MHC class I when compared to
their wild-type littermates, but we found no difference in MHC class I expression in pri-
mary cultures of mixed glial cells (mainly neurons and astrocytes) from the knockout and
wild-type mice. Conclusion.These data suggest that high levels of MeCP2, such as those
found in mature neurons, may contribute to the repression of MHC expression, but we find
no evidence that MeCP2 regulation of MHC class I is important for the pathogenesis of Rett
syndrome.
A.2 Introduction
Mutations in the X-linked gene MECP2 cause Rett syndrome (RTT) [1, 2, 3], a progres-
sive neurodevelopmental disorder that affects around 1 in 10,000 female births [4]. Girls
with RTT develop normally until 6-18 months old, when they begin to regress, losing the
speech and hand skills they had acquired. Most patients develop severe mental retarda-
tion, seizures, repetitive hand movements, irregular breathing and motor-control problems
[5, 6, 7]. MECP2 encodes the methyl-CpG-binding protein 2 (MeCP2) [8, 9], which is thought
to regulate gene expression, but we do not yet understand how mutations in this protein
produce the pathological features of RTT.
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MECP2 knockout mice [10, 11, 12] and mice expressing a truncated form of MeCP2 [13]
display a RTT-like phenotype, demonstrating that MeCP2 deficiency is sufficient to induce
the syndrome. Moreover, mice in which MECP2 was conditionally deleted in neurons had a
similar phenotype to RTT patients [10, 14], and MeCP2-deficient mice were cured by expres-
sion of a transgenic MECP2 gene specifically in post-mitotic neurons [15]. These findings
indicate that the pathology of RTT is due to the lack of MeCP2 in the mature central nervous
system (CNS). Two recent studies have shown that the neurological defects in mutant mice
are reversed by restoration of MeCP2 expression in neurons, even at late postnatal stages
[16, 17], suggesting that gene therapy may be feasible.
The MECP2 mRNA is alternatively spliced to generate two protein isoforms (MeCP2A
and MeCP2B) that differ at their N-termini. Both forms are expressed ubiquitously, but
MeCP2B is more abundant than MeCP2A in the CNS [18, 19]. MeCP2 represses transcrip-
tion [20] by binding through its methyl-CpG-binding domain (MBD) [21] to methylated CpG
nucleotides [22, 23] and recruiting co-repressors that bind to its transcription repression do-
main (TRD) [24, 25, 26, 27]. Other studies, however, indicate that MeCP2 is a multifunctional
protein that affects gene regulation at many levels: MeCP2 interacts with an RNA-binding
protein called Y box-binding protein 1 to regulate splicing of target RNAs [28, 29]; two stud-
ies suggest that MeCP2 influences gene expression by participating in chromatin architec-
ture, independently of its capacity to bind methylated DNA [30, 31]; moreover, MeCP2 as-
sociates with the DNA methyltransferase Dnmt1 bound to hemi-methylated DNA and may
thus participate in maintaining the methylation state of newly synthesised DNA [32, 33].
Our knowledge of the activities of MeCP2 suggests that the pathologies associated with
MECP2 mutations are most likely due to the misregulation of neuronal genes. Several stud-
ies have identified possible target genes that are controlled by MeCP2, including the gene
encoding brain-derived neurotrophic factor (BDNF) [34, 35, 36], genes encoding inhibitors
of differentiation [37], and genes regulated by glucocorticoids [38]; their expression is al-
tered in MECP2 knockout mice, but whether this is responsible for the neuropathology seen
in RTT remains questionable.
We hypothesised that genes encoding MHC class I molecules (MHC class I) might be
amongst those that MeCP2 regulates in the CNS because these genes have a particularly
high CG content [39]. Two studies have demonstrated that expression of MHC class I is dy-
namically regulated during the post-natal development of the CNS and that MHC class I ex-
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pression is necessary for the activity-dependent synaptic rearrangements that occur during
normal brain development and for normal synaptic plasticity in the mature hippocampus
[40, 41]. If MHC class I expression was regulated by MeCP2, defects in these developmental
functions of MHC class I might contribute to the symptoms of RTT.
MHC class I is generally not expressed in adult brain except in response to cytokines (i.e.
inflammation) or injury [42]. This is believed to protect nervous tissue, which regenerates
poorly, from cytotoxic attack by the immune system. Several lines of evidence, however,
suggest that MHC class I is expressed in specific areas of the mature brain, as well as dur-
ing brain development, and they evoke a function for MHC class I molecules in neuronal
signalling [41, 43, 44, 45, 46]. This suggests that, rather than being simply shut down, MHC
class I genes must be very finely regulated throughout the CNS by activators and inhibitors
that, on the one hand, allow their function during development and, on the other hand,
ensure their silencing in the majority of neurons in which their expression could be detri-
mental.
We reasoned that misregulated expression of MHC class I in the brain due to mutations
in MeCP2 might disturb the establishment and maintenance of neuronal connections and
remodelling in the hippocampus during early child development and thus account for the
neurodevelopmental disorders of RTT. We therefore investigated whether MHC class I gene
expression is under the control of MeCP2 in neuronal cell lines in culture and whether MHC
class I gene expression is affected in MECP2 knockout mice.
A.3 Results
A.3.1 Overexpression of MeCP2 downregulates basal MHC class I
To investigate whether MeCP2 represses MHC class I expression, we transfected the
murine neuronal cell line N2A with pCMX plasmids that transiently express either human
or murine MeCP2A. Forty-eight hours after transfection, we evaluated by flow cytometry
the cell surface levels of Kk, Ld and Dd (the three ’classical’ MHC class I molecule heavy
chains expressed by N2A), β-2-microglobulin (the light chain subunit of MHC class I) and,
as control, the transferrin receptor, a cell surface glycoprotein of similar size and half-life to
MHC molecules (Figure A.1). The expression of MeCP2 in transfected cells was detected
by a rabbit anti-MeCP2 polyclonal antibody on cells fixed and permeabilised after they had
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been stained for MHC class I cell surface expression. Dot plot representative examples of
these analyses are shown on Figure A.1A, where each dot represents an individual cell, and
an decrease in MHC staining results in a shift to the left, and an increase in MeCP2 in an
upward shift. Because these are transient transfections, MeCP2 overexpression is detected
in only a certain percentage (typically 20-30%) of the cells. As can be seen for all MHC class
I molecules (Kk, Ld, Dd) and β-2-microglobulin, in the cloud of cells overexpressing MeCP2,
we detected a clear shift to the left compared to the lower cloud of untransfected cells and
to mock-transfected cells, indicating a reduction of the cell surface expression of all these
molecules in the cells that overexpress MeCP2. This effect appears to be specific for these
molecules since the level of transferrin receptor was basically unaffected by MeCP2 over-
expression. The reproducibility and statistical significance of these observations was ascer-
tained by repeating this experiment many times, which also allowed us to conclude that
MeCP2 overexpression results in a similar 40% decrease of all three MHC class I molecules
and of β-2-microglobulin (Figure A.1B). In the experiment shown, the mock-transfected cells
were simply treated with the transfection reagent, but similar results were obtained when
the negative control consisted of empty plasmids, or plasmids expressing other proteins
such as GFP (not shown).
No functional difference has been described between the two isoforms of MeCP2,
MeCP2A and MeCP2B. We therefore explored whether these two isoforms had the same
effect on MHC class I molecules and whether their effects might differ according to the cell
type in which they are expressed. We transfected vectors encoding the Myc-tagged version
of human MeCP2A or MeCP2B into either N2A or the mouse fibroblast cell line NIH 3T3.
In this experiment, we detected MeCP2 expression by using an anti-Myc9E10 monoclonal
antibody because it produced a much stronger signal than the anti-MeCP2 antibody. The
level of MHC class I was evaluated at the same time by using a rat anti-pan-MHC antibody,
M1/42. The double staining in mock-transfected and transfected cells was analysed by flow
cytometry. MeCP2 overexpression induced a similar extent of repression of MHC class I
irrespective of the isoform or cell type in which it was expressed (Figure A.1C): the cell sur-
face level of MHC class I decreased by approximately 35% when compared to the basal level
(p<0.01 in N2A; p<0.001 in NIH 3T3) when either MeCP2A or MeCP2B were overexpressed
in N2A or in NIH 3T3 cells.
We noted a correlation in these experiments between the repressive effect exerted by
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Figure A.1 — MeCP2 overexpression diminishes MHC class I expression. N2A cells trans-
fected with pCMX vectors expressing either murine or human MeCP2 were immunos-
tained for one of the three MHC class I molecules (Kk, Ld or Dd), β2-microglobulin or
the transferrin receptor on the cell surface as well as for intracellular MeCP2. The level
of staining was then analysed by fluorescence-activated cell sorting. Panel A: Dot plots
of the amount of surface antigen (x-axis) against the amount of intracellular MeCP2 (y-
axis) in cells transiently transfected with pCMX expressing human MeCP2 and analysed
48 hrs later. Panel B: For each kind of staining, the variation in expression level was cal-
culated as the ratio of MFI of MeCP2 overexpressing cells over MFI of mock-transfected
cells. The histograms summarise the mean (±SEM) of the variation in cell surface levels
from 15 independent transfections with vectors expressing mouse MeCP2A (grey fill) and
12 independent transfections with vectors expressing human MeCP2A (black fill). Panel
C: N2A and NIH3T3 cells were transfected with empty pcDNA3.1(+) (mock cells) or ex-
pressing Myc-tagged human MeCP2A or B isoforms. 48 h after transfection, cells were
subjected to double staining against cell surface MHC class I molecules and intracellular
Myc-tagged MeCP2, then analyzed by flow cytometry. The variation in expression level
of MHC class I molecules was calculated as the ratio of MFI of MeCP2 over-expressing
cells over the MFI of mock cells. The histograms represent the mean (±SEM) of the cell
surface level variation from 4 independent transfections with each of the vectors. Panel D:
A representative example of dot-plots obtained for double immunostaining of transiently
transfected N2A cells with anti-Myc 9E10 and rat-anti-mouse-MHC I M1/42 monoclonal
antibodies. Dotted and continuous circles indicate the different populations expressing
high and intermediate levels of MeCP2, respectively. Statistical significance of difference
between groups was analysed by using an unpaired t-test (∗∗, p<0.01; ∗∗∗, p<0.001).
MeCP2 on MHC class I and β-2-microglobulin and the quantity of MeCP2 expressed by the
transfected cells: cells expressing high levels of MeCP2 (dotted circle, Figure A.1D) had less
MHC class I on their surface than cells expressing MeCP2 at lower levels (continuous circle),
which expressed levels of MHC class I similar to those in cells in which no MeCP2 staining
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was detected and to those in mock-transfected cells. Repression of MHC class I expression
by MeCP2 therefore appears to require very high levels of MeCP2. We generated stably
transfected lines of N2A expressing either MeCP2A or MeCP2B but the levels of protein
expressed by these cells was relatively low (at best comparable to those in the continuous
circle in Figure A.1D). It is therefore of little surprise that the levels of MHC class I expressed
by those cells was not discernibly different from that of untransfected cells (not shown).
Evaluation by quantitative western blot of the levels of MeCP2 protein expressed in these
various transfected cells revealed bands of comparable intensities in stable transfectants and
in brain extracts, and bands that were two to five fold more intense in transiently transfected
populations (not shown). Since mature neurons represent approximately 15% of all cells in
the brain parenchyma, we can further estimate that our stable transfectants express levels
of MeCP2 which are roughly one sixth of those found in mature neurons. Conversely, since
the efficiency of the transient transfections in this experiment was approximately 10%, we
estimate that the levels of MeCP2 attained in high expressors after transient transfections
are 20 to 50 fold higher than the levels in stable transfectants (and therefore three to eight
fold higher than in intra-cerebral neurons).
A.3.2 Overexpression of MeCP2 markedly reduces MHC class I upregulation by
IFN-γ
The cytokine IFN-γ transactivates MHC class I expression predominantly by binding to
IFN regulatory factor-1, which binds, in turn, to the interferon-stimulated response element,
ISRE, a GC-rich region and therefore a potential binding site also for MeCP2 [47]. Since
MeCP2 appeared to act as a repressor of MHC class I expression (Figure A.1), we wanted
to test whether it would interfere with transactivation of MHC class I expression by IFN-
γ. To do so, we transfected N2A cells with pCMX vectors driving the expression of either
murine or human forms of MeCP2A. The following day, these transiently transfected cells
were divided into two flasks that were either treated or not with IFN-γ for 48hrs. The lev-
els of cell-surface MHC class I, β-2-microglobulin and transferrin receptor, and intracellular
MeCP2, were evaluated by flow cytometry as in the previous experiments (Figure A.2). As
can be seen by the shift of the clouds between the higher and the lower panels, treatment
with IFN-γ resulted in a two- to four-fold induction of MHC class I and β2-microglobulin
in both mock-transfected populations and transfected populations (Figure A.2A). Individ-
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ual transfected cells expressing MeCP2 at high levels, however, had little more Ld and β2-
microglobulin when treated with IFN-? than untreated MeCP2-expressing cells (compare
the populations encircled in Figure A.2A IFN-γ with those without IFN-γ). Cells overex-
pressing MeCP2 therefore appear to respond to IFN-γ by upregulating MHC class I to a
much lesser extent than do cells not expressing MeCP2.
Figure A.2 — Transient overexpression of MeCP2 inhibits MHC class I induction by IFN-
γ. N2A cells transfected with pCMX vectors expressing murine or human MeCP2 were
treated or not with IFN-γ for 48 hrs and then double immunostained for cell surface β2-
microglobulin, transferrin receptor or MHC class I and intracellular MeCP2. Panel A:
Dot-plots of transfected cells analysed by flow cytometry showing the cell surface level of
the MHC class I molecule Ld or β2-microglobulin (x-axis) plotted against the level of intra-
cellular MeCP2 (y-axis). Panel B: The induction factor was calculated as the ratio of MFI
of treated cells (over-expressing MeCP2 or untransfected cells) on MFI of untreated N2A
cells. Values used for the histogram are the mean (±SEM) of induction factors obtained in
seven independent transfection experiments. Statistical significance of difference between
groups was analysed by using an unpaired t-test (∗, p<0.05; ∗∗, p<0.01; ∗∗∗, p<0.001).
The statistical significance of the differences in response to IFN-γ was confirmed for
all three MHC class I molecules expressed by the N2A cell line (Kk, Ld, Dd) and for β-2-
microglobulin in six independent experiments (Figure A.2B), whereas the levels of transfer-
rin receptor were not significantly affected. This effect was also observed in other cell lines
such as NIH 3T3 fibroblasts and human HEK 293 cells (not shown).
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A.3.3 MeCP2 mutants retain their repressive effect on MHC class I expression
Many disease-causing mutations of MECP2 have been described [48]. Among them,
some occur more frequently than others, and/or have been more thoroughly characterised.
To investigate the effect of these MECP2 mutations on MHC class I expression, we tran-
siently transfected the N2A cell line with plasmids expressing well-characterised mutants
of both the A and B isoforms of MeCP2 (T158M, R133C, R306C and R308∗). The point muta-
tions T158M, R133C and R306C are located in the functional MBD and TRD domains of the
protein (Figure A.3A). The mutant form that is truncated after the R308 residue corresponds
to the form of MeCP2 found in the mouse model of RTT generated by Dr. Zoghbi’s group
[13]. We performed mutagenesis on vectors expressing either the A or B form of Myc-tagged
MeCP2. All the mutated plasmids were sequenced and checked for functional expression
and intracellular localisation of the wild-type and mutated MeCP2 proteins by anti-Myc im-
munofluorescence on transiently transfected N2A cells (Figure A.3B). All the mutant forms
of Myc-taged MeCP2 were located in intranuclear punctate structures typical of the wild-
type protein, which forms foci on heterochromatin [49, 23] (data is shown for the R133C
MeCP2A-Myc mutant and the wild-type pMeCP2A-Myc protein only). Subsequently, we
evaluated the cell-surface expression level of MHC class I in the transiently transfected N2A
cells by flow cytometry using the rat anti-pan-MHC I antibody M1/42, as before. The intra-
cellular MeCP2 level was evaluated based on the intensity of immunostaining for the Myc
tag, and was found to be similar to the wild-type for both the A and B forms of the four
mutants. The R133C MeCP2A-Myc mutant had the same effect as its wild-type counterpart
on the cell-surface level of MHC class I (Figure A.3C), whereas neither mutant nor wild-type
had a significant effect on expression of the transferrin receptor (not shown). Similar effects
were found for both A and B isoforms of all four mutants tested (Data for T158M R306C
and R308∗ are not shown). Thus, these mutations responsible for RTT do not abolish the
repressive effect of MeCP2 on MHC class I in cells in culture. These results strongly suggest
that the repressive function of MeCP2 on the levels of MHC molecules expressed by tran-
siently transfected cells in vitro is unlikely to be directly related to the pathogenesis of Rett
syndrome.
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Figure A.3 — TMutant forms of MeCP2 that cause RTT retain their repressive effect on
MHC class I expression. Panel A: Schematic representation of the MeCP2 protein. Red
and orange arrows indicate the positions of the mutations introduced in MeCP2 by site-
directed mutagenesis (MBD: methyl-CpG binding domain, TRD: transcription repression
domain, WW: group II WW-domain-binding region). Panel B: N2A cells transfected
with empty pcDNA3.1 (mock cells), with pcDNA3.1 expressing Myc-tagged MeCP2A
(pMeCP2A-myc) or with pcDNA3.1 expressing Myc-tagged MeCP2A with the R133C
point mutation (pMeCP2A-R133C-myc) were stained with mouse anti-Myc 9E10 mono-
clonal antibody, and FITC-labelled anti-mouse IgG antibody. Coverslips were mounted
in DAPI-containing ProLong Gold antifade reagent (Molecular Probes) before observa-
tion by fluorescence microscopy. Panel C: N2A cells transfected as in panel B were double
immunostained for cell surface MHC class I and intracellular Myc-tagged MeCP2, then
analysed by flow cytometry. Similar data were obtained for all four mutated forms of
MeCP2A and MeCP2B (not shown), and these observations were reproduced in three in-
dependent transfection experiments.
A.3.4 Expression of MHC class I in cells from MeCP2-knockout mice is no dif-
ferent to that in cells from wild-type mice
Our data from experiments with cells in culture (above) suggest that the genes encod-
ing MHC class I and β2-microglobulin are controlled by MeCP2; overexpression of normal
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MeCP2 downregulates their expression. To find out whether this is the case in vivo, we
investigated whether neuronal cells from MeCP2 knockout mice (MeCP2tm1.1Bird) contained
elevated levels of MHC class I by performing immunohistochemistry on frozen brain sec-
tions of MECP2 knockout hemizygous male (-/y) mice and of their wild-type littermates us-
ing two different rat monoclonal antibodies directed against mouse MHC class I molecules.
The results we obtained suggest that there are slightly higher levels of MHC class I expres-
sion in some regions of the brains of MeCP2 knockout mice than in the same regions of
the wild-type control brains (Figure A.4). Although these differences were not always seen
for all brain areas of MECP2 knockout mice compared to their control littermates, when a
difference was seen, it was always for higher expression in MECP2 knockout animals.
Figure A.4 — Evaluation of MHC class I expression in adult mouse brain slices. Serial
frozen sections of adult male wild-type and MeCP2−/y littermates were analysed for ex-
pression of MHC class I by immunohistochemistry using the rat R1-21.2 monoclonal an-
tibody and EnVision detection technology (Dako). For the negative control, the same
staining process was used omitting the primary antibody. Similar results were obtained
with the M1/42 monoclonal antibody. Similar results were obtained in independent ex-
periments on brains from three different pairs of mice.
The immunohistochemistry approach did not allow us to quantify the small variations
we observed in MHC class I expression between MeCP2 knockout and wild-type mice or to
identify the cell types that expressed MHC class I in the absence of MeCP2 (neurons, astro-
cytes, oligodendrocytes or endothelial cells). We therefore decided to look at primary cul-
tures of brain cells (called mixed glial cells; MGCs) and fibroblasts from spleen taken from
individual 2-day-old mice born from crossing a heterozygous female (MeCP2tm1.1Bird+/−)
with a wild-type male. The tail DNA from each newborn mouse used to prepare the cell
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lines was analysed to establish the genotype of each culture. On the second day of culture,
the MGCs were treated with IFN-γ or not and then analysed two days later for expression
of MHC class I on the cell surface by flow cytometry (Figure A.5). The fibroblast cultures,
which took a few more days to establish, were similarly treated with IFN-γ after five days
and analysed on the seventh day. Figure A.5A shows typical examples of histograms ob-
tained with wild-type and MeCP2tm1.1Bird−/y male littermates. Similar data were obtained
for all four genotypes: wild-type female (+/+) and male (+/y), heterozygous mutant female
(MeCP2tm1.1Bird−/+) and hemizygous mutant male (MeCP2tm1.1Bird−/y).
Neurons, which we identified by their expression of βIII-tubulin and their smaller size
(see population R2, inset Figure A.5A), had no detectable MHC class I (grey-filled curves)
when compared to background (white-filled curves), and treatment with IFN-γ induced a
small amount of MHC class I in cells from both the wild-type and knockout animals. As-
trocytes, which comprise the majority of the population of large cells [50] (population R1,
inset Figure A.5A), spontaneously expressed more MHC class I, which was highly induced
by IFN-γ but no significant differences were seen between the two genotypes. Although the
populations in the cultures of spleen-derived fibroblasts were much more heterogeneous,
similar levels of MHC class I were found in the cells from the wild-type and knockout
animals. These measurements were performed on cell cultures derived from 24 newborn
animals from nine independent litters, with very similar results.
To compare data obtained in independent experiments, we plotted the fold-induction
of MHC class I expression after treatment with IFN-γ compared to untreated cells. Figure
A.5B displays the fold-induction of MHC class I by IFN-γ in each cell culture derived from
an individual mouse as well as the mean for cell cultures of each genotype. No signifi-
cant differences were found between wild-type and MeCP2-knockout cells. The deficiency
in MeCP2 thus affects neither the basal nor the inducible MHC class I expression level in
primary MGC cultures.
A.4 Discussion
Reports by Shatz and colleagues [40, 51, 41] have demonstrated clearly that tight regu-
lation of MHC class I genes in the CNS contributes to the establishment and maintenance
of neuronal connections during development, as well as to plastic remodelling in the hip-
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Figure A.5 — Deletion of MECP2 does not affect basal or IFN-γ -induced MHC class I ex-
pression in primary cultures of mixed glial cells. Mixed glial cell cultures established from
two-day old wild-type, MeCP2+/− and MeCP2−/y mice (10, 6 and 8 animals per group,
respectively) were treated or not with IFN-γ on the second day of culture and analysed
two days later by flow cytometry for MHC class I expression. Neurons were identified by
their intracellular staining with an anti-β-III-tubulin antibody (inset). Large cells, contain-
ing mainly astrocytes, were analysed separately by an appropriate forward/side scatter
gate. Primary spleen fibroblasts from the same mice were also subjected or not to IFN-γ
treatment and stained for their MHC class I expression. Panel A: Representative his-
tograms showing cell surface staining (x axis) against cell number (y axis), obtained with
cells from wild-type and MeCP2−/y male littermates. White-filled curves represent back-
ground staining, gray-filled curves represent MHC I-specific staining. Panel B: MHC class
I fold-induction in response to IFN-γ was calculated as the ratio of MFI of treated cells
(induced MHC I level) on MFI of untreated cells (basal MHC I level). Grey-filled squares
show MHC class I fold-induction for individual mice and for each cell type. White-filled
squares represent the group’s mean of fold-inductions (±SD).
pocampus and to neuronal signalling in specific areas of the brain [40, 51, 41]. We reasoned
that the transcriptional repressor MeCP2 might be involved in regulating MHC class I ex-
pression in the CNS for three main reasons. Firstly, expression of MeCP2 is strictly regulated
during development [52, 53, 54] and specifically in various cell types [55] and is highest
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in mature neurons [56, 57], which do not express MHC class I. Secondly, MeCP2 binds to
methylated cytidine residues on CpG dinucleotides [21] and the genes for MHC class I are
particularly rich in C/G residues [39]. Thirdly, mutations in the MECP2 gene are responsible
for the neurodevelopmental disorder RTT. We hypothesised that MeCP2 represses expres-
sion of MHC class I and that mutations responsible for RTT might cause the loss of this
activity.
In support of the first part of this hypothesis, we showed clearly that overexpression of
either of the two isoforms of MeCP2 by transient transfection of neuronal and fibroblastic
cell lines results in reduced levels of MHC class I and β2-microglobulin at the cell surface.
Furthermore, overexpression of MeCP2 blocked induction of MHC class I in these cells in
response to IFN-γ. We could not determine whether this decreased expression of MHC class
I and β2-microglobulin in response to MeCP2 overexpression was due to reduced transcrip-
tion, translation or transport to the cell surface because the cells were transiently transfected;
only cells that expressed high levels of MeCP2 showed reduced levels of MHC class I on
their surface, so we could not quantify the levels of mRNA by RT-PCR or northern blot.
The fact that we observed very similar extents of repression of all three MHC class I
forms (Kk, Ld and Dd) as well as of β2-microglobulin suggests that MeCP2 probably does
not act directly on the promoters of the various loci encoding MHC class I, which are not
identical. These considerations lead us to think that the effect of MeCP2 may be a more
’global’, indirect mechanism than transcriptional repression by binding to methyl cytosine
in the promoters.
The global decrease in cell surface MHC class I in MeCP2-expressing cells might be due
to an effect on chromatin architecture encompassing the whole MHC region, which includes,
in addition to the MHC class I loci, other genes involved in the assembly and transport of
MHC molecules [58, 59] that might contribute to a global effect. If MeCP2 condenses the
chromatin in the MHC region, this might block access of transcription factors and regula-
tory factors to the genes, as suggested by the work of Georgel and colleagues [30]. Such
chromatin condensation would also explain the failure of IFN-γ to induce MHC class I in
cells overexpressing MeCP2 if it prevented IFN regulatory factors from binding to their re-
sponse element.
Our findings that the MeCP2 forms mutated either in the MBD or TRD domains con-
serve their repressive effect on MHC class I expression strengthen this interpretation that
142 MECP2
A.4. Discussion
A
MeCP2 has an indirect effect on transcription through its effect on chromatin architecture.
These mutations affect only transcriptional repression by MeCP2, preventing it from bind-
ing to methylated DNA and from recruiting repressor partners, but the other functions of
the protein are not affected, particularly its capacity to silence gene expression by driving
chromatin condensation [30, 60] and stabilising large silencing chromatin loops [31]. The
ability of MeCP2 to condense chromatin by methylation-independent DNA binding relies
on regions within the N-terminal 294 residues, distinct from the MBD [30, 61].
MeCP2 induces chromatin condensation in three successive steps: first, it binds to the
linker DNA between nucleosomes; second, it brings the nucleosomes together in a ’stem
conformation’ through DNA-protein interactions, and third, it binds to the nucleosomes
themselves to produce full chromatin compaction [60]. Whereas the C-terminal region of
MeCP2 is dispensable for the two first steps, it is apparently required for maximal com-
paction of the chromatin since the R294X mutation abolishes bridging between nucleo-
somes [61, 60]. By contrast, the R133C mutation, which abolishes the selective recognition
of methylated DNA, retains the chromatin compaction properties of the wild-type protein
[30]. The two other point mutations we tested in this study, T158M and R306C, like R133C,
may retain their compaction properties and thus their repressive effect on MHC genes. Our
findings with the truncated form R308∗, which also retains the same repressive effect on
MHC class I expression as the wild-type protein, indicate that the repression of MHC genes
by MeCP2 does not involve the C-terminal portion of the protein. The effects of MeCP2
on MHC expression therefore probably does not involve the third step of MeCP2-induced
chromatin condensation (above) but may involve a conformational change in the ’stem or-
ganization’ of the chromatin around the MHC region [61, 60].
If MeCP2 represses MHC class I expression, we expected to see elevated levels of MHC
class I in the brains of MECP2 knockout mice (strain MeCP2tm1.1Bird) when compared to
mice with fully functional MECP2 [11]. When we stained brain slices immunohistochemi-
cally with two different antibodies, we saw a small but reproducible increase in MHC class I
expression in the brains of three knockout male mice when compared to those of their wild-
type littermates, but these results were purely qualitative, and it was not possible to quantify
these differences by immunohistochemistry. We decided, therefore, to produce primary cul-
tures of MGCs from knockout mice in order to quantify MHC class I expression by flow
cytometry. This approach also allowed us to distinguish a neuronal population, comprised
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of small cells expressing βIII-tubulin, and a population of large cells comprised mostly of
astrocytes. This quantitative analysis detected no difference between MHC class I levels on
the surface of cells derived from animals carrying an inactivated MECP2 gene and those
from their wild-type littermates whether for the basal level of MHC class I expression or for
the level induced by IFN-γ. This was true for the neuronal population and the astrocyte
population, as well as for primary cultures of spleen fibroblasts.
We conclude from these studies that there may be a small quantitative increase in MHC
class I in the brains of MECP2 knockout mice when compared to the wild-type but this
increase is not seen in isolated primary MGCs containing mostly neurons and astrocytes.
The possibility remains that the levels of MeCP2 in these primary cell cultures were in-
sufficient to see a difference. Indeed, our experiments with N2A cells showed that rela-
tively high levels of MeCP2 are necessary to observe its repressive effect on MHC class I
expression. Several studies have shown a direct correlation between age and MeCP2 ex-
pression, with maximal levels of expression in post-mitotic mature and differentiated neu-
rons [62, 52, 53, 56, 57, 55]. Although the neuronal populations in our MGCs expressed
βIII-tubulin, a marker of neuronal differentiation, they were very probably far from being
fully mature. In support of this, we were unable to detect MeCP2 expression in neona-
tal MGCs by flow cytometry (not shown). The neurons that we analysed in neonate MGC
might therefore have been too immature to demonstrate a defect in MHC regulation due to
MeCP2 deficiency. It was, however, not feasible to obtain brain tissue from adult MECP2
knockout animals for these studies because the mice die at around eight weeks old.
Three groups have performed transcriptome analyses on microarrays of cDNA prepared
from post-mortem brain tissue of girls with RTT and from the brains of MECP2 knockout
mice [63, 64, 65]. At least one of these studies supports the idea that MeCP2 may influence
MHC expression in the CNS: Colantuoni et al. [63] found a 5.8-fold increase in expression
of the mRNA for the MHC class I molecule HLA-A in a RTT syndrome patient relative to
matched controls. This small increase in MHC class I expression in the absence of MeCP2 is
consistent with our hypothesis and further suggests that such subtle disregulation might be
detectable only in older mice than those we used in our study.
We found that the forms of MeCP2 carrying RTT-causing mutations retained their re-
pressive function on MHC expression in transiently transfected cells. Although this obser-
vation does not go against our findings that MeCP2 can down-regulate MHC expression in
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cells where it is expressed at high levels, these results lead us to conclude that repression of
MHC class I expression by MeCP2 is very probably not directly relevant to the pathogenesis
of RTT. Mutations in the MECP2 gene are also suspected to be at the origin of a large panel
of other neurological diseases such as autism [66, 67], Angelman syndrome [68], X-linked
mental retardation [69, 70], and severe neonatal encephalopathy [71, 72]. It may therefore
be that those types of mutations responsible for other diseases could be related to the MHC-
regulating activity of MeCP2. Additionally, the majority of MECP2 mutations in RTT are
loss-of-function mutations, but overexpression of MECP2 by gene duplication in a mouse
model [73], as well as in human clinical cases [74, 75, 76, 77], also causes mental retardation
and progressive neurological diseases. Since high levels of MeCP2 can repress cell surface
expression of MHC class I, at least in neuronal cell lines, MeCP2 overexpression might result
in an overrepression of MHC gene expression in the CNS, which may contribute to certain
pathologies by preventing MHC molecules from fulfilling their roles during CNS develop-
ment and in synaptic plasticity [51]. Inappropriate temporal and spatial repression of MHC
genes by overexpressed MeCP2 might induce defects in neuronal functions similar to those
observed in β2m/TAP1 deficient mice [41]. Further experiments will be required to explore
this eventuality.
This leaves us with the important conclusion that high levels of MeCP2, like those found
in mature neurons, repress expression of MHC class I molecules and this may be an impor-
tant physiological factor contributing to the repression of MHC class I in the CNS.
A.5 Materials and Methods
A.5.1 Mice
The MEPC2 knockout mice (MeCP2tm1.1Bird) were obtained from the Institute for Stem
Cell Research, Edinburgh, UK. These mice have a RTT-like progressive neurodevelopmen-
tal disease very similar to that seen in patients; the males (-/y) suffer from a much more
severe form of the disease than the heterozygous (+/-) females, and are sterile. MeCP2+/−
female mice were mated with C57BL/6 male mice purchased from the Centre de Recherche
et d’Élevage, Janvier, France. The litters obtained were genotyped initially as recommended
by the Jackson Laboratory, and later with an optimised set of primers [78]. All experiments
involving animals were performed in compliance with the relevant laws and institutional
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guidelines.
A.5.2 Cell lines
The N2A and NIH 3T3 cell lines were maintained in DMEM with 10% foetal calf serum
(FCS) and antibiotics. For the origin and description of these cell lines see ATCC.
A.5.3 Antibodies
Polyclonal primary antibodies: rabbit anti-MeCP2 polyclonal IgG (Upstate), mouse anti-
C terminal peptide of MeCP2 (Sigma) and rabbit anti-beta III-tubulin polyclonal IgG (Ab-
cam).
Hybridoma supernatants from clones (obtained from ATCC): 9E10 (mouse anti-myc
IgG1), M1/42 (rat anti-H2 IgG2a), R1-21.2 (rat anti-mouse H2 IgG2b), HB25 (mouse anti-
H2 Kk IgG2a), 28.14.8 (mouse anti-H2 Db, Ld and Dq IgG2a), 30.5.7 (mouse anti-H2 Ld, Dq
and Lq IgG2a), 34.4.20 (mouse anti-H2 Dd IgG2a), Y-3 (mouse anti-H2 Kb IgG2b), S19.8 (mouse
anti-beta 2 microglobulin b and c IgG2b), R17.217 (rat anti-mouse transferrin receptor IgG2a).
Secondary fluorescent antibodies: FITC goat anti-mouse IgG (Dako), fluorescein goat
anti-rabbit IgG (H+L) (Molecular Probes, Invitrogen), AlexaFluor 647 goat anti-rat IgG
(H+L) (Molecular Probes, Invitrogen), AlexaFluor 647 and 680 goat anti-mouse IgG (H+L)
(Molecular Probes, Invitrogen).
A.5.4 Plasmids
pCMX vectors expressing mouse MeCP2α, MeCP2β and human MeCP2A were de-
scribed previously [79, 18]. pcDNA3.1(A) vectors expressing Myc-tagged human MeCP2A
and MeCP2B [19] were provided by Dr. Berge A. Minassian of the Hospital for Sick Chil-
dren, Toronto, Ontario, Canada.
A.5.5 Mutagenesis
Site-directed mutagenesis of pcDNA3.1(A) vectors driving expression of Myc-tagged
human MeCP2A and MeCP2B was carried out as described previously [80]. Briefly, dur-
ing a first PCR reaction typically [9× (95°C for 30 s, 55°C for 1 min, 68°C for 1 min)] using
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high-fidelity Taq polymerase (Invitrogen), a DNA template was generated between a for-
ward T7 oligonucleotide (5’-GTAATACGACTCACTATAG-3’) annealing to pcDNA3.1 (A)
upstream of the multiple cloning site and a reverse oligonucleotide annealing to the MeCP2
sequence and carrying the chosen mutations:
⪧ R133C: 5’-aatcaactccactttactgcagaaggcttttccctg-3’
⪧ T158M: 5’-ccctctcccagttaccatgaagtcaaaatcatt-3’
⪧ R306C: 5’-gatgctgaccgtctcacgcgtcttgcacttcttgatggggag-3’
These primers were designed to produce or remove a restriction enzyme site allowing
simple screening of the recovered plasmids (gain of an PstI site for R133C; gain of an NlaIII
site for T158M, and loss of an SmaI site for R306C). During a second PCR reaction [9× (95°C
for 30 s, 68°C for 6 min)], the newly amplified DNA fragments served as megaprimers to
complete the synthesis of the remainder of the plasmids. The extension time of the last cycle
was 16 min, followed by digestion with 10 U DpnI at 37°C for 1 hr to destroy the original
methylated plasmids. The mutated plasmids were recovered by transforming competent
DH5α bacteria and they were screened by restriction digest. The sequence of the inserts
corresponding to the MeCP2 open reading frame was then checked by direct sequencing.
To generate pcDNA3.1 plasmids expressing the R308∗ truncated forms of Myc-tagged
MeCP2A and MeCP2B, a PCR reaction [12× (94°C, 45 s; 50°C, 45 s; 68°C, 2 min 30 s), 12×
(94°C, 45 s; 68°C, 2 min 30 s)] using high-fidelity Taq polymerase (Invitrogen), was carried
out on pcDNA3.1-MeCP2A using the following oligonucleotides:
⪧ Forward T7 primer: 5’-GTAATACGACTCACTATAG-3’
⪧ Reverse primer: 5’-gcgtctagagagggtggacaccagca-3’
The reverse common primer, annealing in the MECP2 sequence, was designed to include
an XbaI restriction site immediately following residue 308 of MeCP2, which is also located
upstream of the sequence encoding the Myc tag in the original pcDNA3.1 Myc plasmid.
The amplified MeCP2(1-308) sequence was digested with XcmI and XbaI and ligated, using
T4 DNA ligase (NEB), into pcDNA3.1 human MeCP2A or B myc-tagged plasmids digested
with the same enzymes. The plasmids expressing truncated Myc-tagged MeCP2A and B
forms were recovered by transforming competent DH5α bacteria and they were screened
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by restriction digest. The sequence of the inserts corresponding to the MeCP2(R308∗) open
reading frame was then checked by direct sequencing.
A.5.6 Transfection
Transfections were carried out using FuGENE 6 (Roche Applied Bioscience), following
the manufacturer’s instructions (using 2 µg of plasmid and 6 µl of transfection reagent).
Briefly, N2A or NIH 3T3 cells were plated in 25 cm2 flasks at least 12 hrs before transfec-
tion. Stable N2A transfectants expressing Myc-tagged wild-type and mutated MeCP2A and
MeCP2B were selected by adding 0.5 mg/ml of G418 three days after transfection, and the
populations obtained were subsequently maintained in this selecting medium.
A.5.7 Quantitative Western Blot
Whole cellular extracts from adult mouse brain, and from transiently and stably trans-
fected N2A cells were prepared, and blotted on nitrocellulose after separation by 4-12%
SDS-PAGE (50 µg of cellular extract per sample). Levels of MeCP2 were then measured on
an Odyssey infrared scanner (Li-Cor) after staining with a mouse anti-MeCP2 polyclonal
antibody (C terminal portion, Sigma), followed by an Alexa 680 anti-mouse secondary an-
tibody. Normalisation between samples was carried out using a mouse monoclonal against
GAPDH (ab9484, abcam) and the same secondary reagent on the lower part of the same
blot.
A.5.8 Cells staining and cytometry
For immunochemical staining of the cell surface for MHC class I, β-2-microglobulin or
transferrin receptor, cells were harvested by trypsinisation and washed once with medium
to obtain a single-cell suspension. The resuspended cells were then incubated on ice with
a saturating concentration of the appropriate hybridoma supernatant. Thirty minutes later,
cells were washed three times in phosphate-buffered saline (PBS) containing 2% FCS, then
incubated for thirty minutes on ice with the suitable secondary reagent and washed three
times before fixation in PBS containing 1% paraformaldehyde. When intracellular MeCP2 or
β-III-tubulin was also analysed, further staining steps were performed as described above,
but adding 0.3% saponin in all buffers. Labelled cells were analysed using a FACScalibur
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cytometer and CellQuest software (BD Biosciences). Dead cells were excluded using appro-
priate forward/side scatter gates.
A.5.9 Immunohistochemistry of brain slices
Brains from adult MeCP2−/y and wild-type mice were embedded in Tissue-Tek OCT
compound (Sakura) and frozen in dry ice-cold isopentane. Serial coronal sections of 10 µm
were cut with a cryostat at ?20°C, placed on Super Frost Plus slides (Menzel-Gläser), air
dried overnight at room temperature and fixed in acetone and air dried rapidly. The tissue
sections were then rehydrated in PBS containing 3% bovine serum albumin (BSA) and en-
dogenous peroxidase activity was quenched by incubating with peroxydase block reagent
(Dako). Following washes in PBS containing 1% BSA, the specimens were incubated with
saturating concentrations of rat hybridoma supernatant for 1 hr and then rinsed in PBS con-
taining 1% BSA before incubation with the rabbit anti-rat Ig antibody Z0494 (Dako). The
sections were then treated with EnVision as instructed by the manufacturer (Dako) using a
labelled polymer-HRP goat anti-rabbit Ig. Finally, slides were mounted in Mowiol. Obser-
vation and image acquisitions were carried out on a Leica RM-IRB microscope using the 10×
objective. Pictures were taken with a COHU CCD camera.
A.5.10 Immunofluorescence staining
N2A cells growing on coverslips were transfected with empty pcDNA3.1(+), with
pcDNA3.1 expressing Myc-tagged wild-type MeCP2A or B, or pcDNA3.1 expressing Myc-
tagged mutated MeCP2A or B containing the T158M, R133C, R306C or R308∗ mutations.
Cells were fixed with acetone and incubated with mouse anti-Myc monoclonal antibody
(9E10) followed by FITC-labelled anti-mouse IgG antibody for 30 min at room temperature.
After the final wash, the coverslips were mounted in DAPI-containing ProLong Gold an-
tifading reagent (Molecular Probes). Observation and image acquisition were carried out on
a Leica RM-IRB microscope using 40× or 20× objectives. Pictures were taken with a COHU
CCD camera and acquired as TIFF stacks of images with Q-Fluoro software, after integra-
tion of the signal for 1 sec for in the case of FITC labelling (no integration of the signal was
necessary for DAPI labelling).
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A.5.11 Primary cultures
Brains removed from two-day old mice were cut in small pieces in ice-cold PBS contain-
ing glucose, then centrifuged at 80 g for 5 min at 4°C and digested with trypsin (Gibco) for
40 min at 37°C. The trypsin was blocked by adding DMEM supplemented with 10% FCS
for 5 min at room temperature. The digested brain material was then washed twice with
DMEM containing 10% FCS and once in neurobasal medium (Gibco) supplemented with
B27 and 2% FCS, and recovered between washes by centrifugation at 80 g for 5 min at 4°C.
During the final wash, mechanical dissociation of the cells into a single-cell suspension was
achieved by pipetting up and down several times. Brain cell suspensions were plated on
six-well plates coated at least 12 hrs before with poly-D-ornithine (SIGMA) and maintained
in neurobasal medium containing B27 and 2% FCS.
For cultures of splenic fibroblasts, spleens were cut into small pieces in PBS/glucose, di-
gested in trypsin and washed, as above, and finally plated on six-well plates and maintained
in RPMI containing 10% FCS.
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